Filing Company:

Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

**Product Name:** Long-Term Care

Project Name/Number: MedAmerica Nationwide 2017 Rate Increase/145MAI01-30.05

# Filing at a Glance

State:

Company: Blue Cross of Northeastern Pennsylvania

Product Name: Long-Term Care State: Pennsylvania

Pennsylvania

TOI: LTC03G Group Long Term Care

Sub-TOI: LTC03G.001 Qualified

Filing Type: Rate - Other (Not M.U. or G.I. Product)

Date Submitted: 03/09/2017

SERFF Tr Num: MILL-130951718

SERFF Status: Assigned

State Tr Num: MILL-130951718

State Status: Received Review in Progress
Co Tr Num: SERIES 11 GROUP (BCNEPA)

Implementation On Approval

Date Requested:

Author(s): Missy Gordon, Travis Reisch, Shawn Stender, Michael Emmert, Bryan Rask, Brandon

Johnson, Jack Bridges, Jenna Roska

Reviewer(s): Jim Laverty (primary)

Disposition Date:
Disposition Status:
Implementation Date:

State Filing Description:

Proposed 69.1% increase on 11 PA policyholders of group LTC form GRP11-342-PA-1100.

SERFF Tracking #: MILL-130951718

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Product Name: Long-Term Care

Project Name/Number: MedAmerica Nationwide 2017 Rate Increase/145MAI01-30.05

# **General Information**

Project Name: MedAmerica Nationwide 2017 Rate Increase Status of Filing in Domicile: Pending

Project Number: 145MAI01-30.05 Date Approved in Domicile:

Domicile Status Comments: Pennsylvania is the state of Requested Filing Mode: Review & Approval

domicile.

Explanation for Combination/Other: Market Type: Group

Submission Type: New Submission Group Market Size: Small and Large

Overall Rate Impact: 69.1% Group Market Type: Employer

Filing Status Changed: 03/10/2017

State Status Changed: 03/10/2017 Deemer Date:

Submitted By: Shawn Stender Created By: Brandon Johnson

Corresponding Filing Tracking Number:

State TOI: LTC03G Group Long Term Care State Sub-TOI: LTC03G.001 Qualified

# Filing Description:

On behalf of BCNEPA, we are submitting the referenced rate filing for your review. This is an existing policy form that provides long-term care coverage. The company issued certificates on this form in Pennsylvania between August 2002 and November 2002, and it is no longer being marketed in any jurisdiction. The company is making a similar request on the Series 11 Individual policy forms in a concurrent filing (SERFF Tracking # MILL-130951717).

This product was designed and priced by MedAmerica Insurance Company (MedAmerica), which is an affinity partner of BCNEPA. These certificates were issued on BCNEPA paper, while MedAmerica administers and manages the block, including underwriting and claims handling. MedAmerica has 100% of the risk on these certificates via a reinsurance arrangement with BCNEPA.

The company is requesting the approval of a premium rate increase on this form, including all associated riders. This form is in need of a premium rate increase due to emerging and projected experience running more adverse than previously expected. The company is requesting a premium rate increase that varies by benefit period. The cumulative rate increase levels were determined to allow certification to rate stability, where applicable, and vary by benefit period to better align the rate increase with the adverse experience.

There has been one prior increase that the Department filed for use in May 2010. The company is seeking this current rate increase request to achieve what it believes is needed to alleviate the poor performance on this block of business.

Similar to the prior increase, the company will offer insureds affected by the premium increase the option of reducing their policy benefits to provide flexibility of choice for those insureds who wish to maintain a premium level reasonably similar to what they were paying prior to the rate increase. The company will offer a contingent benefit upon lapse to insureds that trigger a substantial rate increase. Policyholders who prefer to offset the impact of the requested rate increase may have the option to change one or more of the following plan features to lower their premiums (subject to the minimum benefit options available on the form): (i) reduce their daily benefit; (ii) shorten their benefit period; (iii) lengthen their elimination period; (iv) reduce their inflation protection (e.g., compound inflation to no inflation); or (v) drop rider coverage. Additionally, the company will voluntarily offer a contingent benefit upon lapse to insureds affected by the rate increase, even if the increase is not considered substantial.

As noted above, the requested increase varies by a policyholder's current benefit period. Therefore, in lieu of inflation-based landing spot options, the company is preparing a unique notification letter that provides pre-packaged benefit reduction options

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Product Name: Long-Term Care

Project Name/Number: MedAmerica Nationwide 2017 Rate Increase/145MAI01-30.05

for policyholders. The notification letter will provide distinct pre-packaged benefit reduction options that allow policyholders to easily reduce their benefits to mitigate the increase without calling customer service. The company has indicated that its customer service team is always available to discuss with policyholders their options to reduce their benefit coverage and lower their premiums at any time. At this time the company is in the process of finalizing this letter and will submit the letter for the Department's review once complete in the following weeks.

Please note that in the future slight variations in language may occur that do not materially change the information being provided to the policyholder. It is our understanding that such variations do not need to be filed with the Department.

# **Company and Contact**

# **Filing Contact Information**

Shawn Stender, Assistant Actuary shawn.stender@milliman.com

Milliman, Inc. 952-820-3104 [Phone]

8500 Normandale Lake Blvd.

**Suite 1850** 

Minneapolis, MN 55437

# **Filing Company Information**

(This filing was made by a third party - millimaninc)

Blue Cross of Northeastern CoCode: 54747 State of Domicile:
Pennsylvania Group Code: 1270 Pennsylvania

19 North Main Street Group Name: Hosp Serv Assn of Company Type: HMDI Wilkes-Barre, PA 18711 NEPA Gp State ID Number:

(570) 200-4456 ext. [Phone] FEIN Number: 24-0615177

# **Filing Fees**

Fee Required? No Retaliatory? No

Fee Explanation:

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

**Product Name:** Long-Term Care

Project Name/Number: MedAmerica Nationwide 2017 Rate Increase/145MAI01-30.05

# **Rate Information**

Rate data applies to filing.

Filing Method: Review and Approval

Rate Change Type: Increase
Overall Percentage of Last Rate Revision: 39.000%

Effective Date of Last Rate Revision: 05/13/2010

Filing Method of Last Filing: Review and Approval

# **Company Rate Information**

Company Name:	Overall % Indicated Change:	Overall % Rate Impact:	Written Premium Change for this Program:	Number of Policy Holders Affected for this Program:	Written Premium for this Program:	Maximum % Change (where req'd):	Minimum % Change (where req'd):
Blue Cross of Northeastern Pennsylvania	%	69.100%	\$5,188	11	\$7,511	69.100%	69.100%

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Product Name: Long-Term Care

**Project Name/Number:** MedAmerica Nationwide 2017 Rate Increase/145MAI01-30.05

# Rate/Rule Schedule

Item No.	Schedule Item Status	Document Name	Affected Form Numbers (Separated with commas)	Rate Action	Rate Action Information	Attachments
1		Series 11 Group Rate Tables	GRP11-342-PA-1100	Revised	Previous State Filing Number: MILL-126494138 Percent Rate Change Request: 69.1	PA_BCNEPA_Current Premium Rates_Series 11 Group_20170309.pdf, PA_BCNEPA_Propose d Premium Rates_Series 11 Group_20170309.pdf,

#### Comprehensive Tax Qualified Certificate

#### Group Rates for Lifetime Premium Payment Option 0 Day Elimination Period Current Annual Premium Rates Rates per \$10 Daily Benefit

Certificate: GRP11-342-PA-1100
Base Certificate with No Inflation Protection

Rider: GRP11-SIP-PA-998 Simple Inflation Protection Rider

Issue		В	Benefit Period					Benefit Period	ı				Benefit Period		
Age	2 Years	3 Years	4 Years	5 Years	<u>Lifetime</u>	2 Years	3 Years	4 Years	5 Years	<u>Lifetime</u>	2 Years	3 Years	4 Years	5 Years	Lifetime
<22	6	7	8	8	11	3	4	4	6	7	21	26	32	38	47
22 23	7 7	7 7	8 8	10	13 13	3	4	4 6	6	7 8	21 21	28 29	33 35	38 40	49
23 24	7	8	10	10 10	13	3	4	6	7	8	21	29 29	35 35	40 42	50 51
25	7	8	10	11	14	4	4	6	7	10	24	31	36	42	54
26	7	8	10	11	15	4	6	6	7	10	25	32	39	44	56
27	8	10	11	13	15	4	6	6	7	11	25	32	39	46	58
28	8	10	11	13	17	4	6	7	8	11	25	33	40	47	60
29	8	10	11	14	18	4	6	8	8	11	26	35	43	49	61
30 31	8 10	11 11	13 13	14 15	18 19	6	6 7	8 8	10 10	13 14	28 28	36 38	44 46	51 53	65 67
32	10	13	14	15	21	6	7	8	11	14	29	38	47	56	70
33	10	13	15	17	22	7	8	10	11	15	32	40	49	57	71
34	11	14	15	18	24	7	8	11	11	17	32	40	51	58	74
35	11	14	17	19	25	7	10	11	13	18	33	43	53	60	76
36 37	13 13	15 15	18 18	19 21	26 28	7 8	10 11	11 14	14 15	19 21	33 36	44 46	54 57	64 65	79 82
38	14	17	19	22	31	8	11	14	17	21	36	47	58	68	83
39	14	18	21	25	32	10	11	15	17	24	39	49	61	70	88
40	15	19	22	26	35	10	13	17	18	24	39	50	63	72	89
41	17	21	24	28	36	10	14	18	19	26	40	53	65	75	93
42 43	18 18	22 24	26 28	29 32	39 42	11 13	14 15	18 19	22 22	28 31	42 44	54 56	67 70	78 81	96 99
44	19	25	29	35	44	14	17	22	24	32	46	58	72	82	103
45	21	26	32	36	47	14	18	22	26	35	47	61	74	86	106
46	22	28	33	39	51	15	21	25	29	36	49	63	78	89	108
47	24	31	36	42	54	17	21	26	31	40	50	64	79	92	113
48	26	32	39	44	58	17	24	29	33	43	51	68	82	96	117
49 50	28 29	35 38	42 46	49 53	63 68	19 21	25 26	31 32	36 38	46 49	53 56	70 72	85 88	97 101	121 124
51	32	40	49	57	72	22	29	36	40	53	57	74	90	104	128
52	35	43	53	61	78	24	32	39	44	57	58	76	93	108	132
53	38	47	57	65	85	25	33	42	49	60	60	79	97	113	135
54	40	51	61	71	90	28	36	44	51	65	63	81	100	115	140
55 56	43 47	56 60	67 72	78 83	99 106	31 32	39 42	49 51	56 60	68 75	65 67	83 88	103 107	118 124	145 149
57	51	65	79	90	114	33	44	54	65	81	68	89	110	128	154
58	56	71	86	99	124	36	47	58	70	85	71	92	113	131	158
59	60	76	93	107	135	40	51	64	74	90	72	96	117	135	163
60	65	83	101	117	146	43	56	68	81	97	75	99	121	140	168
61 62	71 76	90 99	110 120	128 139	158 172	46 49	60 64	74 78	85 90	104 110	78 81	101 104	125 128	143 147	172 177
63	83	107	131	152	186	49 51	68	83	96	117	82	104	132	152	182
64	90	117	142	164	202	56	72	89	103	124	85	110	135	157	188
65	99	128	156	179	220	58	76	93	110	132	88	114	139	161	193
66	107	139	168	195	239	63	81	100	117	139	89	117	143	167	197
67 68	117 126	150 164	183 200	213 231	259 281	65 68	86 90	106 110	122 129	147 154	90 93	120 122	146 149	170 174	202 206
69	136	178	217	252	304	72	95	117	135	161	96	124	153	177	210
70	149	193	236	274	329	75	99	122	142	170	97	128	156	181	215
71	161	210	256	297	357	79	103	128	147	178	99	129	160	183	218
72	174	227	278	322	388	82	108	133	154	183	100	132	161	186	220
73	188	246	302	349	420	85	111	138	160	189	101	132	163	189	221
74 75	203 222	265 291	325 356	378 413	452 493	88 90	115 120	142 147	164 171	196 202	101 103	133 135	164 165	189 192	224 224
76	242	317	388	450	537	93	122	152	175	207	103	135	167	192	225
77	263	343	423	491	582	95	126	154	179	213	103	135	167	192	225
78	285	374	459	534	632	97	128	158	183	217	103	135	167	192	225
79	309	406	499	580	687	97	128	158	183	217	103	135	167	192	225
80 81	336 364	442 480	546 592	635 689	751 813	97 97	128 128	158 158	183 183	217 217	103 103	135 135	167 167	192 192	225 225
82	393	520	641	748	880	97	128	158	183	217	103	135	167	192	225
83	425	560	694	808	949	97	128	158	183	217	103	135	167	192	225
84	459	605	749	873	1,024	97	128	158	183	217	103	135	167	192	225
85	495	652	808	942	1,104	97	128	158	183	217	103	135	167	192	225

#### Comprehensive Tax Qualified Certificate

#### Group Rates for 20-Year Premium Payment Option 0 Day Elimination Period Current Annual Premium Rates Rates per \$10 Daily Benefit

Certificate: GRP11-342-PA-1100
Base Certificate with No Inflation Protection

Rider: GRP11-SIP-PA-998 Simple Inflation Protection Rider

Issue		E	Benefit Period	ı			Benefit Period						Benefit Period	ı	
Age	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Year	s 3 Years	4 Years	5 Years	Lifetime
· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·				· · · · · · · · · · · · · · · · · · ·			· · · · · · · · · · · · · · · · · · ·							
<22	10	11	14	15	19	6	7	8	11	15		58 76		108	133
22	10	11	14	15	21	6	8	10	13	15		50 78		111	136
23	10	13	14	17	22	7	8	11	13	15		61 79		113	138
24	11	13	15	17	22	7	10	11	14	18		81 81		115	142
25	11	14	17	18	24	7	10	11	14	18		33 82		117	145
26	11	14	17	19	25	8	10	13	14	19		S5 83		118	146
27	13	15	18	21	26	8	10	13	14	21		35 85		120	149
28	13	15	18	21	28	8	11	14	17	22		37 88		124	152
29	14	17	19	22	29	8	11	15	17	24		37 88		125	154
30	14	17	21	24	31	10	14	15	18	25		70 90		126	157
31	15	18	22	25	32	10	14	17	19	26		70 92		129	160
32	15	19	22	26	35	11	14	18	21	26		2 93		132	161
33	17	21	24	28	36	11	14	19	22	29		2 95		133	165
34	17	21	25	29	39	13	17	21	24	29		74 97		136	167
35	18	22	26	31	40	13	17	22	25	32		75 99		139	170
36 37	19	24	29	33 35	43	14	18	22	25	33		76 100 78 101		140	172
	19	25	31		46	15	19	24	28	35				143	175
38 39	21 22	26 28	32 33	36 39	47 50	17 17	21 22	25 26	29 31	39 40		79 103 31 104		146 147	179 181
40	24	29	36	42	54	18	24	28	32	42		31 104		147	182
41	25	32	38	42	5 <del>4</del> 57	18	24	31	36	44		32 107		153	186
42	26	33	40	45	60	19	26	32	38	47		32 107		153	189
42	28	35	43	49	64	21	28	33	40	50		35 111		157	190
44	29	38	44	51	67	22	29	36	43	54		36 113		160	195
45	31	39	47	56	71	25	32	39	44	57		38 114		161	197
46	33	42	50	58	75	25	33	42	47	60		39 115		164	199
47	35	44	54	63	79	26	35	43	50	64		90 117		165	202
48	38	47	57	65	85	28	38	46	54	67		90 118		168	204
49	39	50	61	70	90	31	39	47	57	70		3 121		171	206
50	42	53	64	75	96	32	42	51	60	74		3 122		172	209
51	44	57	68	79	101	33	44	56	64	79		95 124		175	211
52	47	60	74	85	107	36	47	57	67	85		6 126		178	215
53	50	64	78	90	114	39	50	61	71	89		7 128		179	217
54	53	68	83	96	122	42	53	65	76	93		99 129		182	218
55	57	74	89	103	131	43	56	70	81	97	10			185	221
56	61	78	96	110	139	46	60	72	85	103	10			186	224
57	65	83	101	118	147	47	63	78	89	110	10			188	227
58	70	90	110	126	158	51	65	81	95	115	10			190	228
59	75	96	117	136	168	53	70	86	99	122	10	3 136	167	192	231
60	81	103	126	146	181	56	74	90	104	128	10	)4 138	168	195	234
61	86	111	135	156	193	58	76	96	111	135	10			197	236
62	92	118	145	168	207	63	82	100	115	140	10	7 140	172	199	238
63	99	128	156	179	221	65	85	104	122	147	10	08 142	174	202	240
64	106	136	167	193	238	68	90	110	128	154	11	10 143	175	203	240
65	114	147	179	209	254	71	95	115	133	161	11			204	245
66	122	158	193	224	272	75	97	121	140	170	11	11 146	179	207	246
67	131	170	209	240	293	78	103	125	146	175	11			209	247
68	140	183	224	260	314	82	106	131	152	182	11			210	250
69	152	197	240	279	338	83	110	136	158	189	11			211	252
70	163	213	260	302	364	88	114	140	164	195	11			213	252
71	175	228	281	325	392	90	120	145	170	200	11			214	252
72	188	246	302	350	421	93	122	150	174	207	11			214	253
73	202	264	325	377	452	96	125	154	179	214	11			215	253
74	217	284	349	406	485	97	129	158	183	218	11			215	253
75	236	309	378	439	524	99	131	163	189	222	11			215	253
76	254	334	410	477	567	103	135	165	192	228	11			215	253
77	275	361	445	517	614	104	136	168	196	231	11			215	253
78	297	391	481	560	664	106	139	172	199	235	11			215	253
79	321	423	521	606	717	106	139	172	199	235	11			215	253
80	348	459	566	659	778	106	139	172	199	235	11			215	253
81	375	495	612	712	841	106	139	172	199	235	11			215	253
82	404	534	660	770	906	106	139	172	199	235	11			215	253
83	435	575	712	830	976	106	139	172	199	235	11			215	253
84	468	619	766	895	1,049	106	139	172	199	235	11			215	253
85	503	666	824	962	1,127	106	139	172	199	235	11	15 152	186	215	253

#### Comprehensive Tax Qualified Certificate

#### Group Rates for Lifetime Premium Payment Option 0 Day Elimination Period Annual Premium Rates with the Requested Rate Increase Rates per \$10 Daily Benefit

Certificate: GRP11-342-PA-1100
Base Certificate with No Inflation Protection

Rider: GRP11-SIP-PA-998 Simple Inflation Protection Rider

Issue		Е	Benefit Period				Benefit Period							Benefit Period		
Age	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Years	3 Years	4 Years	5 Years	Lifetime	2	Years	3 Years	4 Years	5 Years	Lifetime
						· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·						· ·		
<22	9	12	14	14	32	5	7	7	9	20		35	45	54	63	136
22	12	12	14	16	36	5	7	7	9	20		35	47	56	63	140
23	12	12	14	16	36	5	7	9	9	24		35	49	59	68	144
24	12	14	16	16	40	5	7	9	12	24		38	49	59	71	148
25	12	14	16	19	40	7	7	9	12	28		40	52	61	71	156
26	12	14	16	19	44	7	9	9	12	28		42	54	66	75	160
27	14	16	19	21	44	7	9	9	12	32		42	54	66	78	168
28	14	16	19	21	48	7	9	12	14	32		42	56	68	80	172
29	14	16	19	24	52	7	9	14	14	32		45	59	73	82	176
30	14	19	21	24	52	9	9	14	16	36		47	61	75	87	188
31	16	19	21	26	56	9	12	14	16	40		47	63	78	89	192
32	16	21	24	26	60	9	12	14	19	40		49	63	80	94	200
33	16	21	26	28	64	12	14	16	19	44		54	68	82	96	203
34	19	24	26	31	68	12	14	19	19	48		54	68	87	99	211
35	19	24	28	33	72	12	16	19	21	52		56	73	89	101	219
36 37	21	26	31	33 35	76 80	12	16	19	24	56		56	75 78	92	108	227
	21	26	31			14	19	24	26	60		61		96	110	235
38 39	24 24	28 31	33 35	38 42	88 92	14 16	19 19	24 26	28 28	60 68		61 66	80 82	99 103	115 118	239 251
40	24	33	38	42	100	16	21	28	31	68		66	85	103	122	255
41	28	35	40	45	104	16	21	31	33	76		68	89	110	127	267
42	31	38	45	49	112	19	24	31	38	80		71	92	113	132	275
43	31	40	47	54	120	21	26	33	38	88		75	94	118	136	283
44	33	42	49	59	128	24	28	38	40	92		78	99	122	139	295
45	35	45	54	61	136	24	31	38	45	100		80	103	125	146	303
46	38	47	56	66	148	26	35	42	49	104		82	106	132	150	311
47	40	52	61	71	156	28	35	45	52	116		85	108	134	155	323
48	45	54	66	75	168	28	40	49	56	124		87	115	139	162	335
49	47	59	71	82	180	33	42	52	61	132		89	118	143	165	347
50	49	63	78	89	196	35	45	54	63	140		94	122	148	172	355
51	54	68	82	96	207	38	49	61	68	152		96	125	153	176	367
52	59	73	89	103	223	40	54	66	75	164		99	129	157	183	379
53	63	80	96	110	243	42	56	71	82	172		101	134	165	190	387
54	68	87	103	120	259	47	61	75	87	188		106	136	169	195	403
55	73	94	113	132	283	52	66	82	94	196		110	141	174	200	415
56	80	101	122	141	303	54	71	87	101	215		113	148	181	209	427
57	87	110	134	153	327	56	75	92	110	231		115	150	186	216	443
58	94	120	146	167	355	61	80	99	118	243		120	155	190	221	455
59	101	129	157	181	387	68	87	108	125	259		122	162	197	228	467
60	110	141	172	197	419	73	94	115	136	279		127	167	204	237	483
61	120	153	186	216	455	78	101	125	143	299		132	172	212	242	495
62	129	167	202	235	495	82	108	132	153	315		136	176	216	249	507
63	141	181	221	256	535	87	115	141	162	335		139	181	223	256	523
64	153	197	240	277	579	94	122	150	174	355		143	186	228	266	539
65	167	216	263	303	630	99	129	157	186	379		148	193	235	273	555
66	181	235	284	329	686	106	136	169	197	399		150	197	242	282	567
67	197	254	310	360	742	110	146	179	207	423		153	202	247	287	579
68	214	277	338	390	806	115	153	186	219	443		157	207	251	294	591
69	230	301	367	425	874	122	160	197	228	463		162	209	259	298	602
70	251	327	400	463	946	127	167	207	240	487		165	216	263	306	618
71	273	355	432	503	1,025	134	174	216	249	511		167	219	270	310	626
72	294	383	470	545	1,113	139	183	226	261	527		169	223	273	315	630
73	317	416	510	590	1,205	143	188	233	270	543		172	223	275	320	634
74	343	449	550	639	1,297	148	195	240	277	563		172	226	277	320	642
75	376	491	602	698	1,416	153	202	249	289	579		174	228	280	324	642
76	409	536	656	761	1,540	157	207	256	296	595		174	228	282	324	646
77	444	580	714	830	1,672	160	214	261	303	610		174	228	282	324	646
78	482	632	776	902	1,815	165	216	268	310	622		174	228	282	324	646
79	522	686	844	980	1,971	165	216	268	310	622		174	228	282	324	646
80	569	747	924	1,074	2,155	165	216	268	310	622		174	228	282	324	646
81	616	811	1,001	1,166	2,334	165	216	268	310	622		174	228	282	324	646
82	665	879	1,083	1,264	2,526	165	216	268	310	622		174	228	282	324	646
83	719	947	1,173	1,365	2,725	165	216	268	310	622		174	228	282	324	646
84	776	1,022	1,267	1,476	2,941	165	216	268	310	622		174	228	282	324	646
85	837	1,102	1,365	1,593	3,168	165	216	268	310	622		174	228	282	324	646

#### Comprehensive Tax Qualified Certificate

#### Group Rates for 20-Year Premium Payment Option 0 Day Elimination Period Annual Premium Rates with the Requested Rate Increase Rates per \$10 Daily Benefit

Certificate: GRP11-342-PA-1100
Base Certificate with No Inflation Protection

Rider: GRP11-SIP-PA-998 Simple Inflation Protection Rider

Issue			Benefit Period					Benefit Period					Benefit Period		
Age	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Years	3 Years	4 Years	5 Years	Lifetime	2 Years	3 Years	4 Years	5 Years	<u>Lifetime</u>
<22	16	19	24	26	56	9	12	14	19	44	99	129	157	183	383
22	16	19	24	26	60	9	14	16	21	44	101	132	160	188	391
23	16	21	24	28	64	12	14	19	21	44	103	134	165	190	395
24	19	21	26	28	64	12	16	19	24	52	103	136	167	195	407
25 26	19 19	24 24	28 28	31 33	68 72	12 14	16 16	19 21	24 24	52 56	106 110	139 141	169 174	197 200	415 419
27	21	26	31	35	76	14	16	21	24	60	110	143	176	202	427
28	21	26	31	35	80	14	19	24	28	64	113	148	181	209	435
29	24	28	33	38	84	14	19	26	28	68	113	148	183	212	443
30 31	24 26	28 31	35 38	40 42	88 92	16 16	24 24	26 28	31 33	72 76	118 118	153 155	186 188	214 219	451 459
32	26	33	38	45	100	19	24	31	35	76	122	157	193	223	463
33	28	35	40	47	104	19	24	33	38	84	122	160	197	226	475
34	28	35	42	49	112	21	28	35	40	84	125	165	200	230	479
35 36	31 33	38 40	45 49	52 56	116 124	21	28 31	38 38	42 42	92 96	127	167	202 204	235 237	487 495
37	33	40 42	49 52	56 59	124	24 26	33	38 40	42 47	100	129 132	169 172	204	242	503
38	35	45	54	61	136	28	35	42	49	112	134	174	212	247	515
39	38	47	56	66	144	28	38	45	52	116	136	176	216	249	519
40	40	49	61	71	156	31	40	47	54	120	136	181	219	251	523
41 42	42 45	54 56	63 68	73 78	164 172	31 33	40 45	52 54	61 63	128 136	139 141	181 183	223 226	259 261	535 543
43	47	59	73	82	184	35	47	56	68	144	143	188	228	266	547
44	49	63	75	87	192	38	49	61	73	156	146	190	233	270	559
45	52	66	80	94	203	42	54	66	75	164	148	193	237	273	567
46 47	56 59	71 75	85 92	99 106	215	42 45	56 59	71 73	80 85	172 184	150 153	195 197	240 242	277 280	571 579
47	63	75 80	92 96	110	227 243	45 47	63	73 78	92	184	153	200	242 247	280 284	579 587
49	66	85	103	118	259	52	66	80	96	200	157	204	249	289	591
50	71	89	108	127	275	54	71	87	101	211	157	207	254	291	599
51	75	96	115	134	291	56	75	94	108	227	160	209	256	296	606
52	80 85	101 108	125	143	307	61 66	80	96	113	243	162	214	259	301	618
53 54	85 89	115	132 141	153 162	327 351	71	85 89	103 110	120 129	255 267	165 167	216 219	263 266	303 308	622 626
55	96	125	150	174	375	73	94	118	136	279	169	219	270	313	634
56	103	132	162	186	399	78	101	122	143	295	169	223	270	315	642
57	110	141	172	200	423	80	106	132	150	315	172	226	275	317	650
58 59	118 127	153 162	186 197	214 230	455 483	87 89	110 118	136 146	160 167	331 351	174 174	226 230	277 282	322 324	654 662
60	136	174	214	247	519	94	125	153	176	367	176	233	284	329	670
61	146	188	228	263	555	99	129	162	188	387	179	235	289	334	678
62	155	200	244	284	595	106	139	169	195	403	181	237	291	336	682
63	167 179	216 230	263	303	634	110	143	176	207	423 443	183	240	294 296	341	690
64 65	179	249	282 303	327 353	682 730	115 120	153 160	186 195	216 226	443 463	186 186	242 244	296 301	343 345	690 702
66	207	268	327	378	782	127	165	204	237	487	188	247	303	350	706
67	221	287	353	407	842	132	174	212	247	503	190	249	303	353	710
68	237	310	378	439	902	139	179	221	256	523	193	249	308	355	718
69 70	256 275	334 360	407 439	472 510	970 1,045	141 148	186 193	230 237	268 277	543 559	193 195	251 254	310 310	357 360	722 722
71	275	385	439 475	550	1,125	153	202	244	287	575	195	254	313	362	722
72	317	416	510	592	1,209	157	207	254	294	595	195	256	315	362	726
73	341	447	550	637	1,297	162	212	261	303	614	195	256	315	364	726
74	367	479	590	686	1,393	165	219	268	310	626	195	256	315	364	726
75 76	400 430	522 564	639 693	743 806	1,504 1,628	167 174	221 228	275 280	320 324	638 654	195 195	256 256	315 315	364 364	726 726
77	465	611	752	874	1,764	174	230	284	331	662	195	256	315	364	726
78	503	660	813	947	1,907	179	235	291	336	674	195	256	315	364	726
79	543	714	881	1,025	2,059	179	235	291	336	674	195	256	315	364	726
80	588	776	956	1,114	2,234	179	235	291	336	674	195	256	315	364	726
81 82	635 684	837 902	1,034 1,116	1,203 1,302	2,414 2,601	179 179	235 235	291 291	336 336	674 674	195 195	256 256	315 315	364 364	726 726
83	736	973	1,203	1,403	2,801	179	235	291	336	674	195	256	315	364	726
84	792	1,046	1,295	1,513	3,012	179	235	291	336	674	195	256	315	364	726
85	851	1,126	1,394	1,626	3,236	179	235	291	336	674	195	256	315	364	726

Filing Company:

Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

Pennsylvania

Product Name: Long-Term Care

State:

Project Name/Number: MedAmerica Nationwide 2017 Rate Increase/145MAI01-30.05

# **Supporting Document Schedules**

Satisfied - Item:	Transmittal Letter (A&H)
Comments:	
Attachment(s):	PA_BCNEPA_Cover Letter_Group_LRRS_20170309.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Actuarial Certification (A&H)
Bypass Reason:	Not applicable as this is not a form filing.
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item:	Actuarial Memorandum and Explanatory Information (A&H)
Comments:	
Attachment(s):	PA_BCNEPA_ActMemo_Group_LRRS_20170307.pdf PA_BCNEPA_Supplement_Group_LRRS_20170307.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Advertisements (A&H)
Bypass Reason:	Not applicable as this is not a form filing.
Attachment(s):	
Item Status:	
Status Date:	
Satisfied - Item:	Authorization to File (A&H)
Comments:	MedAmerica is actively working with BCNEPA to provide an updated letter of authorization for this filing. We will provide the updated letter once available.
Attachment(s):	Authorization to file for BCNEPA_20100111.pdf
Item Status:	
Status Date:	
Bypassed - Item:	Insert Page Explanation (A&H)
Bypass Reason:	Not applicable as this is not a form filing.
Attachment(s):	

SERFF Tracking #:	MILL-130951718	State Tracking #:	MILL-130951718		Company Tracking #:	SERIES 11 GROUP (BCNEPA)
State:	Pennsylvania			Filing Company:	Blue Cross of Nort	heastern Pennsylvania
TOI/Sub-TOI:	LTC03G Group	Long Term Care/LTC03G.00	01 Qualified			
Product Name:	Long-Term Care	e				
Project Name/Number:	MedAmerica Na	tionwide 2017 Rate Increase	e/145MAI01-30.05			
Item Status:						
Status Date:						
Satisfied - Item:	F	Rate Table (A&H)				
Comments:	F	Rate tables are attache	d on the Rate/Rule	Schedule tab.		
Attachment(s):						
Item Status:						
Status Date:						
Bypassed - Item:	F	Replacement Form with	Highlighted Chang	ges (A&H)		
Bypass Reason:		Not applicable as this is				
Attachment(s):						
tem Status:						
Status Date:						
Bypassed - Item:	F	Reserve Calculation (A	&H)			
Bypass Reason:	N	Not applicable as this is	not a form filing.			
Attachment(s):		· ·				
tem Status:						
Status Date:						
Bypassed - Item:	V	/ariability Explanation (	A&H)			
Bypass Reason:	N	Not applicable as this is	not a form filing.			
Attachment(s):						
tem Status:						
Status Date:						
Satisfied - Item:	N	Numerical Data in Exce	I			
Comments:						
Attachment(s):	F	PA_Supplement Attach	ments_20170307.x	lsb		
Item Status:		• •				
Status Date:						

State: Pennsylvania Filing Company: Blue Cross of Northeastern Pennsylvania

TOI/Sub-TOI: LTC03G Group Long Term Care/LTC03G.001 Qualified

**Product Name:** Long-Term Care

Project Name/Number: MedAmerica Nationwide 2017 Rate Increase/145MAI01-30.05

Attachment PA\_Supplement Attachments\_20170307.xlsb is not a PDF document and cannot be reproduced here.



8500 Normandale Lake Blvd. Suite 1850 Minneapolis, MN 55437-3830

Tel +1 952 897 5300 Fax +1 952 897 5301

milliman.com

March 9, 2017

Honorable Teresa Miller Commissioner of Insurance Pennsylvania Department of Insurance (Department)

1326 Strawberry Square Harrisburg, Pennsylvania 17120

Via SERFF

Re: Blue Cross of Northeastern Pennsylvania (BCNEPA)

Company NAIC # 54747

SERFF Tracking # MILL-130951718
Comprehensive Form
Comprehensive Certificate

GRP11-341-PA-200 GRP11-342-PA-1100

#### Dear Commissioner Miller:

On behalf of BCNEPA, we are submitting the referenced rate filing for your review. This is an existing policy form that provides long-term care coverage. The company issued certificates on this form in Pennsylvania between August 2002 and November 2002, and it is no longer being marketed in any jurisdiction. The company is making a similar request on the Series 11 Individual policy forms in a concurrent filing (SERFF Tracking # MILL-130951717).

This product was designed and priced by MedAmerica Insurance Company (MedAmerica), which is an affinity partner of BCNEPA. These certificates were issued on BCNEPA paper, while MedAmerica administers and manages the block, including underwriting and claims handling. MedAmerica has 100% of the risk on these certificates via a reinsurance arrangement with BCNEPA.

The company is requesting the approval of a premium rate increase on the above-listed form, including all associated riders. This form is in need of a premium rate increase due to emerging and projected experience running more adverse than previously expected. The company is requesting a premium rate increase that varies by benefit period as shown in the following table. The cumulative rate increase levels were determined to allow certification to rate stability, where applicable, and vary by benefit period to better align the rate increase with the adverse experience.

Benefit Period	Cumulative Requested Increase	Cumulative Prior Increase	Current Requested Increase
Non-Lifetime	135%	39%	69.1%
Lifetime	299	39	187.1

The cumulative prior increase reflects the prior increase that the Department filed for use in May 2010. The company is seeking this current rate increase request to achieve what it believes is needed to alleviate the poor performance on this block of business.

# Offices in Principal Cities Worldwide

This work product was prepared to provide assistance to MedAmerica. Milliman does not intend to benefit and assumes no duty or liability to other parties who receive this work. Milliman recommends Recipient be aided by its own actuary or other qualified professional when reviewing the Milliman work product.



Similar to the prior increase, the company will offer insureds affected by the premium increase the option of reducing their policy benefits to provide flexibility of choice for those insureds who wish to maintain a premium level reasonably similar to what they were paying prior to the rate increase. The company will offer a contingent benefit upon lapse to insureds that trigger a substantial rate increase. Policyholders who prefer to offset the impact of the requested rate increase may have the option to change one or more of the following plan features to lower their premiums (subject to the minimum benefit options available on the form): (i) reduce their daily benefit; (ii) shorten their benefit period; (iii) lengthen their elimination period; (iv) reduce their inflation protection (e.g., compound inflation to no inflation); or (v) drop rider coverage. Additionally, the company will voluntarily offer a contingent benefit upon lapse to insureds affected by the rate increase, even if the increase is not considered substantial.

As noted above, the requested increase varies by a policyholder's current benefit period. Therefore, in lieu of inflation-based landing spot options, the company is preparing a unique notification letter that provides pre-packaged benefit reduction options for policyholders. The notification letter will provide distinct pre-packaged benefit reduction options that allow policyholders to easily reduce their benefits to mitigate the increase without calling customer service. The company has indicated that its customer service team is always available to discuss with policyholders their options to reduce their benefit coverage and lower their premiums at any time. At this time the company is in the process of finalizing this letter and will submit the letter for the Department's review once complete in the following weeks

Please note that in the future slight variations in language may occur that do not materially change the information being provided to the policyholder. It is our understanding that such variations do not need to be filed with the Department.

The following electronic items are included with this submission:

- cover letter
- letter from BCNEPA authorizing us to submit this filing on their behalf
- actuarial memorandum
- a supplement to the actuarial memorandum
- Microsoft Excel spreadsheet containing all numerical data
- current and proposed premium rate schedules

No filing fee is required for this submission.

The contact person for this filing is:

Shawn Stender Assistant Actuary Milliman, Inc. 8500 Normandale Lake Blvd., Suite 1850 Minneapolis, MN 55437 (952) 820-3104 shawn.stender@milliman.com

Thank you for your assistance in reviewing this filing.

Respectfully,

Missy Gordon, FSA, MAAA Principal and Consulting Actuary

MAG/btj

**Enclosures** 

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

## Series 11 Group Actuarial Memorandum

March 7, 2017

Product
Comprehensive Form
Comprehensive Certificate

Number GRP11-341-PA-200 GRP11-342-PA-1100

This is a group policy form that provides tax-qualified long-term care coverage. Blue Cross of Northeastern Pennsylvania (BCNEPA) issued these forms in Pennsylvania from August 2002 through November 2002, and it is no longer being marketed in any jurisdiction.

The experience provided in this actuarial memorandum reflects the combined experience of the policy forms listed above as well as similar nationwide individual and group policy forms of the same product series. The company is making a similar request on the Series 11 Individual policy forms in a concurrent filing (SERFF tracking # MILL-130951717). Additionally, the company's affinity partner MedAmerica Insurance Company (MedAmerica) is making a similar request on its individual and group business in the concurrent filings (SERFF tracking # MILL-130925276 and MILL-130951675). Section 14 provides a description as to the appropriateness of pooling the experience of these policy forms.

# 1. Purpose of Filing

This actuarial memorandum has been prepared for the purpose of demonstrating that the requested rate increase meets the minimum requirements of your jurisdiction and demonstrating compliance with its pre- and post-rate stability regulation, where applicable. It may not be suitable for other purposes.

# 2. Description of Benefits

These policy forms provide long-term care coverage. Each form has benefit eligibility requirements that involve activities of daily living (ADL) deficiencies or cognitive impairment. Waiver of premium is provided when certain benefits are being paid. A daily benefit, benefit period, and elimination period were selected at issue.

At issue, the insured may have had the option to choose one of the following inflation options, the availability of which varied by policy form: simple inflation for life, simple inflation for 20 years, or compound inflation. The two simple inflation options provide for benefit levels that increase on each anniversary date by 5% of the daily benefit amount chosen at issue for either the life of the insured or 20 years depending on the option chosen. The compound inflation option provides for benefit levels that increase on each anniversary date by 5% compounded annually for the life of the insured. These automatic increasing benefits apply even when the insured is in claim status. For Series 11 Group forms, the insured may have also had the option of a guaranteed purchase option. Under this option, the insured can purchase additional coverage amounts of 5% per year without additional underwriting.

The available choices for benefit period, elimination period, and inflation option are shown in Section 21.

At issue the insured may have had the option of selecting riders that provide the following types of coverage: nonforfeiture, restoration of benefits, return of premium, shortened benefit period, spousal benefit transfer, survivorship benefit, or monthly home health care benefit. The insured may have had the option to select a lifetime, ten-year, or twenty-year premium payment option.

A contingent benefit upon lapse (CBUL) will be available to all insureds at the time of the rate increase.

# 3. Renewability

These policies are guaranteed renewable for life.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

# **Series 11 Group Actuarial Memorandum**

March 7, 2017

# 4. Applicability

This rate increase applies to all policies issued on these forms in this state. The rate changes will apply to the premium of the base form and all applicable options and riders associated with the base form.

# 5. Actuarial Assumptions

The following assumptions are used to project the experience shown in this filing.

- a. Morbidity reflects claim costs developed using the 2014 Milliman Long-Term Care Guidelines (Guidelines) with adjustments for the level of individual vs. group underwriting selection and an all-lives exposure basis. The claim costs were further adjusted based on historical claim experience by policy form cohort, attained age, duration, and coverage type, to the extent credible. One year of retrospective improvement was applied to bring these assumptions forward to 2015 using scalars of 0.990 for females and 0.985 for males.
- b. Mortality Rates reflect the 1994 Group Annuitant Mortality (GAM) Static gender-distinct table with 21 years of retrospective improvement applied to bring this table forward to 2015 using scalars of 0.900 for females and 0.810 for males. These mortality rates are further adjusted based on historical mortality experience by individual/group, issue age band, and duration as shown in the following tables.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

# **Series 11 Group Actuarial Memorandum**

# March 7, 2017

Mortality Durational Adjustment Factors for Individual Business												
						Issue	Age					
Duration*	<25	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
1	25%	25%	25%	25%	25%	25%	25%	25%	25%	25%	25%	20%
2	35	35	35	35	35	35	35	35	35	35	35	30
3	40	40	40	40	40	40	40	40	40	40	40	45
4	43	43	43	43	43	43	43	43	44	45	45	50
5	46	46	46	46	46	46	46	46	48	50	50	55
6	49	49	49	49	49	49	49	49	52	55	55	60
7	52	52	52	52	52	52	52	52	56	60	60	65
8	55	55	55	55	55	55	55	55	60	65	65	70
9	56	56	56	56	56	56	56	56	61	68	69	76
10	57	57	57	57	57	57	57	57	62	71	73	82
11	58	58	58	58	58	58	58	58	63	74	77	88
12	59	59	59	59	59	59	59	59	64	77	81	94
13	60	60	60	60	60	60	60	60	65	80	85	100
14	62	62	62	62	62	62	62	62	69	82	88	101
15	64	64	64	64	64	64	64	64	73	84	91	102
16	66	66	66	66	66	66	66	66	77	86	94	103
17	68	68	68	68	68	68	68	68	81	88	97	104
18	70	70	70	70	70	70	70	70	85	90	100	105
23	70	70	70	70	70	70	70	85	90	100	105	105
28	70	70	70	70	70	70	85	90	100	105	105	105
33	70	70	70	70	70	85	90	100	105	105	105	105
38	70	70	70	70	85	90	100	105	105	105	105	105
43	70	70	70	85	90	100	105	105	105	105	105	105
48	70	70	85	90	100	105	105	105	105	105	105	105
53	70	85	90	100	105	105	105	105	105	105	105	105
58	85	90	100	105	105	105	105	105	105	105	105	105
63	90	100	105	105	105	105	105	105	105	105	105	105
68	100	105	105	105	105	105	105	105	105	105	105	105
73+	105	105	105	105	105	105	105	105	105	105	105	105

<sup>\*</sup> The assumption varies by duration for 18+, but is shown every five years for display purposes.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

# **Series 11 Group Actuarial Memorandum**

March 7, 2017

Mortality Durational Adjustment Factors for Group Business												
					•	Issue						
Duration*	<25	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+
1	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	40%
2	70	70	70	70	70	70	70	70	70	70	70	60
3	80	80	80	80	80	80	80	80	80	80	80	90
4	86	86	86	86	86	86	86	86	88	90	90	100
5	92	92	92	92	92	92	92	92	96	100	100	105
6	83	83	83	83	83	83	83	83	88	94	94	102
7	83	83	83	83	83	83	83	83	90	96	96	104
8	83	83	83	83	83	83	83	83	90	98	98	105
9	81	81	81	81	81	81	81	81	88	98	99	105
10	79	79	79	79	79	79	79	79	86	98	101	105
11	77	77	77	77	77	77	77	77	83	98	102	105
12	74	74	74	74	74	74	74	74	81	97	102	105
13	72	72	72	72	72	72	72	72	78	96	102	105
14	74	74	74	74	74	74	74	74	82	98	105	105
15	76	76	76	76	76	76	76	76	86	99	105	105
16	77	77	77	77	77	77	77	77	90	101	105	105
17	79	79	79	79	79	79	79	79	94	102	105	105
18	81	81	81	81	81	81	81	81	98	104	105	105
23	77	77	77	77	77	77	77	94	99	105	105	105
28	74	74	74	74	74	74	89	95	105	105	105	105
33	70	70	70	70	70	85	90	100	105	105	105	105
38	70	70	70	70	85	90	100	105	105	105	105	105
43	70	70	70	85	90	100	105	105	105	105	105	105
48	70	70	85	90	100	105	105	105	105	105	105	105
53	70	85	90	100	105	105	105	105	105	105	105	105
58	85	90	100	105	105	105	105	105	105	105	105	105
63	90	100	105	105	105	105	105	105	105	105	105	105
68	100	105	105	105	105	105	105	105	105	105	105	105
73+	105	105	105	105	105	105	105	105	105	105	105	105

<sup>\*</sup> The assumption varies by duration for 18+, but is shown every five years for display purposes.

c. <u>Voluntary Lapse Rates</u> vary by policy duration and policy form group.

	Prior to	Series 11	Series 11
Duration	Series 11	Individual	Group
1	16.50%	8.50%	6.50%
2	8.50	4.00	6.00
3	5.00	2.75	4.00
4	3.50	2.00	3.50
5	2.00	1.50	3.00
6	1.50	1.25	2.50
7	1.50	1.25	2.00
8	1.50	1.00	1.50
9	1.50	0.75	1.30
10+	1.00	0.60	1.30

The lapse rates in the above table were adjusted based on the following criteria for the limited-pay options:

• For the ten-pay option, a reduction of 65% of the above lapse rates is assumed for durations one through four, a reduction of 70% of the above lapse rates is assumed for durations five through eight, and 0% lapse thereafter.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

## Series 11 Group Actuarial Memorandum

## March 7, 2017

- For the twenty-pay option, a reduction of 50% of the above lapse rates is assumed for durations one through eight, a reduction of 75% of the above lapse rates is assumed for durations nine through fifteen, and 0% lapse thereafter.
- d. <u>Benefit Expiry Rates</u> reflect assumed policy termination due to exhaustion of benefits on limited benefit period policies. The rates are based on the *Guidelines* with adjustments for historical benefit expiry experience and vary by gender, benefit period, and attained age as shown in the following table.

	Benefit						Attaine	d Age*				
Gender	Period in Years	<65	65	70	75	80	85	90	95	100	105	110+
Female	1	0.0%	0.1%	0.1%	0.3%	0.7%	2.5%	6.1%	10.7%	13.4%	16.7%	33.0%
	2	0.0	0.0	0.1	0.2	0.5	1.6	4.5	8.7	11.7	16.3	33.0
	3	0.0	0.0	0.1	0.1	0.4	1.2	3.4	6.9	9.7	15.0	33.0
	4	0.0	0.0	0.0	0.1	0.3	1.0	2.5	5.0	7.8	13.2	33.0
	5	0.0	0.0	0.0	0.1	0.2	0.7	1.7	3.8	6.3	11.2	33.0
	Unlimited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Male	1	0.0	0.0	0.1	0.2	0.5	1.5	3.9	6.3	7.8	9.4	33.0
	2	0.0	0.0	0.1	0.1	0.3	1.0	2.5	4.3	5.4	7.3	33.0
	3	0.0	0.0	0.1	0.1	0.2	0.7	1.7	3.0	4.0	5.8	33.0
	4	0.0	0.0	0.0	0.1	0.1	0.4	1.1	2.0	2.8	4.6	33.0
	5	0.0	0.0	0.0	0.0	0.1	0.3	8.0	1.5	2.3	3.6	33.0
	Unlimited	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

<sup>\*</sup> The assumption varies by attained age, but is shown every five years for display purposes.

e. <u>Policyholder Behavior Due to the Rate Increase</u>. At the time of a rate increase, insureds have the option to elect a CBUL or reduced benefit options (RBO). An increase in morbidity for adverse selection due to the rate increase based on the percentage of policies that elect CBUL and RBO is assumed.

Insureds who elect a CBUL are modeled as a lapse (i.e., the CBUL benefit is not modeled), which results in a slightly lower lifetime loss ratio than if the CBUL benefit had been modeled. The following table provides the CBUL and RBO election rates, reduction to premiums and benefits due to the impact of RBO elections, and increase in morbidity. These assumptions are shown for each of the requested rate increase cohorts.

Benefit Period	CBUL Election Rate	RBO Election Rate	Approximate Reduction for RBO <sup>[1]</sup>	Morbidity Increase for Adverse Selection
Non-Lifetime	8%	15%	7.5%	2%
Lifetime	12	25	19.0	3

<sup>[1]</sup> The reduction in premiums and benefits due to the impact of RBO election varies based on the level of the rate increase.

- f. Interest Rate of 5.00% is used for accumulating and discounting earned premiums and incurred claims in the calculation of cumulative loss ratios. This rate represents MedAmerica's expectation of its long-term investment earnings rate, which is supported by the average net investment earnings rate projected for MedAmerica's cash flow testing. The maximum valuation interest rate is used to demonstrate compliance with the 58%/85% test required by rate stability regulation, as described in Section 18 below.
- g. <u>Annual Improvement</u> in the mortality and morbidity assumptions is assumed for 15 years starting in 2016. Annual mortality improvement is assumed to be 0.5% and 1.0% for females and males,

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

## **Series 11 Group Actuarial Memorandum**

## March 7, 2017

respectively. Annual morbidity improvement is assumed to be 1.0% and 1.5% for females and males, respectively.

h. <u>Expenses</u> have not been explicitly projected. Originally filed expense assumptions are assumed to remain appropriate, except that reductions are made to the renewal commission rates so that the total commissions paid before and after any increase in premium are similar (i.e., commissions are not paid on the increased premium).

The above assumptions are based on the experience of MedAmerica and its affinity partners that issued the same products, industry experience, and judgment. These assumptions are based on the experience of the particular policy forms in this filing and other similar policy forms where appropriate. In developing the persistency assumptions, policy termination experience through December 31, 2015 was used, whereas for the morbidity assumption, claim experience through December 31, 2014 was used. The above assumptions are deemed reasonable for the particular policy forms in this filing and are considered "most likely" (without explicit margin).

In establishing the assumptions described in this section, the policy design, underwriting, and claims adjudication practices for the above-referenced policy forms were taken into consideration. Appendix A to this memorandum provides a description of the development of and justification for the assumptions used in this filing.

The company is not currently marketing long-term care products. As a result, the requirement to reflect on any assumptions that deviate from those used for pricing other forms currently available for sale is not applicable.

# 6. Marketing Method

These policy forms were marketed by agents and brokers of the company.

# 7. Underwriting Description

Policies on the individual forms were fully underwritten.

On the group forms, actively at work employees were subject to short form underwriting. All others were subject to full underwriting.

Groups of at least 500 employees were eligible to elect modified guaranteed issue underwriting for those actively at work. If the employer agreed to contribute 100% of premium for a base plan for a minimum of three years, no underwriting was required for those actively at work.

For both individual and group business, the company used various underwriting tools in addition to the application, which may have included medical records, an attending physician's statement, telephone interview, and/or face-to-face assessment.

# 8. Premiums

Premiums are unisex and payable for life unless the insured selected a ten-year or twenty-year premium payment option. The premiums may vary by policy form, issue age, elimination period, benefit period, initial daily benefit, inflation option, premium payment option, underwriting class, joint/group discounts, home care percentage, copayment option, marital status at issue, and the selection of any riders.

# 9. Issue Age Range

Issue ages are from 18 to 85.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

# **Series 11 Group Actuarial Memorandum**

March 7, 2017

# 10. Area Factors

Area factors are not used for these products.

#### 11. Premium Modalization Rules

The following modal factors and percent distributions (based on the nationwide combined individual and group forms in-force count as of December 31, 2015) are applied to the annual premium (AP):

Premium Mode	Modal Factors	Percent Distribution	
Annual	1.00*AP	45%	
Semi-Annual	0.52*AP	4	
Quarterly	0.26*AP	22	
Monthly	0.09*AP	29	

## 12. Reserves

Active life reserves and reserves for the election of a CBUL have not been used in this rate increase analysis. Claim reserves as of December 31, 2015 have been discounted to the incurral date of each respective claim and included in historical incurred claims. An incurred but not reported (IBNR) reserve balance as of December 31, 2015 has been allocated to the 2015 calendar year and included in historical incurred claims.

## 13. Trend Assumptions

As this is not medical insurance, an explicit medical cost trend is not included in the projections.

# 14. Actual to Expected Experience

This filing uses nationwide experience of MedAmerica and its affinity partners that issued the above-listed forms and similar individual and group nationwide policy forms. Pooling this experience is appropriate to increase credibility and allow for a uniform rate increase request across similar business. Applying a uniform rate increase to the pool of forms maintains the original pricing relationships of the product design and differences between individual and group business.

Further, pooling MedAmerica's experience with its affinity partners' is considered appropriate because the products issued by each affinity partner are identical to those included in this filing, the marketing and distribution employed by each affinity partner is similar to that of MedAmerica, and because the same company (MedAmerica) administers and manages the entire block (including underwriting and claims handling). MedAmerica has 50% to 100% of the risk of the affinity partner forms via reinsurance arrangements with each affinity partner.

Exhibit I provides a comparison of actual and projected experience using current assumptions to that expected using original pricing assumptions. Values in Exhibit I are shown (a) before and (b) after the requested rate increase. Included are calendar year earned premiums, incurred claims, end of year lives, annual loss ratios, cumulative loss ratios, and the ratio of actual-to-expected (A:E) loss ratios.

Exhibit II provides A:E lifetime loss ratios by policy form cohort and benefit period (non-lifetime versus lifetime), which are subsets of the actual and expected nationwide experience underlying Exhibit I.

Actual experience is provided from inception through 2015 and then projected on a seriatim basis for 60 years using the current assumptions described above in Section 5. The actual and projected experience is based on nationwide premiums that reflect prior rate increases filed for use between 2010 and 2015, which average 30% across all jurisdictions. The after increase projected experience reflects the additional increase needed to achieve the cumulative increase on a seriatim basis.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

## Series 11 Group Actuarial Memorandum

March 7, 2017

Expected experience was projected on a seriatim basis from issue using the original pricing assumptions and the actual mix of policies sold.

Exhibit III provides a comparison of the current and original pricing assumptions, which underlie the actual and expected experience described above.

## 15. History of Previous Rate Revisions

In this jurisdiction, a cumulative increase of 39% has been filed for use on the individual and group policy forms. The department of insurance filed these increases for use in May 2010.

Nationwide, there has been one prior rate increase request on this block of business, which began in December 2009. On average, a cumulative increase of 30% has been filed for use on the above-listed forms and similar individual and group nationwide forms. Departments of insurance filed these increases for use between 2010 and 2015.

Regardless of the prior increase implemented in a particular jurisdiction, the company anticipates requesting an actuarially equivalent cumulative rate increase level in all jurisdictions, except where it is not cost effective to file an increase due to the limited amount of in-force business or regulatory requirements.

## 16. Analysis Performed to Consider a Rate Increase

Exhibit I demonstrates that experience has been more adverse from that expected in original pricing as the A:E loss ratio exceeds 1.0. The adverse experience is due to a combination of higher persistency and lower interest.

Exhibit IV provides a comparison of actual and projected nationwide experience to that expected in pricing with respect to morbidity, mortality, lapse, interest, and improvement. Please note that to isolate the impact of each changed assumption from pricing, the experience in Exhibit IV has been restated to reflect no prior rate increases.

For the business subject to rate stability regulation, an analysis of the projected loss ratio compared to that assumed at the time of original pricing revealed that experience has unfolded more than moderately adverse and crossed the original pricing threshold for which the company could consider a rate increase. At the time the product was priced, MedAmerica management determined the threshold for future increases would be defined as experience exhibiting deterioration of more than 10% of premium compared to that assumed in pricing. The lifetime loss ratio based on the current assumptions described above in Section 5 is over 100% and well in excess of this original pricing threshold.

# 17. Requested Rate Increase

The company is requesting a rate increase that varies by benefit period as shown in the following table. The company is seeking this current rate increase request to achieve what it believes is needed to alleviate the poor performance on this block of business. While a significantly larger rate increase is needed to restore the performance to the original pricing expectation, the company is willing to shoulder a portion of the needed rate increase for consumers.

The cumulative rate increase levels were determined to allow certification to rate stability, where applicable, and vary by benefit period to better align the rate increase with the adverse experience. MedAmerica's goal is equity across all jurisdictions, to the extent practical. The rate increase was determined in such a way that minimizes subsidization across jurisdictions due to differences in the previously filed rate increases.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

## Series 11 Group Actuarial Memorandum

## March 7, 2017

The table below provides the cumulative requested increase for each benefit period cohort, as well as the average cumulative prior increase and resulting current requested premium rate increase based on the nationwide distribution of combined individual and group business as of December 31, 2015.

Benefit Period	Cumulative Requested Increase	Cumulative Prior Increase	Current Requested Increase
Non-Lifetime	135%	28.5%	82.9%
Lifetime	299	33.5	198.8

For policies with a non-lifetime benefit period, the cumulative rate increase was determined such that the business would break even going forward under moderately adverse conditions for the subset of policies with a lifetime-pay option (i.e., 0% profit margin going forward).

Using a similar approach for policies with a lifetime benefit period, a significantly higher increase is needed (400%+ cumulative increase). Therefore, to reduce the impact of the rate increase on policyholders to the extent possible, the company capped the cumulative rate increase at 299%.

For policies with a non-lifetime benefit period, company management has indicated that if the requested rate increase described above is filed for use, no future premium rate increases are anticipated on policies with a non-lifetime benefit period unless the non-lifetime benefit period experience deteriorates beyond an 85% lifetime loss ratio. Moderately adverse experience (MAE) for the purposes of certification to rate stability is then defined as an approximate 10% multiplicative increase in the lifetime loss ratio for experience of non-lifetime benefit period policies, as shown in Exhibit II (i.e.,  $85\% \approx 1.10 \times 78\%$  after increase lifetime loss ratio). This 10% multiplicative increase may be due to any combination of deterioration in the experience from that expected using the current assumptions described in Section 5.

Because policies with a lifetime benefit period have a voluntarily capped requested rate increase, it may not be sufficient to alleviate poor performance and the company may request future increases.

Corresponding rate tables reflecting the proposed rate increases for policy forms affected by this rate increase are enclosed with this filing. Please note that the actual rates implemented may vary from those in the enclosed rate tables slightly due to implementation rounding algorithms.

As the company is not currently marketing new business, the required statement that the renewal premium rate schedules are not greater than the new business premium rate schedules is not applicable.

# 18. Demonstration of Satisfaction of Loss Ratio Requirements

Projected experience assuming the requested increase is implemented is shown in Exhibit I. As shown in Exhibit I, the anticipated lifetime loss ratio without and with the requested rate increase exceeds that expected in original pricing. The projected lifetime loss ratio after the requested increase using the maximum valuation interest rate for contract reserves applicable for the year of issue (ranges from 3.5% to 5.5% and averages 4.3%) is 94%, which is well in excess of the minimum loss ratio required by loss ratio regulation.

Exhibit V provides a demonstration that the requested rate increase meets the 58%/85% test required by rate stability regulation. This exhibit shows that the sum of the accumulated value of incurred claims without the inclusion of active life reserves, and the present value of projected incurred claims, without the inclusion of active life reserves, will not be less than the sum of the following:

- 1. Accumulated value of the initial earned premium times 58%,
- 2. 85% of the accumulated value of prior premium rate schedule increases,
- 3. Present value of projected initial earned premium times 58%, and
- 4. 85% of the present value of projected premium in excess of the projected initial earned premium.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

# Series 11 Group Actuarial Memorandum

March 7, 2017

The projected incurred claims in Exhibit V were increased by 14% from the current assumptions described in Section 5 to reflect assumptions that include moderately adverse conditions. A 14% increase in projected incurred claims was determined as one scenario that results in a lifetime loss ratio of 85% (which is the threshold for MAE as described above). It is among many possible alternative adverse experience scenarios, but considered one of the simplest since it involves only one assumption shift. Present and accumulated values in Exhibit V are determined at the maximum valuation interest rate for contract reserves applicable for the year of issue, which as described above, averages 4.3%.

# 19. Average Annual Premium in Pennsylvania (Based on December 31, 2015 In-Force<sup>[1]</sup>)

The number of insureds and the corresponding average annual premium that will be affected by this and the identical, concurrent rate increase filings are:

	Number	Before Increase	After Increase
Benefit Period & Cumulative Increase <sup>[2]</sup>	of Insureds	Premium	Premium
Pennsylvania	a - MedAmerica		
Series 11 and Prior Individual	<u>290</u>	<u>\$2,026</u>	<u>\$3,989</u>
Non-Lifetime Benefit Periods & 135%	242	1,855	3,136
Lifetime Benefit Period & 299%	48	2,888	8,291
Series 11 Group	<u>68</u>	<u>\$1,361</u>	<u>\$2,302</u>
Non-Lifetime Benefit Periods & 135%	68	1,361	2,302
Lifetime Benefit Period & 299%	0	0	0
Pennsylva	nia - BCNEPA		
Series 11 Individual	<u>108</u>	<u>\$1,709</u>	<u>\$2,957</u>
Non-Lifetime Benefit Periods & 135%	105	1,700	2,874
Lifetime Benefit Period & 299%	3	2,036	5,845
Series 11 Group	<u>11</u>	<u>\$683</u>	<u>\$1,154</u>
Non-Lifetime Benefit Periods & 135%	11	683	1,154
Lifetime Benefit Period & 299%	0	0	0

<sup>[1]</sup> Excludes policies assumed to be paid up prior to implementation of the requested rate increase. Annualized premium reflects all rate increases filed for use as of December 31, 2016.

# 20. Proposed Effective Date

This rate increase will apply to policies on their next premium payment date following at least a 60-day policyholder notification period following being filed for use by the department of insurance.

# 21. Distribution of Business as of December 31, 2015 (Based on Nationwide In-Force Insured Count of Combined Individual and Group Forms)

Issue Ages	Percent Distribution
<40	8%
40-44	6
45-49	11
50-54	16
55-59	20
60-64	18
65-69	12
70-74	7
75+	2

<sup>[2]</sup> Cumulative increase reflects any prior implemented increases and the requested increase.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

# **Series 11 Group Actuarial Memorandum**

March 7, 2017

Elimination Period	Percent Distribution
0-Day	5%
20-Day	22
30-Day	<1
60-Day	6
90-Day	52
100-Day	5
180-Day	10
365-Day	<1

Benefit Period	Percent Distribution
1-Year	<1%
2-Year	17
3-Year	38
4-Year	8
5-Year	18
Lifetime	19

Inflation Option	Percent Distribution
None	41%
Simple for Life	3
Compound for Life	37
Simple for 20 Years	19
GPO	<1

Premium Payment Option	Percent Distribution
Ten-Pay	14%
Twenty-Pay	9
Lifetime-Pay	77

Coverage Type	Percent Distribution
Facility Only	12%
Comprehensive	87
Home Health Only	1

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

# **Series 11 Group Actuarial Memorandum**

March 7, 2017

# 22. Number of Insureds and Annualized Premium (Based on December 31, 2015 In-Force<sup>[1]</sup>)

The number of insureds and annualized premium that will be affected by this and the identical, concurrent rate increase filings are:

Policy Forms	Number of Insureds	Annualized Premium				
Pennsylvania - MedAmerica						
Series 11 and Prior Individual	290	\$587,524				
Series 11 Group	68	92,571				
Total	358	680,095				
Pennsylvania - BCNEPA						
Series 11 Individual	108	\$184,614				
Series 11 Group	11	7,511				
Total	119	192,125				
Nationwide	Nationwide - MedAmerica and Affinity Partners					
Series 11 and Prior Individual	9,001	\$16,082,991				
Series 11 Group	5,171	5,851,060				
Total	14,172	21,934,051				

<sup>[1]</sup> Excludes policies assumed to be paid up prior to implementation of the requested rate increase. Annualized premium reflects all rate increases filed for use nationwide as of December 31, 2016.

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

## **Series 11 Group Actuarial Memorandum**

March 7, 2017

# 23. Actuarial Certification

I am a Principal and Consulting Actuary for Milliman, Inc. and retained by MedAmerica to render an opinion with regard to long-term care insurance rates. I am a member of the American Academy of Actuaries. I meet the Academy's qualification standards to render this actuarial opinion and am familiar with the requirements for filing long-term care insurance premiums and rate increases.

This memorandum has been prepared in conformity with all applicable Actuarial Standards of Practice, including Actuarial Standards of Practice No. 8, "Regulatory Filings for Health Benefits, Accident and Health Insurance, and Entities Providing Health Benefits" and 18, "Long-Term Care Insurance".

I hereby certify that, to the best of my knowledge and judgment, this rate submission is in compliance with the applicable laws and regulations of this jurisdiction and the rules of the department of insurance.

In my opinion, the rates are not excessive or unfairly discriminatory, and bear reasonable relationship to the benefits based on the loss ratio standards of this jurisdiction.

For policies with a non-lifetime benefit period, if the requested premium rate schedule increase is implemented and the underlying assumptions, with moderately adverse conditions reflected, are realized, no further premium rate schedule increases are anticipated on such policies. Moderately adverse conditions are defined as any combination of deterioration in the experience or assumptions that results in a lifetime loss ratio for non-lifetime benefit period policies in excess of 85%.

For policies with a lifetime benefit period, this filing will enhance premium adequacy, but may not be sufficient to prevent future rate action. Therefore, rate stability under moderately adverse conditions cannot be certified to, as required by regulation, for the lifetime benefit period policies.

In forming my opinion, I have used actuarial assumptions and actuarial methods (which gave consideration to policy design, underwriting, and claim adjudication) and such tests of the actuarial calculations as I considered necessary. Based on these assumptions, or statutory requirements where necessary, the premium rate filing is in compliance with the loss ratio standards of this jurisdiction.

I have relied on data and information provided by MedAmerica to develop this memorandum, including but not limited to management's view of when a rate change may be considered, policy design, underwriting and claim adjudication process, seriatim in-force data, claim data, and the company's long-term earnings rate. I have not audited or independently verified the data and information provided, but have reviewed it for reasonableness.

The basis for contract reserves has been previously filed and there is no anticipation of any changes.

Missy Gordon, FSA, MAAA Principal and Consulting Actuary

Date: March 7, 2017

# Exhibit I-a MedAmerica and Affinity Partners Actual-to-Expected Experience by Calendar Year Nationwide Experience Before Requested Rate Increase Series 11 and Prior Policy Forms

			Actual or Projectusing Current			Expected Experience using Pricing Assumptions				Cumulative Loss Ratios with Interest		
		A	B B	C = B / A	D	E	using Pricing F	G = F / E	Н	Cumulative	J	K = I / J
				,				.,-		Actual (Column C)	Expected (Column G)	Actual-to-
	Calendar Year	Earned Premium	Incurred Claims	Incurred Loss Ratio	End of Year Lives	Earned Premium	Incurred Claims	Incurred Loss Ratio	End of Year Lives	with 5.00% Interest	with Average 7.24% Interest	Expected Ratio
	1992	17,324	0	0%	111	16,565	3,460	21%	110	0%	21%	0.00
	1993	557,528	112,935	20%	634	556,576	127,290	23%	664	20%	23%	0.86
	1994 1995	1,501,263 2,485,725	28,746 109,652	2% 4%	1,377 1,944	1,556,224 2,626,940	431,321 825,928	28% 31%	1,446 2,090	7% 6%	26% 29%	0.27 0.19
	1996	3,463,885	134,262	4%	2,689	3,655,699	1,213,762	33%	2,838	5%	31%	0.16
	1997	4,394,237	264,541	6%	3,003	4,557,379	1,550,641	34%	3,068	5%	32%	0.17
	1998	5,341,744	631,867	12%	3,666	5,238,873	1,842,618	35%	3,506	7%	32%	0.22
	1999 2000	6,829,900 8,941,708	1,469,714 1,172,992	22% 13%	4,764 6,200	6,315,324 7,989,544	2,175,807 2,546,851	34% 32%	4,387 5,580	11% 11%	33% 32%	0.33 0.35
	2000	11,912,872	2,210,887	19%	8,456	10,492,015	2,959,250	28%	7,606	13%	32%	0.35
	2002	16,102,548	4,131,980	26%	11,472	14,152,917	3,467,804	25%	10,303	16%	30%	0.53
Historical	2003	21,498,563	3,506,680	16%	17,713	18,850,587	4,189,633	22%	16,163	16%	28%	0.57
Experience	2004	27,112,675	6,602,535	24%	19,114	23,841,586	5,075,261	21%	17,327	18%	27%	0.66
	2005 2006	28,577,291 28,838,021	6,824,784 7,359,318	24% 26%	20,242 20,095	24,495,154 24,112,407	5,782,321 6,452,826	24% 27%	18,002 17,519	19% 20%	26% 26%	0.71 0.75
	2007	28,383,240	10,552,392	37%	20,146	23,121,105	7,118,474	31%	17,282	22%	27%	0.81
	2008	27,837,724	8,394,073	30%	19,941	22,245,491	7,783,650	35%	16,837	23%	28%	0.82
	2009	26,881,835	11,313,758	42%	19,482	21,096,208	8,413,116	40%	16,173	24%	28%	0.86
	2010 2011	25,544,191 24,603,117	15,723,015 13,541,344	62% 55%	18,494 17,664	19,836,480 18,515,528	9,005,281 9,540,277	45% 52%	15,500 14,878	27% 29%	29% 30%	0.92 0.95
	2012	25,248,567	17,141,023	68%	17,596	17,260,679	10,108,733	59%	14,699	31%	32%	0.98
	2013	24,384,255	14,626,127	60%	17,264	15,689,414	10,688,938	68%	14,145	32%	33%	0.99
	2014	22,506,450	22,967,435	102%	16,809	14,048,401	11,280,560	80%	13,595	35%	34%	1.04
	2015 2016	21,584,067 21,357,049	20,806,755 19,334,171	96% 91%	16,292 15,800	12,930,951 11,987,427	11,880,612 12,477,661	92% 104%	13,054 12,419	38% 39%	35% 36%	1.07 1.08
	2016	20,472,802	21,088,277	103%	15,305	11,103,840	13,071,513	118%	11,811	41%	38%	1.00
	2018	19,369,621	22,918,883	118%	14,806	10,227,054	13,665,357	134%	11,225	43%	39%	1.11
	2019	18,406,508	24,740,141	134%	14,304	9,482,088	14,256,157	150%	10,658	45%	40%	1.13
	2020 2021	17,470,951 16,538,030	26,500,160 28,210,705	152% 171%	13,798 13,291	8,784,402 8,115,800	14,832,531 15,406,878	169% 190%	10,108 9,577	47% 50%	41% 43%	1.14 1.16
	2021	15,596,044	29,815,323	191%	12,781	7,468,255	15,975,430	214%	9,063	52%	44%	1.18
	2023	14,489,872	31,375,747	217%	12,273	6,733,253	16,534,812	246%	8,565	54%	45%	1.20
	2024	13,397,604	32,971,001	246%	11,765	6,043,030	17,067,285	282%	8,083	57%	46%	1.22
	2025	12,476,171	34,561,357	277%	11,259 10,756	5,475,192	17,573,477	321%	7,617	59%	47% 48%	1.24
Projected	2026 2027	11,620,802 10,822,954	36,172,635 37,816,276	311% 349%	10,756	4,968,176 4,514,355	18,057,192 18,522,411	363% 410%	7,167 6,733	61% 64%	48% 49%	1.26 1.29
Future	2028	10,000,914	39,512,240	395%	9,763	4,060,850	18,956,201	467%	6,314	66%	50%	1.31
Experience	2029	9,271,931	41,185,438	444%	9,275	3,672,763	19,351,676	527%	5,911	68%	51%	1.33
(60 Years)	2030	8,576,548	42,755,298	499%	8,794	3,315,943	19,702,876	594%	5,524	71%	52%	1.35
	2031 2032	7,910,616 7,271,681	44,446,472 46,240,732	562% 636%	8,319 7,851	2,985,585 2,679,836	19,993,572 20,211,586	670% 754%	5,152 4,796	73% 75%	53% 54%	1.37 1.39
	2032	6,661,754	47,792,004	717%	7,390	2,398,298	20,342,430	848%	4,455	78%	55%	1.41
	2034	6,080,987	49,155,738	808%	6,939	2,139,370	20,391,336	953%	4,130	80%	56%	1.44
	2035	5,529,732	50,362,279	911%	6,498	1,902,009	20,339,645	1,069%	3,821	82%	56%	1.46
	2036 2037	5,008,443 4,517,582	51,278,195 51,873,842	1,024% 1,148%	6,067 5,648	1,685,080 1,487,391	20,170,560 19,884,616	1,197% 1,337%	3,527 3,249	85% 87%	57% 58%	1.48 1.50
	2038	4,057,385	52,130,147	1,285%	5,243	1,308,096	19,493,671	1,490%	2,986	89%	58%	1.52
	2039	3,627,888	52,101,378	1,436%	4,851	1,146,276	19,007,851	1,658%	2,738	91%	59%	1.54
	2040	3,228,952	51,679,979	1,601%	4,475	1,000,696	18,430,215	1,842%	2,506	93%	59%	1.56 1.58
	2041 2042	2,860,493 2,522,341	50,967,588 49,872,848	1,782% 1,977%	4,116 3,775	870,303 753,998	17,768,381 17,026,548	2,042% 2,258%	2,289 2,086	94% 96%	60% 60%	1.58 1.60
	2042	2,522,341	48,483,371	2,190%	3,775	650,748	16,213,604	2,258% 2,492%	2,086 1,897	98%	60%	1.60
	2044	1,934,179	46,882,208	2,424%	3,148	559,501	15,348,616	2,743%	1,722	99%	61%	1.63
	2045	1,681,891	45,060,682	2,679%	2,863	479,283	14,446,595	3,014%	1,561	100%	61%	1.64
	2046-2050	5,488,041	190,766,034	3,476%	10,711	1,509,875	58,130,778	3,850%	5,799 3,381	105% 108%	62% 62%	1.70
	2051-2055 2056-2060	2,424,067 992,438	128,724,395 76,404,751	5,310% 7,699%	6,298 3,589	634,353 250,171	36,722,123 21,163,743	5,789% 8,460%	3,381 1,880	108%	62% 62%	1.73 1.74
	2061-2065	383,592	41,684,985	10,867%	1,948	93,253	11,560,061	12,396%	966	109%	62%	1.75
	2066-2070	138,711	20,516,091	14,791%	951	32,089	5,999,597	18,697%	429	110%	63%	1.75
	2071-2075	45,729	8,673,354	18,967%	386	9,810	2,666,351	27,181%	150	110%	63%	1.75

# Exhibit I-b MedAmerica and Affinity Partners Actual-to-Expected Experience by Calendar Year Nationwide Experience After Requested Rate Increase Series 11 and Prior Policy Forms

			Actual or Projec				Expected E					_
	1	A	using Current	Assumptions C = B / A	D	Е	using Pricing	Assumptions G = F / E	Н	Cumulative	Loss Ratios with	Interest K = I / J
		^	ь	C=B/A	Ь		r	G=F/E		Actual	Expected	
	Calendar Year	Earned Premium	Incurred Claims	Incurred Loss Ratio	End of Year Lives	Earned Premium	Incurred Claims	Incurred Loss Ratio	End of Year Lives	(Column C) with 5.00% Interest	(Column G) with Average 7.24% Interest	Actual-to- Expected Ratio
	1992	17,324	0	0%	111	16,565	3,460	21%	110	0%	21%	0.00
	1993	557,528	112,935	20%	634	556,576	127,290	23%	664	20%	23%	0.86
	1994 1995	1,501,263 2,485,725	28,746 109,652	2% 4%	1,377 1,944	1,556,224 2,626,940	431,321 825,928	28% 31%	1,446 2,090	7% 6%	26% 29%	0.27 0.19
	1996	3,463,885	134,262	4%	2,689	3,655,699	1,213,762	33%	2,838	5%	31%	0.16
	1997	4,394,237	264,541	6%	3,003	4,557,379	1,550,641	34%	3,068	5%	32%	0.17
	1998	5,341,744	631,867	12%	3,666	5,238,873	1,842,618	35%	3,506	7%	32%	0.22
	1999 2000	6,829,900 8,941,708	1,469,714 1,172,992	22% 13%	4,764 6,200	6,315,324 7,989,544	2,175,807 2,546,851	34% 32%	4,387 5,580	11% 11%	33% 32%	0.33 0.35
	2001	11,912,872	2,210,887	19%	8,456	10,492,015	2,959,250	28%	7,606	13%	31%	0.33
	2002	16,102,548	4,131,980	26%	11,472	14,152,917	3,467,804	25%	10,303	16%	30%	0.53
Historical	2003	21,498,563	3,506,680	16%	17,713	18,850,587	4,189,633	22%	16,163	16%	28%	0.57
Experience	2004 2005	27,112,675 28,577,291	6,602,535 6,824,784	24% 24%	19,114 20,242	23,841,586 24,495,154	5,075,261 5,782,321	21% 24%	17,327 18,002	18% 19%	27% 26%	0.66 0.71
	2006	28,838,021	7,359,318	24% 26%	20,242	24,495,154	6,452,826	24% 27%	17,519	20%	26%	0.71
	2007	28,383,240	10,552,392	37%	20,146	23,121,105	7,118,474	31%	17,282	22%	27%	0.81
	2008	27,837,724	8,394,073	30%	19,941	22,245,491	7,783,650	35%	16,837	23%	28%	0.82
	2009 2010	26,881,835 25,544,191	11,313,758 15,723,015	42% 62%	19,482 18,494	21,096,208 19,836,480	8,413,116 9,005,281	40% 45%	16,173 15,500	24% 27%	28% 29%	0.86 0.92
	2010	24,603,117	13,541,344	55%	17,664	18,515,528	9,540,277	52%	14,878	29%	30%	0.92
	2012	25,248,567	17,141,023	68%	17,596	17,260,679	10,108,733	59%	14,699	31%	32%	0.98
	2013	24,384,255	14,626,127	60%	17,264	15,689,414	10,688,938	68%	14,145	32%	33%	0.99
	2014 2015	22,506,450 21,584,067	22,967,435 20,806,755	102% 96%	16,809 16,292	14,048,401 12,930,951	11,280,560 11,880,612	80% 92%	13,595 13,054	35% 38%	34% 35%	1.04 1.07
	2016	21,357,049	19,334,171	91%	15,800	11,987,427	12,477,661	92% 104%	12,419	39%	36%	1.07
	2017	22,583,348	20,688,725	92%	14,753	11,103,840	13,071,513	118%	11,811	41%	38%	1.09
	2018	31,032,913	20,353,300	66%	13,841	10,227,054	13,665,357	134%	11,225	42%	39%	1.08
	2019 2020	30,913,659 29,403,820	21,517,495 22,963,832	70% 78%	13,368 12,902	9,482,088 8,784,402	14,256,157 14,832,531	150% 169%	10,658 10,108	43% 44%	40% 41%	1.07 1.07
	2021	27,844,194	24,394,151	88%	12,434	8,115,800	15,406,878	190%	9,577	45%	43%	1.06
	2022	26,258,749	25,736,673	98%	11,964	7,468,255	15,975,430	214%	9,063	47%	44%	1.07 1.07
	2023	24,378,350	27,045,226	111%	11,495	6,733,253	16,534,812	246%	8,565	48%	45%	1.07
	2024 2025	22,514,244 20,961,536	28,386,826 29,732,623	126% 142%	11,026 10,558	6,043,030 5,475,192	17,067,285 17,573,477	282% 321%	8,083 7,617	50% 51%	46% 47%	1.07 1.08
	2026	19,521,016	31,110,143	159%	10,093	4,968,176	18,057,192	363%	7,167	53%	48%	1.00
Projected	2027	18,184,397	32,524,059	179%	9,631	4,514,355	18,522,411	410%	6,733	54%	49%	1.10
Future	2028	16,805,411	33,989,625	202%	9,174	4,060,850	18,956,201	467%	6,314	56%	50%	1.11
Experience (60 Years)	2029 2030	15,582,294 14,414,799	35,449,678 36,828,290	227% 255%	8,722 8,275	3,672,763 3,315,943	19,351,676 19,702,876	527% 594%	5,911 5,524	57% 59%	51% 52%	1.12 1.13
(60 Teals)	2031	13,296,068	38,320,299	288%	7,835	2,985,585	19,993,572	670%	5,152	61%	53%	1.13
	2032	12,222,121	39,906,539	327%	7,400	2,679,836	20,211,586	754%	4,796	62%	54%	1.15
	2033	11,196,397	41,294,287	369%	6,971	2,398,298	20,342,430	848%	4,455	64%	55%	1.17
	2034 2035	10,219,348 9,291,779	42,528,304 43,632,182	416% 470%	6,551 6,139	2,139,370 1,902,009	20,391,336 20,339,645	953% 1,069%	4,130 3,821	66% 67%	56% 56%	1.18 1.20
	2036	8,414,582	44,489,420	529%	5,737	1,685,080	20,170,560	1,197%	3,527	69%	57%	1.21
	2037	7,588,607	45,072,217	594%	5,346	1,487,391	19,884,616	1,337%	3,249	71%	58%	1.22
	2038	6,814,260	45,359,929	666%	4,967	1,308,096	19,493,671	1,490%	2,986	72%	58%	1.24
	2039 2040	6,091,626 5,420,469	45,399,463 45,089,432	745% 832%	4,600 4,248	1,146,276 1,000,696	19,007,851 18,430,215	1,658% 1,842%	2,738 2,506	74% 75%	59% 59%	1.25
	2041	4,800,652	44,530,891	928%	3,910	870,303	17,768,381	2,042%	2,289	76%	60%	1.27 1.28
	2042	4,231,786	43,632,878	1,031%	3,590	753,998	17,026,548	2,258%	2,086	78%	60%	1.29
	2043	3,712,865	42,483,318	1,144%	3,286	650,748	16,213,604	2,492%	1,897	79%	60%	1.30
	2044 2045	3,242,305 2,817,854	41,140,419 39,597,301	1,269% 1,405%	2,999 2,730	559,501 479,283	15,348,616 14,446,595	2,743% 3,014%	1,722 1,561	80% 81%	61% 61%	1.32
	2046-2050	9,173,643	168,070,583	1,832%	10,243	1,509,875	58,130,778	3,850%	5,799	85%	62%	1.33 1.37
	2051-2055	4,021,162	113,671,834	2,827%	6,054	634,353	36,722,123	5,789%	3,381	87%	62%	1.39
	2056-2060	1,624,306	67,465,499	4,153%	3,467	250,171	21,163,743	8,460%	1,880	87%	62%	1.40
	2061-2065 2066-2070	617,110 219,541	36,830,659 18,132,511	5,968% 8,259%	1,890 925	93,253 32,089	11,560,061 5,999,597	12,396% 18,697%	966 429	88% 88%	62% 63%	1.41 1.41
	2071-2075	71,513	7,646,541	10,692%	376	9,810	2,666,351	27,181%	150	88%	63%	1.41

Exhibit II

MedAmerica and Affinity Partners

Actual-to-Expected Experience by Policy Form Cohort and Benefit Period

Nationwide Experience

		Lifetim	e Loss Ratio with	Actual-to-Expected		
Policy Form		Before	After		Before	After
Cohort	Benefit Period	Increase	Increase	Expected	Increase	Increase
Prior to Series 11	All	97%	88%	66%	1.47	1.34
Series 11 Individual	All	117%	90%	58%	2.02	1.56
Series 11 Group	All	108%	82%	70%	1.56	1.18
All	Non-Lifetime	93%	78%	64%	1.46	1.22
All	Lifetime	153%	113%	59%	2.57	1.90
All	All	110%	88%	63%	1.75	1.41

Current Assumptions	Series 11 and Prior
Original Assumptions	Prior to Series 11
	Series 11

#### Morbidity

Expected claim costs are developed using the 2014 Milliman Long-Term Care Guidelines (Guidelines) with adjustments for individual vs. group underwriting selection and an all-lives exposure basis. The claim costs are further adjusted based on historical claim experience by policy form group, attained age, duration, and coverage type, to the extent credible. One year of retrospective improvement was applied to bring these assumptions forward to 2015 using scalars of 0.990 for females and 0.985 for males.

For Series 5, the original pricing expected nursing home incidence rates and continuance tables were developed from a number of sources, but primarily using data published by the Connecticut Department of Health Services. The 1985 National Nursing Home Survey was also used. Selected frequencies were adjusted up for up to the first 12 years following issue to reflect the favorable morbidity expected as a result of the underwriting process. Frequency and length of treatment of the home care and adult day care benefit were based on the 1982 National Long-Term Care Survey. They are adjusted to reflect the effects of elimination periods, policy maximums, and eligibility standards.

For Series 8 and 9, the Institutional Benefit rates were developed using source data from the 1977 and 1985 National Nursing Home Surveys. The Home and Community Benefits were developed using source data from the 1989 National Long-Term Care Survey. Adjustments were made to the source data to reflect the selection effect of underwriting and the non-duplication of benefits with other payment sources.

The original pricing expected nursing home and home care incidence rates and continuance tables were taken from the 1997 *Guidelines* and adjusted for MedAmerica's experience available at the time this rate schedule was developed relative to the *Guidelines*. All values were adjusted to reflect the effects of product types, elimination periods, policy maximums, and the eligibility standards.

Current Assumptions	Series 11 and Prior			
Original Assumptions	Prior to Series 11			
	Series 11 Individual			
	Series 11 Group			

#### Mortality

1994 Group Annuitant Mortality (GAM) Static gender-distinct table with 21 years of retrospective improvement applied to bring this table forward to 2015 using scalars of 0.900 for females and 0.810 for males. These mortality rates are further adjusted based on historical mortality experience by individual/group, issue age band, and duration. Tables providing these adjustment factors are provided in Section 5 of the actuarial memorandum.

Series 5 policy forms used the 1965-70 US Society of Actuaries Basic Mortality Table without selection.

Series 8 and Series 9 policy forms used the 1980 Commissioners Standard Ordinary Basic Mortality Tables assuming a gender mix of 60% female and 40% male and without selection.

1980 Commissioners Standard Ordinary Basic Mortality Table.

Premier Group policy forms use the 1980 Commissioners Standard Ordinary Basic Mortality Table. TNSE policy forms use the 1983 GAM Static table.

Current Assumptions	Series 11 and Prior
------------------------	---------------------

# Lapse Rates

Voluntary lapse rates (excludes benefit expiry) vary by policy duration and policy form group.

Lif	etime-Pay	Lapse Ra	tes
	Prior to	Series 11	Series 11
Duration	Series 11	Individual	Group
1	16.50%	8.50%	6.50%
2	8.50%	4.00%	6.00%
3	5.00%	2.75%	4.00%
4	3.50%	2.00%	3.50%
5	2.00%	1.50%	3.00%
6	1.50%	1.25%	2.50%
7	1.50%	1.25%	2.00%
8	1.50%	1.00%	1.50%
9	1.50%	0.75%	1.30%
10+	1.00%	0.60%	1.30%

For the 10-pay option, a reduction of 65% of these lapse rates is assumed for durations 1 to 4, a reduction of 70% of these lapse rates is assumed for durations 5 to 8, and 0% lapse thereafter. For the 20-pay option, a reduction of 50% of these lapse rates is assumed for durations 1 to 8, a reduction of 75% of these lapse rates is assumed for durations 9 to 15, and 0% lapse thereafter.

#### Lapse Rates

Lapse rates vary by policy form series, duration, premium payment option, and issue age.

					Series 5 La	apse Rates	S						
		Issue Age											
Duration	<61	61	62	63	64	65	66	67	68	69	70+		
1	20.00%	19.00%	18.00%	17.00%	16.00%	15.00%	14.00%	13.00%	12.00%	11.00%	10.00%		
2	15.00%	14.00%	13.00%	12.00%	11.00%	10.00%	9.00%	8.00%	7.00%	6.00%	5.00%		
3	10.00%	9.40%	8.80%	8.20%	7.60%	7.00%	6.40%	5.80%	5.20%	4.60%	4.00%		
4	8.00%	7.60%	7.20%	6.80%	6.40%	6.00%	5.60%	5.20%	4.80%	4.40%	4.00%		
5	6.00%	5.70%	5.40%	5.10%	4.80%	4.50%	4.20%	3.90%	3.60%	3.30%	3.00%		
6	5.00%	4.80%	4.60%	4.40%	4.20%	4.00%	3.80%	3.60%	3.40%	3.20%	3.00%		
7	5.00%	4.80%	4.60%	4.40%	4.20%	4.00%	3.80%	3.60%	3.40%	3.20%	3.00%		
8	5.00%	4.80%	4.60%	4.40%	4.20%	4.00%	3.80%	3.60%	3.40%	3.20%	3.00%		
9+	5.00%	4.70%	4.40%	4.10%	3.80%	3.50%	3.20%	2.90%	2.60%	2.30%	2.00%		

Serie	s 8 Lapse	Rates					
	Issue Age						
Duration	ation <85						
1	15.00%	12.00%					
2	10.00%	8.00%					
3	8.00%	6.40%					
4	6.00%	4.80%					
5+	5.00%	4.00%					

	Series 9 Lapse Rates												
		Issue Age											
Duration	<76	<76											
1	15.00%	14.70%	14.40%	14.10%	13.80%	13.50%	13.20%	12.90%	12.60%	12.30%	12.00%		
2	10.00%	9.80%	9.60%	9.40%	9.20%	9.00%	8.80%	8.60%	8.40%	8.20%	8.00%		
3	8.00%	7.84%	7.68%	7.52%	7.36%	7.20%	7.04%	6.88%	6.72%	6.56%	6.40%		
4	6.00%	5.88%	5.76%	5.64%	5.52%	5.40%	5.28%	5.16%	5.04%	4.92%	4.80%		
5+	5.00%	4.90%	4.80%	4.70%	4.60%	4.50%	4.40%	4.30%	4.20%	4.10%	4.00%		

Policy Form Series 8 and 9 issued business under a group trust in a small number of jurisdictions. The original pricing assumptions for claim costs, mortality, and interest did not vary between individual and group trust business but the original pricing voluntary termination rates did. The Series 8 and 9 group trust original pricing voluntary termination rates are shown in the following table:

				Series 8	and 9 Gro	up Trust							
		Issue Age											
Duration	<25	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65+			
1	16.00%	15.00%	13.50%	12.00%	11.00%	10.00%	8.00%	6.00%	4.00%	3.00%			
2	11.00%	10.00%	8.50%	7.00%	7.00%	7.00%	5.50%	4.50%	3.50%	3.00%			
3	7.00%	6.00%	6.00%	6.00%	6.00%	6.00%	5.00%	4.50%	3.00%	2.00%			
4	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	4.50%	3.00%	2.00%			
5	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	4.50%	3.00%	2.00%			
6	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%	4.50%	3.00%	2.00%			
7 +	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%			

The original pricing voluntary lapse rates were expected to be 0.0% for durations 10 and later for policyholders who selected the 10-pay option.

Original Assumptions Prior to Series 11

# Lapse Rates

Lapse rates vary by duration, premium payment option, and issue age. Lapse rates for the lifetime payment option are provided in the tables below for Series 11 Individual, Premier Group, and TNSE policy forms.

	Series 11 Individual												
		Lapse Rates by Issue Age											
Duration	<60	<60 60-64 65-69 70-74 75-79 80+											
1	10.00%	11.00%	12.00%	12.00%	12.00%	12.00%							
2	7.00%	7.00%	7.00%	6.00%	4.00%	2.00%							
3	5.00%	4.00%	3.00%	3.00%	3.00%	2.00%							
4	3.00%	3.00%	2.00%	2.00%	2.00%	2.00%							
5	3.00%	2.00%	2.00%	2.00%	2.00%	2.00%							
6+	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%							

Premier Group						
		Lapse Rates by Issue Age				
Duration	<60 60-64 65-69 70-74 75-79 80+				80+	
1	10.00%	11.00%	12.00%	12.00%	12.00%	12.00%
2	7.00%	7.00%	7.00%	6.00%	4.00%	2.00%
3	5.00%	4.00%	3.00%	3.00%	3.00%	2.00%
4	3.00%	3.00%	2.00%	2.00%	2.00%	2.00%
5	3.00%	2.00%	2.00%	2.00%	2.00%	2.00%
6+	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%

	TNSE				
		Lapse F	Rates by Is	sue Age	
Duration	<60	60-64	65-69	70-79	80+
1	5.00%	5.00%	5.00%	4.00%	3.00%
2	5.00%	5.00%	5.00%	4.00%	3.00%
3	5.00%	4.00%	3.00%	3.00%	3.00%
4	4.00%	4.00%	3.00%	3.00%	3.00%
5	4.00%	3.00%	3.00%	3.00%	3.00%
6+	3.00%	3.00%	3.00%	3.00%	3.00%

For the 10-pay option, a reduction of 50% of these lapse rates is assumed for durations 1 to 6, and 0% lapse thereafter. For the 20-pay option, a reduction of 50% of these lapse rates is assumed for durations 1 to 13, and 0% lapse thereafter.

Original Series 11

Current Assumptions	Series 11 and Prior	
Original Assumptions	Series 11 and Prior	

|--|

Benefit expiry rates reflect assumed policy termination due to exhaustion of benefits on limited benefit period policies. The rates are based on the *Guidelines* with adjustments for historical benefit expiry experience and vary by gender, benefit period, and attained age. A table containing the benefit expiry rates is provided in Section 5 of the actuarial memorandum.

Benefit expiry was not separated from the lapse assumption.

	Current Assumptions	Series 11 and Prior	
		Prior to Series 11	
A	Original Assumptions	Series 11 Individual	
		Series 11 Group	

	Interest Rate
5.00%	

Series 5 policy forms used 7.10% and Series 8 and 9 policy forms used 7.50%.

7.50%

Premier Group policy forms used 7.50% and TNSE policy forms used 6.00%.

Current Assumptions	Series 11 and Prior	
Original Assumptions	Series 11 and Prior	

# Improvement

Annual improvement in the mortality and morbidity assumptions is assumed for 15 years starting in 2016. Annual mortality improvement is assumed to be 0.5% and 1.0% for females and males, respectively. Annual morbidity improvement is assumed to be 1.0% and 1.5% for females and males, respectively.

No mortality or morbidity improvement was assumed.

#### **Exhibit IV**

# MedAmerica and Affinity Partners Nationwide Experience Restated to No Prior Rate Increases Impact of Changing from Pricing to Current Assumptions Series 11 and Prior Policy Forms

Scenario	Lifetime Loss Ratio	Impact of Each Assumption on the Lifetime Loss Ratio <sup>[1]</sup>	Increase Needed to Produce Lifetime Loss Ratio Expected in Pricing <sup>[1][2]</sup>
Original Pricing Assumptions	63%	N/A	N/A
Historical Experience through 2015 & Projections			
with Original Pricing Assumptions	69%	10%	103%
Historical Experience through 2015 & Projections			
with Prior Assumptions except for Current:			
Morbidity	69%	0%	4%
Mortality	83%	21%	192%
Voluntary Lapse and Benefit Expiry	72%	5%	47%
Interest	88%	29%	223%
Improvement <sup>[3]</sup>	64%	-7%	-41%
Historical Experience through 2015 & Projections			
with All Current Most Likely Assumptions <sup>[4]</sup>	118%	89%	528%

<sup>[1]</sup> Isolates the impact on the lifetime loss ratio/needed increase due to changes in each projection assumption. To isolate these changes, these rows show the increase impact/needed increase relative to a lifetime loss ratio of 69% (i.e., actual historical experience with projections using pricing assumptions). However, the "Historical Experience through 2015 & Projections with Original Pricing Assumptions" row is calculated with regard to 63% to show the isolated impact of historical deviations from that expected based on original pricing from inception.

<sup>[2]</sup> Calculated without regard to CBUL, RBO, adverse selection, and higher waiver claims due to the needed rate increase.

<sup>[3]</sup> As a modeling simplification, the isolated impact of improvement on the lifetime loss ratio was approximated by removing the improvement assumption from a projection based on all current assumptions.

<sup>[4]</sup> The lifetime loss ratios for each change in the rows above do not reflect any synergy of the changes. As a result, compositing across rows will not equal the value in the last row, which is calculated relative to 63% and captures all changes in unison.

# Exhibit V Demonstration that the Requested Cumulative Rate Increase Passes the 58%/85% Loss Ratio Minimum MedAmerica and Affinity Partners' Nationwide Experience with Prior Approved Increases Series 11 and Prior Policy Forms

Accumulated value of initial earned premium	561,186,775 x	58%	=	325,488,330		
2a Accumulated value of earned premium 2b Accumulated value of prior premium rate schedule increases (2a - 1)	579,746,867 18,560,092 x	85%	=	15,776,078		
3 Present value of future projected initial earned premium	130,305,350 x	58%	=	75,577,103		
4a Present value of future projected premium 4b Present value of future projected premium in excess of the projected initial earned premiums (4a - 3)	309,359,645 179,054,295 x	85%	=	152,196,151		
5 Lifetime Earned Premium Times Prescribed Factor: Sum of 1, 2b, 3, and 4b				569,037,662		
6a Accumulated value of incurred claims without the inclusion of active life reserves 6b Present value of future projected incurred claims without the inclusion of active life reserves				220,537,499 706,064,111		
7 Lifetime Incurred Claims with Rate Increase: Sum 6a and 6b				926,601,610		
8 Test: 7 is not less than 5				Pass		
All values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue, which ranges from 3.5% to 5.5%. Future projected initial earned premium schedule (i.e., without the requested rate increase) reflects the assumed impact of CBUL and RBO. The future projected incurred claims (item 6b) were increased by 14% to reflect assumptions with moderately adverse experience.						

Actuarial Memorandum Exhibits

The assumptions for mortality, voluntary lapse, benefit expiry, and morbidity were developed by Milliman based on historical experience. Where actual experience had low credibility or did not exist, industry experience was also used. The experience used to develop these assumptions includes historical experience of MedAmerica Insurance Company (MAPA); MAPA's two sister companies, MedAmerica Insurance Company of Florida (MAFL) and MedAmerica Insurance Company of New York (MANY) (MAPA, MAFL, and MANY collectively referred to as MedAmerica); and MedAmerica's affinity partners that issued the same products. For persistency, policy termination experience through December 31, 2015 was used, except to develop the limited-pay voluntary lapse assumption, which used experience through March 31, 2015. For morbidity, claim experience through December 31, 2014 was used. The methodology used to develop these assumptions is provided below.

### Persistency

The assumptions for mortality and lifetime-pay voluntary lapse were developed based on detailed historical experience through December 31, 2015 for MedAmerica's organic (including affinity partners) and acquired business. For the acquired business, experience prior to acquisition was excluded as it predates MedAmerica's administration of the block.

The benefit expiry assumption was developed using the 2014 Milliman Long-Term Care Guidelines (Guidelines) with adjustments based on MedAmerica's actual benefit expiry experience through December 31, 2015 on its organic business.

Mortality Durational Factors for Individual Policies

Exhibit A-1a supports the individual business mortality assumption and provides the following information for all companies and products (both individual and group) combined, but separately for issue age bands (i) 75 and older, (ii) 70 to 74, (iii) 65 to 69, and (iv) 60 to 64:

- Exposure that reflects a full year of exposure for each death and the length of time a covered life is exposed
  to the risk of death during the year for each life that does not die.
- Mortality rates for actual, expected, and an additional standard table for comparison. All of these rates were brought forward to 2015 for consistency with the basis of the expected table by applying mortality improvement factors that reflect annual improvement of 0.5% for females and 1.0% for males.
  - Actual mortality rates equal the number of deaths divided by exposure. The number of deaths includes a scalar to capture improvement between the year of death and 2015. For example, if 10 males died in 2010, then the number of deaths (10) would be multiplied by 5 years of improvement (0.951).
  - 2015GAM mortality rates equal 94GAM with 21 years of improvement, which results in scalars of 0.900 for females and 0.810 for males. These are the expected mortality rates to which the factors in Section 5 of the actuarial memorandum are applied.
  - 2015IAM is equal to 2012 Individual Annuity Mortality Period (2012IAM) standard table mortality rates with 3 years of improvement (scalars of 0.985 for females and 0.970 for males).
- Ratios of actual and standard table mortality rates to the 2015GAM expected (A:E) mortality rates.
- Credibility percentage based on the number of deaths (with improvement scalars described above) and the credibility measure described at the end of this appendix.
- A:E ratio that is credibility weighted with the two standard table options for a complement.
- Smoothed durational factors that correspond to that shown in Section 5 of the actuarial memorandum.

We developed the smoothed factors by issue age band and duration. We started with the older issue ages to develop an ultimate factor and then worked backward to younger issue age bands, making experience adjustments for the first 20 durations. In developing these experience adjustments, we considered the A:E ratios, level of credibility, whether in the select or ultimate period, and A:E credibility-weighted ratios.

An ultimate level of 105% of 2015GAM was assumed based on the combined experience of issue ages 70 and older for attained ages older than 95 to the extent credible. For the first 20 durations, the factors were pegged for the midpoint of a quinquennial durational band and then interpolated in between to develop smoothed factors. The smoothed factors were determined such that the bands of quinquennial durations reproduced the actual experience, to the extent credible.

Theoretical adjustments are made, following the diagonal, according to the adjustments made for older issue age bands to maintain mortality relationships across attained ages. For example, we assume an 85% factor for attained age 80, which appears in duration 18 for issue age 62 and duration 23 for issue age 57 as shown in Section 5 of the actuarial memorandum; following along this diagonal the assumption is consistent.

Exhibit A-1b provides similar information as Exhibit A-1a for individual business only with issue ages under 60. For issue ages under 60, the experience was split between individual and group because there is a material amount of group experience under 60. Mortality can differ between individual and group business because of adverse selection associated with group underwriting.

### Mortality Durational Factors for Group Certificates

Exhibit A-1c supports the group business mortality assumption and provides exposure, actual and expected mortality rates, mortality A:E ratios, credibility percent, and smoothed scalars. The expected mortality rates include the individual durational mortality factors described above. The smoothed scalars were developed based on group products for issue ages under 60 only because it captures most of the group experience. We did not analyze group experience for other issue ages. These scalars are applied to the individual mortality durational factors, but capped at 105%, to produce the group mortality durational factors shown in Section 5 of the actuarial memorandum.

### Lifetime-Pay Voluntary Lapse Rates

Exhibit A-2a provides total exposure, composite termination rates, expected mortality rates, derived voluntary lapse rates, credibility percent, and smoothed voluntary lapse rates for Prior to Series 11 policies by duration. Exhibit A-2b and Exhibit A-2c provide similar information for Series 11 Individual and Series 11 Group policies, respectively.

In general, the smoothed voluntary lapse rates were set in such a way that the combined duration smoothed rates were close to the derived voluntary lapse rates (see the rows at the bottom of the exhibits). The smoothed voluntary lapse rates in the early durations were chosen to reproduce actual history, to the extent possible, so that the transition from historical to projected policy persistency was smooth. In developing the ultimate voluntary lapse rate, the level of credibility of the actual voluntary lapse experience and the experience of other form groups were considered, as applicable. The degree of closeness of the smoothed voluntary lapse rate compared to actual experience depends on the level of credibility.

The actual composite (mortality and voluntary lapse) termination rates were calculated by duration as follows:

Annualized Composite Termination Rate = Number of Deaths and Voluntary Lapses during the Year

Number of Lives Exposed during the Year

A death or voluntary lapse (excluding benefit expiry) was assigned to the duration in which it occurred, or the preceding duration, if the termination was on the anniversary date. Each death or voluntary lapse contributes 1.0 to the numerator and a full year to the denominator. For lives whose benefits expire or do not terminate, the number of lives exposed to termination is based on the length of time a covered life is exposed to the risk of termination due to death or voluntary lapse during the year. This calculation logic is consistent with that used in the LTC Insurance Persistency Experience reports sponsored by LIMRA International and the SOA LTC Experience Committee.

The expected mortality rate assumes the gender-distinct 2015GAM table with the durational factors shown in Section 5 of the actuarial memorandum applied by duration.

The derived voluntary lapse rate is then calculated according to the following formula:

Derived Voluntary Lapse Rate = 1 - 1 - Composite Termination Rate 1 - Expected Mortality Rate

#### Limited-Pay Voluntary Lapse Rates

The algorithm for the limited-pay options is similar to that used in original pricing. The smoothed lapse rates are a scalar of the lifetime-pay lapse rates. Only 23% of the in-force policies on these forms have a limited-pay option and thus the impact of these assumptions on the projections is assumed to be immaterial.

For the 10-pay and 20-pay options, the scalars were developed from a comparison of the lifetime-pay derived lapse rates to the limited-pay option's derived lapse rates based on MedAmerica and its affinity partners' experience on all

products combined. The relationships derived from this analysis were used to develop the smoothed lapse assumptions for the 10- and 20-pay options shown in Section 5 of the actuarial memorandum.

#### Benefit Expiry

Benefit expiry rates reflect assumed policy lapses due to exhaustion of benefits based on the 2014 *Guidelines* with adjustments for historical benefit expiry experience and vary by attained age, gender, and benefit period. Policies with lifetime benefits do not have an expiry assumption (i.e., rate of 0%).

We compared MedAmerica's actual benefit expiry experience through December 31, 2015 to that expected by the 2014 *Guidelines*. We developed adjustment factors by attained age based on the experience of a subset of MedAmerica's organic business, which included the Series 11 and Prior business. Factors were developed by quinquennial attained age band and then interpolated to produce scalars for each attained age. These scalars were then applied to the benefit expiry rates developed by the 2014 *Guidelines* in order to produce the final benefit expiry assumptions shown in Section 5 of the actuarial memorandum.

Exhibit A-3 provides exposure, actual and expected benefit expiry rates, A:E ratios, credibility percent, credibility-weighted A:E ratios, and smoothed adjustment factors. The exposure used reflects a full year of exposure for each benefit expiry and the length of time a covered life is exposed to the risk of benefit expiry during the year for each life that does not expire benefits.

#### Morbidity

The claims costs were developed using the 2014 *Guidelines*. A:E experience analyses were performed to develop most likely (with no explicit margin) morbidity experience adjustments to be applied to the 2014 *Guidelines* claim costs. The experience used includes historical experience for all products of MedAmerica, its affinity partners, and any acquired business from 2004 through 2014, with runout through June 2015. The claim costs were then further adjusted based on historical claim experience by policy duration, attained age, and coverage-type, to the extent credible.

A:E adjustment factors were developed using a complex and proprietary Excel-based model. Adjustments were developed by the following parameters: policy duration, attained age, coverage type, group/individual, benefit payment type, company, and product. The adjustment factors were calculated using an algorithm that simultaneously and iteratively updates the adjustment factors until the adjusted expected incurred claims match actual incurred claims, to the extent credible. The adjusted expected incurred claims equal the 2014 *Guidelines* (with adjustments for historical improvement) multiplied by the A:E adjustment factors. The iterative process normalizes the adjustments for each parameter because the adjusted expected incurred claims capture the adjustments made for the other characteristics and thus normalizes the underlying mix differences.

Exhibit A-4a provides separate A:E adjustment factors for the Prior to Series 11, Series 11 Individual, and Series 11 Group blocks after multiplying the appropriate combination of factors for policy duration, attained age, and coverage type.

Exhibit A-4b provides an indication of the goodness of fit for each product. Exhibit A-4b provides the credibility and ratio of actual to adjusted expected incurred claims by policy duration band and attained age band. The credibility and ratio's numerator (actual incurred claims) is shown for the Prior to Series 11, Series 11 Individual, and Series 11 Group blocks' separate experience. The ratio's denominator (adjusted expected incurred claims) is equal to the unadjusted expected incurred claims (2014 *Guidelines*) multiplied by the A:E adjustment factors. The actual-to-adjusted expected ratio provides an indication of the goodness of fit of the assumption relative to actual experience, where a ratio close to 1.00 is a good fit. The actual-to-adjusted expected ratio is close to 1.00 where the experience is fully credible. As can be seen from the Total row (shaded grey), the actual to adjusted expected ratio is close to 1.00. The goodness-of-fit test by attained age band includes only experience for durations seven and later to reduce the impact of the selection period.

#### **Improvement**

For projected mortality improvement, levels of 0.5% and 1.0% are assumed for 15 years beginning in calendar year 2016 for females and males, respectively. The Society of Actuaries (SOA) June 2011 study, *Global Mortality Improvement Experience and Projection Techniques*, provides most-likely mortality improvement assumptions for the period 2011 to 2025 by gender and attained age, for individual annuitants and the general population. For individual annuitants, the average annual improvement rates for males and females are approximately 1.5% and 1.0%, respectively. These rates were about 25 basis points higher than that for the general population. Based on this

study, a reasonable range for mortality improvement is 0.0% to 1.5% for males and 0.0% to 1.0% for females for 10 to 20 years.

For projected morbidity improvement, levels of 1.0% and 1.5% are assumed for 15 years beginning in calendar year 2016 for females and males, respectively. This assumption is reasonable based on the SOA July 2016 study, *Long Term Care Morbidity Improvement Study: Estimates for the Non-Insured U.S. Elderly Population Based on the National Long Term Care Survey 1984-2004.* This study reported population annual morbidity improvement of 2.3% for unisex, 2.5% for males, and 2.1% for females. The SOA July 2016 study uses population data, so it is uncertain how well these findings will translate to an insured population. The SOA June 2011 study suggests that an annuitant cohort has more mortality improvement over the general population, so it is possible that this could be true for morbidity as well. Based on these studies, a reasonable range for morbidity improvement is between 0.0% to 2.5% for males and 0.0% to 2.1% for females for 10 to 20 years.

#### Rate Increase Dependent Assumptions

At the time of a rate increase, insureds have options to elect a contingent benefit upon lapse (CBUL) or reduced benefit options (RBO). Adverse selection is assumed relative to CBUL elections. In determining the justified rate increase amounts, rate increase dependent assumptions were also developed. Very little industry data exists to help determine these assumptions, especially for the magnitude of rate increases that are requested. These insured behavior assumptions are provided below, and are based on MedAmerica's actual CBUL/RBO election experience to the extent applicable, assumptions for rate increase filings of other carriers in the LTC industry, and actuarial judgment.

#### Contingent Benefit Upon Lapse Election

Based on the average rate increase requests nationwide, we assume a CBUL election rate of 8% for the rate increase for non-lifetime benefit periods and 12% for lifetime benefit periods. No CBUL elections are assumed for limited-pay policies.

#### Reduced Benefit Options

It is assumed that there will be an approximate 7.5% reduction to premium and benefits due to RBO elections for non-lifetime benefit period policies and an approximate 19% reduction to premium and benefits due to RBO elections for lifetime benefit period policies. These assumed reductions to premium and benefits due to RBO elections were derived from actual RBO election rates based on the combined experience of MedAmerica and its affinity partners following a prior rate increase on this and similar blocks of business along with actuarial judgment. We assume that those electing RBO will reduce their benefits so that premiums after the increase are closer to those before the increase. We assume that the percent reduction in premium corresponds to an equivalent percent reduction in claims. Based on the nationwide average rate increase requested on these policy forms, we assume 15% of non-lifetime benefit period policies and 25% of lifetime benefit period policies will elect RBO. The reduction to premium and claims can then be determined as follows:

Reduction to premium and claims due to the election of RBO

= 1 – (Average premium level after the rate increase with RBO election / Premium level after the full rate increase without any RBO election), where

Average premium level after the rate increase with RBO election

= weighted average premium level of those assumed to elect RBO with those assumed to accept the full rate increase

#### Adverse Selection

The 2% to 3% increase to morbidity due to adverse selection was developed from the following formula and actuarial judgment. We assume that at the time of the rate increase, insureds that elect a CBUL will be selective in that their relative morbidity is 25% lower than that of the remaining pool.

PoolMorb = AdvSelMorb x (1 - CBUL) + [(1 - 25%) x AdvSelMorb] x CBUL, where

PoolMorb = morbidity of the pool before the rate increase = 1.0

AdvSelMorb = adverse morbidity of the remaining pool after the rate increase due to selective lapses

CBUL = percentage of policies that elect CBUL

Solving the above for the adverse selection component results in the following formula:

```
Adverse Selection = 1 / (1 - 25\% \times CBUL)
1.02 ~ 1 / (1 - 25\% \times 8\%) for non-lifetime benefit period policies
1.03 ~ 1 / (1 - 25\% \times 12\%) for lifetime benefit period policies
```

#### Credibility

The methodology employed to develop the assumptions considers actual historical experience and its associated credibility. The credibility percentage for each assumption was determined as (Number of Events / Credibility Threshold)<sup>1/2</sup>, with events defined as deaths, voluntary lapses, benefit expiries, or claims. A credibility standard of a 90% confidence interval for the number of events with an error of plus or minus 7.5% was chosen. Based on these parameters, 481 events is the criterion for full credibility.

Exhibit A-1a Actual-to-Expected (A:E) Mortality Experience through December 31, 2015 All Products

			Mortality Rate		Ratios to	2015GAM		A:E Credibility-	Weighted with:	Smoothed
		Actual	2015GAM	2015IAM	Actual	2015IAM	Credibility	2015GAM	2015IAM	Durational
Duration	Exposure	(A)	(E)	(X)	(A:E)	(X:E)	Percent	(E:E=1.00)	(X:E)	Factors
	'				. ,	, ,	I.	1 ( /	. , , , ,	
	Issue Age 75+									
1-5	24,998	1.8%	4.4%	3.1%	0.40	0.70	95%	0.43	0.41	0.41
6-10	20,553	5.0%	7.0%	5.5%	0.71	0.78	100%	0.71	0.71	0.71
11-15	11,268	10.1%	10.5%	8.8%	0.96	0.84	100%	0.96	0.96	0.96
16-20	3,330	16.3%	16.1%	14.2%	1.02	0.88	100%	1.02	1.02	1.04
21-25	415	25.3%	22.2%	20.6%	1.14	0.93	47%	1.07	1.03	1.05
26+	25	7.8%	32.1%	30.8%	0.24	0.96	6%	0.95	0.91	1.05
21+	440	24.3%	22.8%	21.2%	1.07	0.93	47%	1.03	0.99	1.05
All	60,589	5.4%	7.2%	5.7%	0.75	0.79	100%	0.75	0.75	0.75
							•	•	•	
					lssue Ages 70					
1-5	39,706	0.9%	2.2%	1.4%	0.41	0.64	87%	0.49	0.45	0.40
6-10	38,186	2.4%	3.7%	2.5%	0.66	0.67	100%	0.66	0.66	0.65
11-15	27,286	4.9%	6.0%	4.4%	0.83	0.74	100%	0.83	0.83	0.84
16-20	10,157	9.1%	9.4%	7.7%	0.98	0.82	100%	0.98	0.98	0.98
21-25	2,029	14.6%	14.3%	12.3%	1.02	0.86	78%	1.02	0.99	1.04
26+	138	25.8%	20.4%	18.6%	1.27	0.91	27%	1.07	1.01	1.05
21+	2,167	15.3%	14.7%	12.7%	1.04	0.87	83%	1.03	1.01	1.04
All	117,501	3.3%	4.4%	3.2%	0.75	0.73	100%	0.75	0.75	0.75
	07.004	0.00/	4.40/		Issue Ages 65		000/		2.11	
1-5	67,094	0.6%	1.4%	0.9%	0.42	0.65	90%	0.48	0.44	0.40
6-10	65,409	1.4%	2.2%	1.4%	0.64	0.64	100%	0.64	0.64	0.65
11-15	50,103	2.9%	3.7%	2.4%	0.78	0.66	100%	0.78	0.78	0.79
16-20	23,101	5.3%	5.9%	4.3%	0.90	0.74	100%	0.90	0.90	0.90
21-25	6,829	9.5%	9.3%	7.6%	1.03	0.82	100%	1.03	1.03	0.99
26+	533	13.8%	13.6%	11.6%	1.01	0.86	39%	1.01	0.92	1.04
21+	7,362	9.8%	9.6%	7.9%	1.03	0.82	100%	1.03	1.03	0.99
All	213,069	2.2%	3.0%	2.0%	0.75	0.69	100%	0.75	0.75	0.74
					Issue Ages 60	64				
1-5	93,335	0.3%	0.9%	0.6%	0.41	0.72	82%	0.51	0.46	0.39
6-10	95,335 85,284	0.3%	1.4%	0.0%	0.41	0.65	100%	0.57	0.40	0.59
11-15	58,636	1.5%	2.3%	1.5%	0.57	0.65	100%	0.68	0.68	0.59
16-20	27,386	3.2%	3.8%	2.5%	0.85	0.67	100%	0.85	0.85	0.83
21-25	9,435	5.5%	6.1%	4.5%	0.90	0.75	100%	0.90	0.90	0.90
26+	782	9.5%	9.1%	7.5%	1.05	0.82	39%	1.02	0.91	0.97
21+	10,217	5.8%	6.3%	4.8%	0.92	0.76	100%	0.92	0.92	0.91
All	274,857	1.2%	1.8%	1.2%	0.68	0.68	100%	0.68	0.68	0.67
All	217,001	1.4/0	1.070	1.4 /0	0.00	0.00	10070	0.00	0.00	0.01

Exhibit A-1b
Actual-to-Expected (A:E) Mortality Experience through December 31, 2015
Individual Products

			Mortality Rate		Ratios to	2015GAM		A:E Credibility-	Weighted with:	Smoothed
		Actual	2015GAM	2015IAM	Actual	2015IAM	Credibility	2015GAM	2015IAM	Durational
Duration	Exposure	(A)	(E)	(X)	(A:E)	(X:E)	Percent	(E:E=1.00)	(X:E)	Factors
_										
					Issue Age <	60				
1-5	213,822	0.1%	0.3%	0.2%	0.39	0.86	66%	0.59	0.55	0.38
6-10	134,800	0.3%	0.5%	0.4%	0.54	0.77	88%	0.59	0.56	0.54
11-15	57,646	0.6%	0.9%	0.7%	0.61	0.69	83%	0.67	0.62	0.60
16-20	24,577	1.1%	1.5%	1.0%	0.70	0.67	74%	0.78	0.69	0.70
21-25	9,193	1.7%	2.4%	1.6%	0.70	0.67	57%	0.83	0.68	0.79
26+	759	2.9%	4.4%	3.1%	0.65	0.72	21%	0.93	0.70	0.87
21+	9,952	1.8%	2.6%	1.7%	0.69	0.68	61%	0.81	0.68	0.80
All	440,797	0.3%	0.6%	0.4%	0.56	0.75	100%	0.56	0.56	0.57

Exhibit A-1c
Actual-to-Expected (A:E) Mortality Experience through December 31, 2015
Group Products

		Actual	Expected			
		Mortality	Mortality	Mortality	Credibility	Smoothed
Duration	Exposure	Rate	Rate <sup>[1]</sup>	A:E	Percent	Scalars

	Issue Age <60						
1-5	120,598	0.2%	0.1%	2.00	65%	2.00	
6-10	109,681	0.3%	0.2%	1.48	85%	1.50	
11-15	71,689	0.5%	0.4%	1.20	83%	1.20	
16-20	25,556	0.7%	0.6%	1.15	59%	1.15	
21-25	11,926	0.8%	0.9%	0.93	45%	1.10	
26-30	305	1.3%	1.2%	1.06	9%	1.05	
31+	0	N/A	N/A	N/A	0%	1.00	

<sup>[1]</sup> Includes the durational adjustment factors developed for individual business.

Exhibit A-2a
Derived Lifetime-Pay Voluntary Lapse Experience through December 31, 2015
Prior to Series 11 Policy Forms

		Composite	Expected	Derived		Smoothed
		Termination	Mortality	Lapse	Credibility	Lapse
Duration	Exposure	Rates	Rates	Rates	Percent	Rates
1	5,409	16.9%	0.6%	16.4%	100%	16.50%
2	4,493	9.3%	0.9%	8.4%	89%	8.50%
3	4,076	6.5%	1.3%	5.2%	68%	5.00%
4	3,810	5.3%	1.5%	3.6%	55%	3.50%
5	3,607	4.0%	1.9%	2.0%	41%	2.00%
6	3,457	3.1%	2.0%	0.9%	34%	1.50%
7	3,345	3.7%	2.3%	1.2%	29%	1.50%
8	3,209	4.6%	2.5%	1.8%	33%	1.50%
9	3,047	4.0%	2.8%	1.0%	30%	1.50%
10	2,913	4.5%	3.1%	1.2%	31%	1.00%
11	2,765	5.4%	3.4%	1.8%	27%	1.00%
12	2,604	5.2%	3.7%	1.3%	25%	1.00%
13	2,447	5.5%	3.9%	1.4%	22%	1.00%
14	2,289	5.6%	4.2%	1.2%	20%	1.00%
15	2,087	4.9%	4.6%	0.2%	16%	1.00%
16	1,858	5.7%	5.0%	0.6%	18%	1.00%
17	1,504	6.8%	5.5%	1.3%	18%	1.00%
18	1,104	6.6%	6.0%	0.5%	9%	1.00%
19	710	7.2%	6.6%	0.5%	8%	1.00%
20	422	8.8%	7.1%	1.7%	6%	1.00%
21	224	8.9%	7.5%	1.4%	6%	1.00%
22	99	12.1%	8.9%	3.5%	6%	1.00%
23	28	7.2%	10.6%	-3.8%	5%	1.00%
24	1	0.0%	12.6%	-14.4%	0%	1.00%
1-3	13,978	11.4%	0.9%	10.5%	100%	10.6%
4-6	10,875	4.1%	1.8%	2.2%	77%	2.4%
7-9	9,601	4.1%	2.5%	1.4%	53%	1.5%
5+	37,720	4.8%	3.4%	1.3%	100%	1.3%
6+	34,113	4.9%	3.6%	1.2%	92%	1.2%
7+	30,656	5.1%	3.8%	1.2%	85%	1.2%
8+	27,311	5.3%	4.0%	1.2%	80%	1.1%
9+	24,103	5.4%	4.2%	1.1%	73%	1.1%
10+	21,056	5.6%	4.3%	1.1%	66%	1.0%
All	55,509	6.5%	2.7%	3.8%	100%	3.8%

Exhibit A-2b
Derived Lifetime-Pay Voluntary Lapse Experience through December 31, 2015
Series 11 Individual Policy Forms

		Composite	Expected	Derived		Smoothed
		Termination	Mortality	Lapse	Credibility	Lapse
Duration	Exposure	Rates	Rates	Rates	Percent	Rates
1	12,157	8.6%	0.2%	8.3%	100%	8.50%
2	11,116	4.4%	0.4%	4.0%	96%	4.00%
3	10,632	3.4%	0.5%	2.8%	79%	2.75%
4	10,244	2.6%	0.6%	2.0%	65%	2.00%
5	9,933	2.1%	0.8%	1.3%	54%	1.50%
6	9,696	2.3%	0.9%	1.4%	54%	1.25%
7	9,432	2.4%	1.1%	1.3%	52%	1.25%
8	9,116	2.1%	1.3%	0.8%	41%	1.00%
9	8,825	2.4%	1.5%	0.9%	38%	0.75%
10	8,499	2.5%	1.7%	0.8%	36%	0.60%
11	8,129	2.5%	1.9%	0.6%	34%	0.60%
12	7,460	2.7%	2.1%	0.5%	31%	0.60%
13	5,806	3.0%	2.4%	0.5%	25%	0.60%
14	4,305	3.2%	2.8%	0.4%	23%	0.60%
15	2,813	3.4%	3.2%	0.2%	12%	0.60%
16	1,878	3.6%	3.4%	0.2%	8%	0.60%
17	1,351	5.0%	3.5%	1.6%	8%	0.60%
18	108	2.8%	3.7%	-1.0%	0%	0.60%
1-3	33,905	5.6%	0.4%	5.2%	100%	5.2%
4-6	29,874	2.4%	0.8%	1.6%	100%	1.6%
7-9	27,373	2.3%	1.3%	1.0%	76%	1.0%
5+	87,352	2.6%	1.6%	0.9%	100%	0.9%
6+	77,419	2.6%	1.8%	0.8%	100%	0.8%
7+	67,722	2.7%	1.9%	0.8%	100%	0.8%
8+	58,290	2.7%	2.0%	0.7%	89%	0.7%
9+	49,175	2.8%	2.1%	0.6%	80%	0.6%
10+	40,349	2.9%	2.3%	0.6%	70%	0.6%
All	131,501	3.3%	1.2%	2.1%	100%	2.1%

Exhibit A-2c
Derived Lifetime-Pay Voluntary Lapse Experience through December 31, 2015
Series 11 Group Policy Forms

		Composite	Expected	Derived		Smoothed
		Termination	Mortality	Lapse	Credibility	Lapse
Duration	Exposure	Rates	Rates	Rates	Percent	Rates
1	7,058	6.4%	0.1%	6.3%	95%	6.50%
2	6,497	6.4%	0.2%	6.2%	91%	6.00%
3	5,951	4.4%	0.2%	4.2%	71%	4.00%
4	5,489	4.0%	0.3%	3.7%	63%	3.50%
5	5,008	3.3%	0.3%	3.0%	56%	3.00%
6	4,811	2.7%	0.4%	2.3%	46%	2.50%
7	4,644	2.2%	0.4%	1.8%	40%	2.00%
8	4,498	2.3%	0.5%	1.8%	40%	1.50%
9	4,297	1.7%	0.6%	1.1%	32%	1.30%
10	4,093	2.0%	0.6%	1.4%	36%	1.30%
11	3,468	2.4%	0.7%	1.7%	32%	1.30%
12	2,846	1.8%	0.8%	1.0%	26%	1.30%
13	1,498	1.3%	0.8%	0.5%	12%	1.30%
14	346	3.2%	0.7%	2.5%	10%	1.30%
15	74	1.4%	0.9%	0.5%	5%	1.30%
16	31	3.2%	1.0%	2.2%	5%	1.30%
17	3	0.0%	1.5%	-1.5%	0%	1.30%
1-3	19,506	5.8%	0.2%	5.6%	100%	5.6%
4-6	15,308	3.4%	0.3%	3.0%	96%	3.0%
7-9	13,439	2.1%	0.5%	1.6%	65%	1.6%
5+	35,618	2.3%	0.5%	1.8%	100%	1.8%
6+	30,609	2.2%	0.6%	1.6%	98%	1.6%
7+	25,799	2.1%	0.6%	1.5%	87%	1.5%
8+	21,154	2.0%	0.6%	1.4%	77%	1.3%
9+	16,656	1.9%	0.7%	1.3%	66%	1.3%
10+	12,359	2.0%	0.7%	1.3%	57%	1.3%
All	60,612	3.6%	0.4%	3.2%	100%	3.2%

Exhibit A-3
Actual-to-Expected (A:E) Benefit Expiration Experience through December 31, 2015
Subset of MedAmerica Organic Business

		Actual	Expected			Credibility-	Smoothed
Attained		Expiry	Expiry	Expiry	Credibility	Weighted	Adjustment
Age Band	Exposure	Rate	Rate	A:E	Percent	A:E	Factors
<80	528,089	0.03%	0.04%	0.70	56%	0.83	0.85
80-84	50,683	0.52%	0.41%	1.27	74%	1.20	1.25
85-89	22,568	1.52%	1.04%	1.46	85%	1.39	1.45
90+	6,638	4.43%	2.47%	1.79	78%	1.62	1.65
All	607,979	0.17%	0.14%	1.28	100%	1.28	1.28

Exhibit A-4a
MedAmerica and Affinity Partners
Actual-to-Expected Morbidity Adjustment Factors
Series 11 and Prior Policy Forms

	Prior to	Series 11	Series 11	
	Series 11	Individual	Group	
	Adjustment	Adjustment	Adjustment	
Duration	Factor	Factor	Factor	
1	1.05	0.84	0.51	
2	1.02	0.85	0.55	
3	1.00	0.86	0.59	
4	0.97	0.88	0.64	
5	0.95	0.89	0.69	
6	0.93	0.90	0.74	
7	0.90	0.91	0.79	
8	0.88	0.92	0.85	
9	0.86	0.91	0.87	
10	0.84	0.90	0.89	
11	0.83	0.89	0.91	
12	0.81	0.87	0.93	
13	0.79	0.86	0.95	
14	0.80	0.89	0.94	
15	0.81	0.92	0.92	
16	0.83	0.95	0.91	
17	0.84	0.98	0.90	
18	0.85	1.01	0.89	
19	0.84	1.00	0.89	
20	0.84	0.99	0.88	
21	0.83	0.99	0.88	
22	0.83	0.98	0.88	
23	0.82	0.97	0.87	
24	0.83	0.97	0.88	
25	0.84	0.97	0.89	
26	0.85	0.98	0.90	
27	0.86	0.98	0.91	
28	0.86	0.98	0.92	
29	0.86	0.98	0.92	
30+	0.86	0.98	0.92	

	Prior to	Series 11	Series 11
	Series 11	Individual	Group
Attained	Adjustment	Adjustment	Adjustment
Age	Factor	Factor	Factor
<65	0.91	0.90	0.88
65-69	1.08	1.10	1.01
70-74	0.99	1.18	1.04
75-79	0.94	1.10	1.07
80-84	1.06	1.49	1.08
85-89	1.15	1.29	1.20
90+	1.09	1.24	1.22

Coverage	Adjustment
Type	Factor
Comprehensive	0.90
Nursing Home Only	1.09
Home Care Only	1.23

Exhibit A-4b
MedAmerica and Affinity Partners
Actual to Adjusted Expected Incurred Claims
Series 11 and Prior Policy Forms

	Experience By Policy Duration									
	All Durations									
	Prior to S	Series 11	Series 11	Series 11 Group						
		Actual to		Actual to		Actual to				
		Adjusted		Adjusted		Adjusted				
Duration	Credibility	Expected	Credibility	Expected	Credibility	Expected				
1	0%	1.00	8%	0.62	9%	0.95				
2	0%	1.00	18%	1.31	6%	0.09				
3	5%	1.00	21%	0.46	18%	1.23				
4	10%	3.50	31%	1.56	16%	1.02				
5	11%	0.50	31%	0.80	13%	1.11				
6	15%	0.93	38%	0.87	16%	1.14				
7	23%	0.80	40%	1.04	14%	0.62				
8	28%	1.58	46%	1.20	17%	0.63				
9	34%	1.32	53%	0.97	16%	0.84				
10	37%	0.74	50%	0.89	18%	1.37				
11	40%	0.80	54%	0.95	18%	1.56				
12	39%	0.92	49%	0.93	5%	0.44				
13	41%	1.03	49%	1.24	9%	3.42				
14	46%	1.20	37%	0.95	0%	0.32				
15	39%	0.92	37%	0.97	0%	0.16				
16	37%	0.87	28%	1.06	0%	0.98				
17	34%	1.10	0%	1.10	0%	1.00				
18	32%	0.99	0%	1.00	0%	1.00				
19	27%	1.03	0%	0.08	0%	1.00				
20	20%	1.01	0%	1.00	0%	1.00				
21	16%	0.99	0%	1.00	0%	1.00				
22	6%	0.31	0%	1.00	0%	1.00				
23	0%	1.00	0%	1.00	0%	1.00				
1-5	16%	1.28	53%	1.00	29%	0.89				
6-10	64%	1.09	100%	0.99	36%	0.93				
11-15	92%	0.98	100%	1.00	21%	1.28				
16-20	69%	0.99	28%	1.05	0%	0.98				
21-25	17%	0.85	0%	1.00	0%	1.00				
Total	100%	1.01	100%	1.00	51%	0.99				

	Experience By Attained Age										
	Durations 7 and Later										
	Prior to S	Series 11	Series 11	Individual	Series 1	1 Group					
		Actual to		Actual to		Actual to					
Attained		Adjusted		Adjusted		Adjusted					
Age	Credibility	Expected	Credibility	Expected	Credibility	Expected					
<65	14%	1.32	19%	0.86	21%	1.26					
65-69	22%	1.97	33%	1.15	16%	0.94					
70-74	33%	0.85	50%	1.12	18%	0.91					
75-79	51%	0.92	65%	0.93	16%	0.87					
80-84	68%	1.01	83%	1.04	11%	0.70					
85-89	72%	0.99	61%	0.95	10%	1.85					
90+	56%	0.95	38%	0.99	-	0.00					
<70	27%	1.75	38%	1.05	27%	1.12					
<75	43%	1.19	63%	1.09	32%	1.05					
<80	66%	1.04	91%	1.01	36%	1.02					
<85	95%	1.03	100%	1.03	38%	0.98					
65-79	65%	1.02	89%	1.03	29%	0.91					
70-84	91%	0.96	100%	1.02	27%	0.85					
75-89	100%	0.98	100%	0.99	22%	0.97					
70+	100%	0.97	100%	1.01	28%	0.94					
75+	100%	0.98	100%	0.99	22%	0.96					
<b>80</b> +	100%	1.00	100%	1.01	15%	1.04					
85+	91%	0.98	72%	0.96	10%	1.72					

#### **BLUE CROSS OF NORTHEASTERN PENNSYLVANIA**

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

#### **Supplement to the Series 11 Group Actuarial Memorandum**

#### March 7, 2017

Product
Comprehensive Form
Comprehensive Certificate

Number GRP11-341-PA-200 GRP11-342- PA-1100

#### 1. Purpose of Filing

This supplement has been prepared for the purpose of demonstrating that the requested rate increase complies with Chapter 18 Section 3803(c) and (e), and Reg. 89.83 of the Insurance Regulations for the state of Pennsylvania. It may not be appropriate for other purposes.

The experience provided in this supplement reflects the combined experience of the policy form listed above as well as similar nationwide individual and group policy forms of the same product series. The company is making a similar request on the Series 11 Individual policy forms in a concurrent filing (SERFF tracking # MILL-130951717). Additionally, the company's affinity partner MedAmerica Insurance Company (MedAmerica) is making a similar request on its individual and group business in the concurrent filings (SERFF tracking # MILL-130925276 and MILL-130951675).

#### 2. Demonstration of Compliance with Chapter 18 Section 3803

(c) and (e): We believe that we comply with these subsections of the regulation by submitting these rates before they are being used.

#### 3. Demonstration of Compliance with Reg. 89.83

- 89.83 (a): This subsection requires no action.
- 89.83 (b): This subsection is not applicable since this filing is not for rates for a new policy form.
- 89.83 (c): Revision of Current Rates
- (1): For policies issued prior to September 16, 2002, the effective date of rate stability in Pennsylvania, the minimum loss ratio requirement is 60%, as specified in Reg. 89a.117.(b). For policies issued on or after September 16, 2002, the loss ratio requirements are specified in Reg. 89a.118.(c)(2), (i.e., the 58%/85% test). Demonstration of satisfaction of these requirements is discussed in Section 18 of the enclosed actuarial memorandum.

As of December 31, 2015, 161 of the 477 policies that are in force and subject to the requested rate increase in Pennsylvania were issued on or after September 16, 2002 (approximately 34%). However, because the company manages this block of business as a whole, this rate increase filing complies with both sets of requirements for all of the policies, regardless of issue date.

- (2): Section 2 of the actuarial memorandum provides a description of benefits. A copy of the affected policy forms may be provided upon request.
- (2)(i): The primary reason why these forms are in need of a premium rate increase is due to emerging experience running more adverse than expected in pricing. A rate increase is considered an effective way to reduce projected losses.

The company is requesting a premium rate increase that varies by benefit period as described in Section 17 of the enclosed actuarial memorandum. The cumulative rate increase shown in a table in Section 17 was determined to allow certification to rate stability, where applicable, and varies by benefit period to better align the rate increase with the adverse experience. The table provides the cumulative requested increase for each benefit period cohort, as well as the average cumulative prior increase and resulting current requested premium rate increase based on the nationwide distribution of combined individual and group business as of December 31, 2015. For policies with a non-lifetime benefit period, the cumulative rate increase was determined such that the business would break even going forward under moderately adverse conditions for the subset of policies with a lifetime-pay option (i.e., 0% profit margin going forward).

The current rate schedules along with the proposed rate schedules are enclosed with this filing. Please

#### **BLUE CROSS OF NORTHEASTERN PENNSYLVANIA**

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

#### **Supplement to the Series 11 Group Actuarial Memorandum**

#### March 7, 2017

note that the actual rates implemented may vary slightly from those shown due to rounding algorithms.

Attachment 1 to this supplement provides actual and projected nationwide experience using current assumptions, as described in Section 5 of the actuarial memorandum. Included are calendar year earned premiums, incurred claims, annual loss ratios, end of year lives, and cumulative loss ratios with interest. The without interest experience underlying Attachment 1 is identical to Exhibit I of the actuarial memorandum. Attachment 2 to this supplement provides nationwide experience showing written premium, paid claims, and cumulative loss ratios. Values in Attachments 1 and 2 are shown both before and after the requested rate increase. The interest rate used in Attachments 1 and 2 to accumulate and discount values is the maximum valuation interest rate for contract reserves applicable for the year of issue (which ranges from 3.5% to 5.5%).

Attachments 3 and 4 to this supplement provide similar information as Attachments 1 and 2, respectively, for Pennsylvania-specific experience. Please note that Pennsylvania-specific experience is not considered fully credible, but is being provided as required.

Additionally, it is worth noting that calculating the lifetime loss ratio using written premium and paid claims for Pennsylvania-specific experience results in a loss ratio that falls below the 60% minimum required by loss ratio regulation in Pennsylvania. However, as Pennsylvania Code Section 89.a.117 requires the expected loss ratio to be calculated using "incurred claim experience and earned premiums", we understand that a revision to the requested rate increase is not necessary.

(2)(ii)(A): In Pennsylvania, a cumulative increase of 39% has been implemented on the individual and group policy forms. The department of insurance filed these increases for use on May 13, 2010.

(2)(ii)(B): Table 1a shows the original pricing commission scales by issue age and duration for lifetime-pay individual policies.

Table 1a
Commission Percentages by Issue Age and Duration<sup>[1]</sup>

	Issue	Commi	ssions by D	uration
Individual Policy Form	Ages	1	2-10	11+
LTC-LBP-2PA LTC-LBP8-MA-PA LTC-CD5-2PA LTC-CD8-MA-PA	<71 71-79 80+	45-78 40-68 35-58	10-21 8-18 5-15	0-5 0-5 0-5
LTC-CD9-MA-PA	All Ages	30-50	5-10	5-10
LTQ11-336-PA-998 NTQ11-337-PA-998 HTQ11-338-PA-998 LTQ11-336-MA-PA-998 NTQ11-337-MA-PA-998 HTQ11-338-MA-PA-998 LTQ11-336-MA-PA-601 HTQ11-338-MA-PA-601 NTQ11-337-MA-PA-601	<75 75+	30-50 20-40	5-10 5-10	0-10 0-10
FLQ11-336-PA-998	<75	25-45	0-5	0-5
FLQ11-336-MA-PA-601	75+	15-35	0-5	0-5

<sup>[1]</sup> The maximum writing agent commissions are 50% in the first policy year and 10% for policy years two through ten.

Table 1b provides similar information for lifetime-pay group certificates by duration and whether the group was sold by a commissioned agent. The commission scale, without other sales and marketing

#### **BLUE CROSS OF NORTHEASTERN PENNSYLVANIA**

Address: 19 N Main St, Wilkes-Barre, Pennsylvania 18711

#### **Supplement to the Series 11 Group Actuarial Memorandum**

March 7, 2017

expenses, was not readily available.

# Table 1b Commission Percentages by Duration and Agent Type Group Policy Forms: GRP11-341-MA-PA-601 and GRP11-341-PA-200

Duration	Commissioned	Non-Commissioned
1	30%	40%
2+	7%	0%

Commissions for limited-pay policies are reduced to levels that are approximately equivalent to the above commissions for lifetime-pay policies and certificates, on a present value basis, based on original pricing assumptions.

The actual commission scales will differ slightly from those that appear in Table 1 as the company adjusts renewal commission rates so that the total commissions paid before and after any increase in premium are similar (i.e., commissions are not paid on the increased premium).

(2)(ii)(C)(I): Premiums earned and written since inception for nationwide experience can be found in Attachments 1 and 2, respectively. Premiums earned and written since inception for Pennsylvania-specific experience can be found in Attachments 3 and 4, respectively. Attachment 5 supplement provides reserve balances and the calculation basis for both nationwide and Pennsylvania-specific experience. Please note that Pennsylvania-specific experience is not considered fully credible, but is being provided as required.

(2)(ii)(C)(II): Attachment 5 to this supplement provides a breakdown of historical incurred claims and active life reserve balance, including a description of the calculation basis, for both nationwide and Pennsylvania-specific experience. Please note that Pennsylvania-specific experience is not considered fully credible, but is being provided as required.

Attachment 6 to this supplement provides actual and projected experience on a durational basis using current assumptions. Included are policy year earned premiums, incurred claims, durational loss ratios, end of year lives, and cumulative loss ratios with interest. Values in Attachment 6 are shown both before and after the requested rate increase. The number of durations shown was chosen to capture the majority of the durations underlying Attachment 1. Similar to Attachments 1 through 4, the values used to calculate the cumulative loss ratios are accumulated and discounted at the maximum valuation interest rate.

Attachment 7 to this supplement provides similar information to Attachment 6 for Pennsylvania-specific experience. Please note that Pennsylvania-specific experience is not considered fully credible, but is being provided as required.

(2)(ii)(D): We believe that we have provided information sufficient to support the rate increase requested in this filing.

(2)(iii): We understand that data used in this rate increase filing is in agreement with those used in the annual statement filed with the department.

89.83 (d): We believe the proposed rate tables provided with this filing comply with this subsection.

#### Attachment 1-a **MedAmerica and Affinity Partners**

### Earned Premium and Incurred Claim Experience and Projections by Calendar Year Nationwide Experience Before Requested Rate Increase Series 11 and Prior Policy Forms

		Ad	Actual or Projected Experience using Current Assumptions					
						Cumulative		
	Calendar	Earned	Incurred	Incurred	End of Year	Loss Ratio		
	Year	Premium	Claims	Loss Ratio	Lives	w/ Interest <sup>[1]</sup>		
	1992 1993	17,32 <sup>2</sup> 557,528		0% 20%	111 634	0% 19%		
	1993	1,501,263	· · · · · · · · · · · · · · · · · · ·		1,377	7%		
	1995	2,485,725		4%	1,944	6%		
	1996	3,463,885		4%	2,689	5%		
	1997	4,394,237	-	6%	3,003			
	1998	5,341,744		12%	3,666			
	1999	6,829,900		22%	4,764			
	2000	8,941,708		13%	6,200	11%		
	2001	11,912,872	2,210,887	19%	8,456	13%		
	2002	16,102,548	4,131,980	26%	11,472	16%		
Historical	2003	21,498,563	3,506,680	16%	17,713	16%		
Experience	2004	27,112,675		24%	19,114	18%		
	2005	28,577,291		24%	20,242	19%		
	2006	28,838,021			20,095	20%		
	2007	28,383,240		37%	20,146			
	2008	27,837,724		30%	19,941	23%		
	2009	26,881,835		42%	19,482	25%		
	2010 2011	25,544,191 24,603,117		62% 55%	18,494 17,664	27% 29%		
	2011	25,248,567		68%	17,596			
	2012	24,384,255		60%	17,390	33%		
	2014	22,506,450		102%	16,809	36%		
	2015	21,584,067		96%	16,292	38%		
	2016	21,357,049		91%	15,800	40%		
	2017	20,472,802		103%	15,305	42%		
	2018	19,369,621	22,918,883	118%	14,806			
	2019	18,406,508		134%	14,304	46%		
	2020	17,470,951		152%	13,798	48%		
	2021	16,538,030		171%		51%		
	2022	15,596,044	' '	191%	12,781	53%		
	2023	14,489,872		217%	12,273			
	2024 2025	13,397,604 12,476,171		246% 277%	11,765 11,259	58% 60%		
	2025	11,620,802		311%	10,756			
Projected	2027	10,822,954		349%	10,257	66%		
Future	2028	10,000,914		395%	9,763			
Experience	2029	9,271,931		444%	9,275			
(60 Years)	2030	8,576,548		499%	8,794	73%		
, ,	2031	7,910,616	44,446,472	562%	8,319	76%		
	2032	7,271,681		636%	7,851	78%		
	2033	6,661,754		717%	1			
	2034	6,080,987		808%	6,939			
	2035	5,529,732		911%	6,498	86%		
	2036	5,008,443		1,024%	6,067	89%		
	2037	4,517,582	· · ·	1,148%	5,648	91% 94%		
	2038 2039	4,057,385 3,627,888		1,285% 1,436%	5,243 4,851	96%		
	2040	3,228,952	, ,	1,601%	4,475	98%		
	2041	2,860,493		1,782%	4,116			
	2042	2,522,341		1,977%	3,775			
	2043	2,213,884		2,190%	3,452	104%		
	2044	1,934,179		2,424%	3,148			
	2045	1,681,891	45,060,682	2,679%	2,863	107%		
	2046-2050	5,488,041	190,766,034	3,476%	10,711	113%		
	2051-2055	2,424,067		5,310%	6,298			
	2056-2060	992,438		7,699%	3,589	118%		
	2061-2065	383,592		10,867%	1,948	119%		
	2066-2070	138,711		14,791%	951	119%		
[1] With interest v	2071-2075	45,729	8,673,354	18,967%	386	119%		

<sup>[1]</sup> With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.

#### Attachment 1-b **MedAmerica and Affinity Partners**

### Earned Premium and Incurred Claim Experience and Projections by Calendar Year Nationwide Experience After Requested Rate Increase Series 11 and Prior Policy Forms

		Ac	tual or Projected E	Experience using (	Current Assumption	ons
	Calendar	Earned	Incurred	Incurred	End of Year	Cumulative Loss Ratio
	Year	Premium	Claims	Loss Ratio	Lives	w/ Interest <sup>[1]</sup>
	1992	17,324		0%	111	0%
	1993	557,528	· ·	20%	634	19%
	1994	1,501,263	,	2%	1,377	7%
	1995	2,485,725		4%	1,944	6%
	1996	3,463,885	· ·	4%	2,689	5%
	1997	4,394,237		6%	3,003	5%
	1998	5,341,744	,	12%	3,666	7%
	1999	6,829,900	· · · · ·	22%	4,764	11%
	2000	8,941,708		13%	6,200	11%
	2001	11,912,872	1 - 1	19%	8,456	13%
Lliatoriaal	2002	16,102,548	1	26%	11,472	16%
Historical	2003	21,498,563	· · · · ·	16%	17,713	16%
Experience	2004	27,112,675	· · · · ·	24%	19,114	18%
	2005 2006	28,577,291 28,838,021		24% 26%	20,242 20,095	19% 20%
	2007		1 - 1	37%	20,095	20%
	2007	28,383,240 27,837,724	· · · · ·	30%	19,941	23%
	2008	26,881,835		42%	19,482	25%
	2009	25,544,191	· · · · ·	62%	18,494	27%
	2010	24,603,117		55%	17,664	29%
	2012	25,248,567		68%	17,596	31%
	2013	24,384,255	1	60%	17,264	33%
	2014	22,506,450	· · · · ·	102%	16,809	36%
	2015	21,584,067	20,806,755	96%	16,292	38%
	2016	21,357,049		91%	15,800	40%
	2017	22,583,348	1 - 1	92%	14,753	42%
	2018	31,032,913	1	66%	13,841	43%
	2019	30,913,659	· · · · ·	70%	13,368	44%
	2020	29,403,820		78%	12,902	45%
	2021	27,844,194		88%	12,434	46%
	2022	26,258,749	25,736,673	98%	11,964	48%
	2023	24,378,350	27,045,226	111%	11,495	49%
	2024	22,514,244	28,386,826	126%	11,026	51%
	2025	20,961,536	29,732,623	142%	10,558	52%
	2026	19,521,016	31,110,143	159%	10,093	54%
Projected	2027	18,184,397	32,524,059	179%	9,631	55%
Future	2028	16,805,411	1	202%	9,174	57%
Experience	2029	15,582,294	, ,	227%	8,722	59%
(60 Years)	2030	14,414,799	, ,	255%	8,275	61%
	2031	13,296,068	1	288%	7,835	63%
	2032	12,222,121	39,906,539	327%	7,400	64%
	2033	11,196,397		369%	6,971	66%
	2034	10,219,348		416%	6,551	68%
	2035	9,291,779		470%	6,139	70%
	2036	8,414,582		529%	5,737	72%
	2037	7,588,607	, ,	594%	5,346	74%
	2038	6,814,260		666%	4,967	75%
	2039	6,091,626	· · · · ·	745%	4,600	77%
	2040	5,420,469		832%	4,248	79%
	2041	4,800,652		928%	3,910	80%
	2042 2043	4,231,786	· · · · ·	1,031%	3,590	82% 83%
	2043	3,712,865		1,144%	3,286	83%
		3,242,305		1,269%	2,999	
	2045 2046-2050	2,817,854 9,173,643	, ,	1,405% 1,832%	2,730 10,243	85% 90%
	2046-2050	4,021,162		2,827%	6,054	90%
	2051-2055	1,624,306	, ,	4,153%	3,467	94%
	2056-2060	617,110		5,968%	1,890	94%
	2061-2063	219,541	· · · · ·	8,259%	925	94%
	2071-2075	71,513		10,692%	376	94%
	2011-2013	11,513	7,040,341	10,032/0	370	34 /0

<sup>[1]</sup> With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.

#### Attachment 2-a

# MedAmerica and Affinity Partners Written Premium and Paid Claim Experience and Projections by Calendar year Nationwide Experience Before Requested Rate Increase Series 11 and Prior Policy Forms

		Actual or Pr	ojected Experienc	e using Current	
			Without Interest	1	Cumulative
	Calendar	Written	Paid	Loss	Loss Ratio
	Year	Premium	Claims	Ratio	w/ Interest <sup>[1]</sup>
	1992	127,778	0	0%	0%
	1993	820,223	435	0%	0%
	1994	1,860,836	45,498	2%	2%
	1995	2,807,659	63,694	2%	2%
	1996	3,906,748	75,596	2%	2%
	1997	4,554,590	67,538	1%	2%
	1998	5,682,429	125,276	2%	2%
	1999	7,358,841	465,964	6%	3%
	2000	9,566,086	970,921	10%	5%
	2001	12,773,231	1,121,497	9%	6%
	2002	17,229,046	1,445,750	8%	6%
Historical	2003	23,330,280	2,546,158	11%	7%
Experience	2004	27,584,148	3,105,399	11%	8%
	2005	28,676,089	4,315,104	15%	9%
	2006	28,690,868	5,258,176	18%	11%
	2007	28,300,085	6,694,088	24%	12%
	2008	27,582,944	8,446,221	31%	14%
	2009	26,641,442	8,314,848	31%	15%
	2010	25,163,440	9,151,070	36%	17%
	2010	24,652,291		46%	19%
			11,323,437		
	2012	25,256,514	13,322,263	53%	21%
	2013	23,690,009	15,681,015	66%	23%
	2014	22,141,756	17,656,283	80%	25%
	2015	21,495,073	20,902,456	97%	28%
	2016	21,155,201	20,292,780	96%	30%
	2017	20,147,875	19,708,269	98%	32%
	2018	19,098,209	21,910,247	115%	34%
	2019	18,154,047	21,547,060	119%	36%
	2020	17,220,976	23,470,838	136%	38%
	2021	16,293,480	25,278,372	155%	41%
	2022	15,340,594	27,005,339	176%	43%
	2023	14,148,829	28,731,403	203%	45%
	2024	13,158,370	30,480,671	232%	47%
	2025	12,248,632	32,253,769	263%	50%
	2026	11,420,361	34,015,481	298%	52%
Projected	2027	10,587,452	35,779,326	338%	55%
Future	2028	9,816,134	37,556,642	383%	57%
Experience	2029	9,097,277	39,344,164	432%	60%
(60 Years)	2030	8,411,694	41,120,033	489%	62%
	2031	7,754,022	42,907,016	553%	65%
	2032	7,123,450	44,730,701	628%	67%
	2033	6,521,907	46,542,563	714%	70%
	2034	5,949,504	48,291,258	812%	72%
	2035	5,406,552	49,947,090	924%	75%
	2036	4,893,659	51,463,649	1,052%	77%
	2037	4,411,092	52,791,481	1,197%	80%
	2038	3,959,161	53,886,336	1,361%	82%
	2039	3,537,720	54,724,361	1,547%	85%
	2040	3,146,558	55,268,479	1,756%	87%
	2041	2,785,834	55,501,979	1,992%	89%
	2042	2,455,027	55,402,386	2,257%	91%
	2043	2,153,667	54,966,298	2,552%	93%
	2043	1,880,574	54,210,818	2,883%	95%
	2045	1,634,492	53,154,529	3,252%	97%
	2046-2050	5,327,580	240,332,585	4,511%	
	2051-2055	2,350,461	181,836,188	7,736%	109%
	2056-2060	962,321	120,035,154	12,474%	112%
	2061-2065	372,427	71,164,750	19,108%	113%
	2066-2070	135,019	38,470,201	28,492%	113%
	2071-2075	44,693	18,632,214	41,689%	114%

<sup>[1]</sup> With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.

## Attachment 2-b

# MedAmerica and Affinity Partners Written Premium and Paid Claim Experience and Projections by Calendar year Nationwide Experience After Requested Rate Increase Series 11 and Prior Policy Forms

		Actual or Pro		e using Current A	
			Without Interest		Cumulative
	Calendar	Written	Paid	Loss	Loss Ratio
	Year	Premium	Claims	Ratio	w/ Interest <sup>[1]</sup>
	1992	127,778	0	0%	0%
	1993	820,223	435	0%	0%
	1994	1,860,836	45,498	2%	2%
	1995	2,807,659	63,694	2%	2%
	1996	3,906,748	75,596	2%	2%
	1997	4,554,590	67,538	1%	2%
	1998	5,682,429	125,276	2%	2%
	1999	7,358,841	465,964	6%	3%
	2000	9,566,086	970,921	10%	5%
	2001	12,773,231	1,121,497	9%	6%
	2002	17,229,046	1,445,750	8%	6%
Historical	2003	23,330,280	2,546,158	11%	7%
Experience	2004	27,584,148	3,105,399	11%	8%
	2005	28,676,089	4,315,104	15%	9%
	2006	28,690,868	5,258,176	18%	11%
	2007	28,300,085	6,694,088	24%	12%
	2008	27,582,944	8,446,221	31%	14%
	2009	26,641,442	8,314,848	31%	15%
	2010	25,163,440	9,151,070	36%	17%
	2011	24,652,291	11,323,437	46%	19%
	2012	25,256,514	13,322,263	53%	21%
	2013	23,690,009	15,681,015	66%	23%
	2014	22,141,756	17,656,283	80%	25%
	2015	21,495,073	20,902,456	97%	28%
	2016	21,156,701	20,292,780	96%	30%
	2017	24,740,035	19,622,430	79%	32%
	2018	31,488,422	21,268,076	68%	33%
	2019	30,525,496	20,321,716	67%	35%
	2020	28,984,782	21,632,029	75%	36%
	2021	27,432,861	22,883,767	83%	37%
	2022	25,826,226	24,107,665	93%	39%
	2023	23,791,197	25,377,947	107%	40%
	2024	22,106,766	26,714,353	121%	42%
	2025	20,575,367	28,112,907	137%	43%
5	2026	19,180,114	29,531,748	154%	45%
Projected	2027	17,783,719	30,976,449	174%	47%
Future	2028	16,489,904	32,451,643	197%	49%
Experience	2029	15,283,416	33,953,327	222%	50%
(60 Years)	2030	14,132,123	35,461,051	251%	52%
	2031	13,027,070	36,993,132	284%	54%
	2032	11,967,034	38,569,868	322%	56%
	2033	10,955,305	40,148,414	366%	57%
	2034	9,992,355	41,683,795	417%	59%
	2035	9,078,837	43,149,083	475%	61%
	2036	8,215,928	44,502,720	542%	63%
	2037	7,404,071	45,700,606	617%	65%
	2038	6,643,857	46,702,672	703%	67%
	2039	5,935,037	47,486,356	800%	68%
	2040	5,277,180	48,016,648	910%	70%
	2041	4,670,640	48,278,774	1,034%	72%
	2042	4,114,379	48,251,567	1,173%	73%
	2043	3,607,682	47,932,217	1,329%	75%
	2044	3,148,498	47,334,046	1,503%	76%
	2045	2,734,764	46,471,442	1,699%	78%
	2046-2050	8,890,808	210,810,359	2,371%	83%
	2051-2055	3,890,192	160,125,390	4,116%	87%
	2056-2060	1,570,310	105,876,761	6,742%	89%
	2061-2065	597,008	62,813,531	10,521%	90%
	2066-2070	212,916	33,982,244	15,960%	90%
	2071-2075	69,681	16,457,690	23,619%	90%

<sup>[1]</sup> With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.

# Attachment 3-a

#### **MedAmerica and BCNEPA**

### Earned Premium and Incurred Claim Experience and Projections by Calendar Year Pennsylvania-Specific Experience Before Requested Rate Increase Series 11 and Prior Policy Forms

1996				Actual or Projected Experience using Current Assumptions					
Prenium		0 - 1 1		E	La compania	I a a company	F - 1 - ( ) (		
1992									
1983			-					w/ Interest <sup>11</sup>	
1994					-				
1996									
1996				, ,				5%	
1997   1,439,721   114,890   8%   953   55   57   1998   1,286,588   377,829   29%   872   99   2000   1,265,552   481,212   38%   859   12°   2001   1,225,656   713,556   58%   897   16°   2002   1,431,991   745,816   52%   1,036   1,078   20°   20°   20°   1,431,991   745,816   52%   1,036   1,078   20°   20°   20°   20°   1,585,702   464,534   30%   1,078   20°   20°   20°   1,597,640   656,165   41%   1,089   24°   20°   20°   1,498,556   747,377   50%   1,021   26°   20°   20°   1,498,556   747,377   50%   1,021   26°   20°   20°   1,241,706   771,521   62%   858   30°   20°   20°   1,241,706   771,521   62%   858   30°   20°   20°   1,241,706   771,521   62%   858   30°   20°   20°   1,241,398   811,757   72%   72°   32°   20°   20°   1,071,361   1,323,126   123%   60°   36°   36°   20°   40°   20°   40°   20°   40°   20°   40°   40°   20°   40							· ·	4%	
1998								5%	
2000		1998		1,346,982	235,553		912	7%	
Historical   2001		1999		1,286,588	377,829	29%	872	9%	
Historical 2002   1,431,991   745,816   52%   1,036   1078   200   Experience   2004   1,651,973   958,964   58%   1,139   233   236   2006   1,498,556   747,377   50%   1,021   268   2007   1,403,165   934,466   67%   963   288   2009   1,241,706   771,521   62%   858   300   2011   1,132,398   811,757   72%   720   322   2011   1,041,534   1,402,724   135%   664   349   2013   2013   1,063,818   996,135   94%   553   388   2014   999,939   1,300,809   130%   516   400   433   2015   912,184   1,856,480   204%   477   422   422   2012   10,713,61   1,325,680   204%   477   422   428   4		2000		1,267,352	481,212	38%	859	12%	
Experience   2003								16%	
Experience         2004         1,651,973         958,964         58%         1,139         23%           2006         1,597,640         666,165         41%         1,089         24%           2007         1,403,165         934,466         67%         983         288           2009         1,241,706         771,521         62%         858         300           2010         1,132,398         811,757         72%         720         329           2011         1,041,534         1,402,724         135%         664         344           2012         1,071,361         1,323,126         123%         605         368           2013         1,063,818         996,135         94%         553         389           2014         996,939         1,300,809         130%         516         40%           2016         843,833         337,699         99%         450         43           2017         788,770         880,533         108%         424         444           2018         736,159         864,544         117%         399         45           2021         566,181         878,491         128%         376         468					•		· ·	19%	
2006				·	•		· ·	20%	
2006	Experience			·	•			23%	
2007									
2008   1,241,706   771,521   62%   858   309     2010   1,132,938   811,757   72%   720   329     2011   1,041,534   1,402,724   135%   664   349     2012   1,071,361   1,323,126   123%   605   369     2013   1,063,818   996,135   94%   553   388     2014   996,939   1,300,809   130%   516   409     2015   912,184   1,856,480   204%   477   429     2018   2017   788,770   850,533   108%   424   449     2019   686,181   878,491   128%   376   469     2020   639,007   890,011   139%   353   479     2021   592,749   901,156   152%   331   479     2022   546,478   909,792   166%   311   488     2024   432,332   936,016   217%   274   509     2026   332,696   990,320   298%   240   519     2026   2027   302,378   1,030,977   341%   225   529     Future   2028   275,106   1,071,505   389%   210   539     Experience   2029   251,097   1,114,342   444%   197   549     2033   169,541   1,250,699   738%   147   589     2034   2034   152,197   1,114,342   444%   197   549     2035   188,034   1,214,780   646%   159   579     2036   2037   106,918   1,250,699   738%   147   588     2037   106,918   1,250,699   738%   147   588     2038   83,198   1,271,015   1,352%   97   629     2039   82,122   1,243,402   1,514%   89   629     2044   33,123   937,272   2,616%   53     2039   82,122   1,243,402   1,514%   89   629     2031   2037   106,918   1,250,699   738%   147   588     2033   82,122   1,243,402   1,514%   89   629     2044   38,123   937,272   2,616%   53   659     2045   2046   33,123   937,272   2,616%   53   669     2046   2047   30,133,243   1,244,400   1,244,780   646%   159   579     2038   2039   82,122   1,243,402   1,514%   89   629     2044   38,123   937,272   2,616%   53   659     2045   2046   33,298   2,308,154   6,922%   56   66     2047   2048   2049   2055   33,384   1,046,818   10,980%   32   688     2066-2070   281   67,763   24,98%   2   688     2066-2070   281   67,763   24,98%   2   688     2066-2070   281   67,763   24,98%   2									
2009									
2010									
2011					,				
2012				·	•				
2013								36%	
2014   996,939   1,300,809   130%   477   429				·				38%	
2016					•	130%	516		
2017		2015		912,184	1,856,480			42%	
2018				,				43%	
2019				·	•			44%	
2020				•	•				
2021				,	•				
2022 546,478 909,792 166% 311 489, 2023 498,059 922,086 185% 292 499, 2024 432,332 936,016 217% 274 509, 2025 363,366 952,921 262% 256 519, 2026 332,696 990,320 298% 240 519, 2026 2027 302,378 1,030,977 341% 225 529, 210, 2028 275,106 1,071,505 389% 210 539, 2030 228,674 1,150,960 503% 183 559, 2031 207,708 1,180,902 569% 171 569, 2032 188,034 1,214,780 646% 159 579, 2033 189,541 1,250,699 738% 147 589, 2034 152,197 1,274,288 837% 136 589, 2035 135,994 1,295,074 952% 126 599, 2036 120,911 1,300,176 1,075% 116 609, 2037 106,918 1,293,790 1,210% 106 619, 2038 93,988 1,271,015 1,352% 97 629, 2039 82,122 1,243,402 1,514% 89 629, 2040 71,315 1,207,867 1,694% 81 639, 2041 61,553 1,159,643 1,884% 73 649, 2044 38,123 997,272 2,616% 53 659, 2044 38,123 997,272 2,616% 53 659, 2044 38,123 997,272 2,616% 53 659, 2044 38,123 997,272 2,616% 53 659, 2044 38,123 997,272 2,616% 53 659, 2044 38,123 997,272 2,616% 53 659, 2045 2045 32,084 942,188 2,937% 47 659, 2045 2046 94,964 3,819,166 4,022% 165 679, 2056-2060 94,964 3,819,166 4,022% 165 679, 2056-2060 95,534 1,046,818 10,980% 32 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 668, 2066-2070 281 67,763 24,089% 2 2 668, 2066-2070 281 67,763 24,089% 2 2 668, 2066-2070 281 67,763 24,089% 2 2 668, 2066-2070 281 67,763 24,089% 2 2 668, 2066-2070 281 67,763 24,089% 2 2 668, 2066-2070 281 67,763 24,089% 2 2 668, 2066-2070 281 67,763 24,089% 2 2 668, 2066-2070 281 67,763 24,089% 2 2 668, 2066-2070 281 67,763 24,089% 2 2 668, 2066-2070 281 67,763 24,089% 2 2 668, 2066				·	•				
2023									
2024				·	•				
Projected   2025   363,366   952,921   262%   256   519				·	•				
Projected 2026 332,696 990,320 298% 240 519 Future 2028 275,106 1,071,505 389% 210 539 Experience 2029 251,097 1,114,342 444% 197 549 (60 Years) 2030 228,674 1,150,960 503% 183 559 2031 207,708 1,180,902 569% 171 569 2032 188,034 1,214,780 646% 159 579 2033 169,541 1,250,699 738% 147 589 2034 152,197 1,274,288 837% 136 589 2035 135,994 1,295,074 952% 126 5599 2036 120,911 1,300,176 1,075% 116 609 2037 106,918 1,293,790 1,210% 106 619 2038 93,988 1,271,015 1,352% 97 629 2039 82,122 1,243,402 1,514% 89 629 2040 771,315 1,207,867 1,694% 81 639 2041 61,553 1,159,643 1,884% 73 649 2042 52,802 1,104,790 2,092% 66 649 2043 45,007 1,046,361 2,325% 59 659 2044 38,123 997,272 2,616% 53 669 2045 32,084 942,188 2,937% 47 659 2046-2050 94,964 3,819,166 4,022% 165 679 2056-2060 9,534 1,046,818 10,980% 32 689 2061-2065 2,057 333,843 16,230% 10 669				·	•				
Projected Future 2028 275,106 1,030,977 341% 225 529 Experience 2029 251,097 1,114,342 444% 197 549 (60 Years) 2030 228,674 1,150,960 503% 183 559 2031 207,708 1,180,902 569% 171 569 2032 188,034 1,214,780 646% 159 579 2033 169,541 1,250,699 738% 147 589 2034 152,197 1,274,288 837% 136 589 2035 135,994 1,295,074 952% 126 599 2036 120,911 1,300,176 1,075% 116 609 2037 106,918 1,293,790 1,210% 106 619 2038 93,988 1,271,015 1,352% 97 629 2039 82,122 1,243,402 1,514% 89 629 2040 71,315 1,207,867 1,694% 81 639 2041 61,553 1,159,643 1,884% 73 649 2042 52,802 1,104,790 2,092% 66 649 2043 45,007 1,046,361 2,325% 59 659 2044 38,123 997,272 2,616% 53 659 2045 2045 32,084 942,188 2,937% 47 659 2046-2050 94,964 3,819,166 4,022% 165 679 2067-2065 2,057 333,843 16,230% 10 689 2067-2065 2,057 333,843 16,230% 10 689 2067-2065 2,057 333,843 16,230% 10 689 2067-2065 2,057 333,843 16,230% 10 689 2067-2065 2,057 333,843 16,230% 10 689					•			51%	
Future         2028         275,106         1,071,505         389%         210         539           Experience         2029         251,097         1,114,342         444%         197         549           (60 Years)         2030         228,674         1,150,960         503%         183         559           2031         207,708         1,180,902         569%         171         569           2032         188,034         1,214,780         646%         159         577           2033         169,541         1,250,699         738%         147         589           2034         152,197         1,274,288         837%         136         589           2035         135,994         1,295,074         952%         126         599           2036         120,911         1,300,176         1,075%         116         609           2037         106,918         1,293,790         1,210%         106         619           2038         93,988         1,271,015         1,352%         97         629           2039         82,122         1,243,402         1,514%         89         629           2040         71,315         1,207,867	Projected							52%	
(60 Years) 2030 228,674 1,150,960 503% 183 559 2031 207,708 1,180,902 569% 171 569 2032 188,034 1,214,780 646% 159 579 2033 169,541 1,250,699 738% 147 589 2034 152,197 1,274,288 837% 136 589 2035 135,994 1,295,074 952% 126 599 2036 120,911 1,300,176 1,075% 116 609 2037 106,918 1,293,790 1,210% 106 619 2038 93,988 1,271,015 1,352% 97 629 2039 82,122 1,243,402 1,514% 89 629 2040 71,315 1,207,867 1,694% 81 639 2041 61,553 1,159,643 1,884% 73 649 2042 52,802 1,104,790 2,092% 66 649 2043 45,007 1,046,361 2,325% 59 659 2044 38,123 997,272 2,616% 53 659 2045 2044 38,123 997,272 2,616% 53 659 2046-2050 94,964 3,819,166 4,022% 165 679 2056-2060 9,534 1,046,818 10,980% 32 689 2066-2070 281 67,763 24,089% 2 689	Future			275,106	1,071,505	389%	210	53%	
2031         207,708         1,180,902         569%         171         569           2032         188,034         1,214,780         646%         159         579           2033         169,541         1,250,699         738%         147         589           2034         152,197         1,274,288         837%         136         589           2035         135,994         1,295,074         952%         126         599           2036         120,911         1,300,176         1,075%         116         609           2037         106,918         1,293,790         1,210%         106         619           2038         93,988         1,271,015         1,352%         97         629           2039         82,122         1,243,402         1,514%         89         629           2040         71,315         1,207,867         1,694%         81         639           2041         61,553         1,159,643         1,884%         73         649           2042         52,802         1,104,790         2,092%         66         649           2043         45,007         1,046,361         2,325%         59         659	Experience	2029		251,097	1,114,342	444%	197	54%	
2032         188,034         1,214,780         646%         159         579           2033         169,541         1,250,699         738%         147         589           2034         152,197         1,274,288         837%         136         589           2035         135,994         1,295,074         952%         126         599           2036         120,911         1,300,176         1,075%         116         609           2037         106,918         1,293,790         1,210%         106         619           2038         93,988         1,271,015         1,352%         97         629           2039         82,122         1,243,402         1,514%         89         629           2040         71,315         1,207,867         1,694%         81         639           2041         61,553         1,159,643         1,884%         73         649           2042         52,802         1,104,790         2,092%         66         649           2043         45,007         1,046,361         2,325%         59         659           2044         38,123         997,272         2,616%         53         659	(60 Years)							55%	
2033         169,541         1,250,699         738%         147         589           2034         152,197         1,274,288         837%         136         589           2035         135,994         1,295,074         952%         126         599           2036         120,911         1,300,176         1,075%         116         609           2037         106,918         1,293,790         1,210%         106         619           2038         93,988         1,271,015         1,352%         97         629           2039         82,122         1,243,402         1,514%         89         629           2040         71,315         1,207,867         1,694%         81         639           2041         61,553         1,159,643         1,884%         73         649           2042         52,802         1,104,790         2,092%         66         649           2043         45,007         1,046,361         2,325%         59         659           2044         38,123         997,272         2,616%         53         659           2045         32,084         942,188         2,937%         47         659								56%	
2034         152,197         1,274,288         837%         136         589           2035         135,994         1,295,074         952%         126         599           2036         120,911         1,300,176         1,075%         116         609           2037         106,918         1,293,790         1,210%         106         619           2038         93,988         1,271,015         1,352%         97         629           2039         82,122         1,243,402         1,514%         89         629           2040         71,315         1,207,867         1,694%         81         639           2041         61,553         1,159,643         1,884%         73         649           2042         52,802         1,104,790         2,092%         66         649           2043         45,007         1,046,361         2,325%         59         659           2044         38,123         997,272         2,616%         53         659           2045         32,084         942,188         2,937%         47         659           2051-2055         33,298         2,308,154         6,932%         79         689 <td></td> <td></td> <td></td> <td>,</td> <td></td> <td></td> <td></td> <td></td>				,					
2035         135,994         1,295,074         952%         126         599           2036         120,911         1,300,176         1,075%         116         609           2037         106,918         1,293,790         1,210%         106         619           2038         93,988         1,271,015         1,352%         97         629           2039         82,122         1,243,402         1,514%         89         629           2040         71,315         1,207,867         1,694%         81         639           2041         61,553         1,159,643         1,884%         73         649           2042         52,802         1,104,790         2,092%         66         649           2043         45,007         1,046,361         2,325%         59         659           2044         38,123         997,272         2,616%         53         659           2045         32,084         942,188         2,937%         47         659           2046-2050         94,964         3,819,166         4,022%         165         679           2051-2055         33,298         2,308,154         6,932%         79         689				•					
2036         120,911         1,300,176         1,075%         116         60%           2037         106,918         1,293,790         1,210%         106         61%           2038         93,988         1,271,015         1,352%         97         62%           2039         82,122         1,243,402         1,514%         89         62%           2040         71,315         1,207,867         1,694%         81         63%           2041         61,553         1,159,643         1,884%         73         64%           2042         52,802         1,104,790         2,092%         66         64%           2043         45,007         1,046,361         2,325%         59         65%           2044         38,123         997,272         2,616%         53         65%           2045         32,084         942,188         2,937%         47         65%           2046-2050         94,964         3,819,166         4,022%         165         67%           2051-2055         33,298         2,308,154         6,932%         79         68%           2061-2065         2,057         333,843         16,230%         10         68%				,					
2037         106,918         1,293,790         1,210%         106         619           2038         93,988         1,271,015         1,352%         97         629           2039         82,122         1,243,402         1,514%         89         629           2040         71,315         1,207,867         1,694%         81         639           2041         61,553         1,159,643         1,884%         73         649           2042         52,802         1,104,790         2,092%         66         649           2043         45,007         1,046,361         2,325%         59         659           2044         38,123         997,272         2,616%         53         659           2045         32,084         942,188         2,937%         47         659           2046-2050         94,964         3,819,166         4,022%         165         679           2051-2055         33,298         2,308,154         6,932%         79         689           2056-2060         9,534         1,046,818         10,980%         32         689           2061-2065         2,057         333,843         16,230%         10         689 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
2038         93,988         1,271,015         1,352%         97         629           2039         82,122         1,243,402         1,514%         89         629           2040         71,315         1,207,867         1,694%         81         639           2041         61,553         1,159,643         1,884%         73         649           2042         52,802         1,104,790         2,092%         66         649           2043         45,007         1,046,361         2,325%         59         659           2044         38,123         997,272         2,616%         53         659           2045         32,084         942,188         2,937%         47         659           2046-2050         94,964         3,819,166         4,022%         165         679           2051-2055         33,298         2,308,154         6,932%         79         689           2056-2060         9,534         1,046,818         10,980%         32         689           2061-2065         2,057         333,843         16,230%         10         689           2066-2070         281         67,763         24,089%         2         689				•	, ,	·			
2039       82,122       1,243,402       1,514%       89       629         2040       71,315       1,207,867       1,694%       81       639         2041       61,553       1,159,643       1,884%       73       649         2042       52,802       1,104,790       2,092%       66       649         2043       45,007       1,046,361       2,325%       59       659         2044       38,123       997,272       2,616%       53       659         2045       32,084       942,188       2,937%       47       659         2046-2050       94,964       3,819,166       4,022%       165       679         2051-2055       33,298       2,308,154       6,932%       79       689         2056-2060       9,534       1,046,818       10,980%       32       689         2061-2065       2,057       333,843       16,230%       10       689         2066-2070       281       67,763       24,089%       2       689				•	, ,	·			
2040       71,315       1,207,867       1,694%       81       639         2041       61,553       1,159,643       1,884%       73       649         2042       52,802       1,104,790       2,092%       66       649         2043       45,007       1,046,361       2,325%       59       659         2044       38,123       997,272       2,616%       53       659         2045       32,084       942,188       2,937%       47       659         2046-2050       94,964       3,819,166       4,022%       165       679         2051-2055       33,298       2,308,154       6,932%       79       689         2056-2060       9,534       1,046,818       10,980%       32       689         2061-2065       2,057       333,843       16,230%       10       689         2066-2070       281       67,763       24,089%       2       689								62%	
2041       61,553       1,159,643       1,884%       73       649         2042       52,802       1,104,790       2,092%       66       649         2043       45,007       1,046,361       2,325%       59       659         2044       38,123       997,272       2,616%       53       659         2045       32,084       942,188       2,937%       47       659         2046-2050       94,964       3,819,166       4,022%       165       679         2051-2055       33,298       2,308,154       6,932%       79       689         2056-2060       9,534       1,046,818       10,980%       32       689         2061-2065       2,057       333,843       16,230%       10       689         2066-2070       281       67,763       24,089%       2       689				•				63%	
2042     52,802     1,104,790     2,092%     66     649       2043     45,007     1,046,361     2,325%     59     659       2044     38,123     997,272     2,616%     53     659       2045     32,084     942,188     2,937%     47     659       2046-2050     94,964     3,819,166     4,022%     165     679       2051-2055     33,298     2,308,154     6,932%     79     689       2056-2060     9,534     1,046,818     10,980%     32     689       2061-2065     2,057     333,843     16,230%     10     689       2066-2070     281     67,763     24,089%     2     689								64%	
2044     38,123     997,272     2,616%     53     659       2045     32,084     942,188     2,937%     47     659       2046-2050     94,964     3,819,166     4,022%     165     679       2051-2055     33,298     2,308,154     6,932%     79     689       2056-2060     9,534     1,046,818     10,980%     32     689       2061-2065     2,057     333,843     16,230%     10     689       2066-2070     281     67,763     24,089%     2     689		2042		52,802	1,104,790	2,092%	66	64%	
2045     32,084     942,188     2,937%     47     659       2046-2050     94,964     3,819,166     4,022%     165     679       2051-2055     33,298     2,308,154     6,932%     79     689       2056-2060     9,534     1,046,818     10,980%     32     689       2061-2065     2,057     333,843     16,230%     10     689       2066-2070     281     67,763     24,089%     2     689				45,007	1,046,361	2,325%		65%	
2046-2050     94,964     3,819,166     4,022%     165     679       2051-2055     33,298     2,308,154     6,932%     79     689       2056-2060     9,534     1,046,818     10,980%     32     689       2061-2065     2,057     333,843     16,230%     10     689       2066-2070     281     67,763     24,089%     2     689				•	•	·		65%	
2051-2055     33,298     2,308,154     6,932%     79     689       2056-2060     9,534     1,046,818     10,980%     32     689       2061-2065     2,057     333,843     16,230%     10     689       2066-2070     281     67,763     24,089%     2     689								65%	
2056-2060     9,534     1,046,818     10,980%     32     689       2061-2065     2,057     333,843     16,230%     10     689       2066-2070     281     67,763     24,089%     2     689				•		·		67%	
2061-2065				•		·			
2066-2070 281 67,763 24,089% 2 68%									
					•	·			
ZUZ   = ZUZ   = ZUZ     ZUZ     ZUZ   ZU		2006-2070		17	8,017	24,089% 47,975%	0	68%	

[1] With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.

# Attachment 3-b

#### **MedAmerica and BCNEPA**

### Earned Premium and Incurred Claim Experience and Projections by Calendar Year Pennsylvania-Specific Experience After Requested Rate Increase Series 11 and Prior Policy Forms

		Act	ual or Projected E	xperience using (	Current Assumption	
	Calendar	Earned	Incurred	Incurred	End of Year	Cumulative Loss Ratio
	Year	Premium	Claims	Loss Ratio	Lives	w/ Interest <sup>[1]</sup>
	1992	17,324	0	0%	111	0%
	1993	547,119	112,935	21%	580	19%
	1994	1,334,319	28,746	2%	1,191	8%
	1995	1,802,510	55,039	3%	1,165	5%
	1996	1,608,559	5,871	0%	1,055	4%
	1997	1,439,721	114,890	8%	953	5% 7%
	1998 1999	1,346,982 1,286,588	235,553 377,829	17% 29%	912 872	9%
	2000	1,267,352	481,212	38%	859	12%
	2001	1,235,656	713,556	58%	897	16%
	2002	1,431,991	745,816	52%	1,036	19%
Historical	2003	1,554,702	464,534	30%	1,078	20%
Experience	2004	1,651,973	958,964	58%	1,139	23%
	2005	1,597,640	656,165	41%	1,089	24%
	2006	1,498,556	747,377	50%	1,021	26%
	2007	1,403,185	934,486	67%	983	28%
	2008	1,324,328	889,567	67%	906	29%
	2009	1,241,706	771,521	62%	858	30%
	2010 2011	1,132,398	811,757 1,402,724	72% 135%	720 664	32% 34%
	2012	1,041,534 1,071,361	1,323,126	123%	605	36%
	2013	1,063,818	996,135	94%	553	38%
	2014	996,939	1,300,809	130%	516	40%
	2015	912,184	1,856,480	204%	477	42%
	2016	843,833	837,699	99%	450	43%
	2017	869,698	833,018	96%	407	44%
	2018	1,109,557	761,527	69%	371	44%
	2019	1,068,173	759,576	71%	349	45%
	2020	998,318	767,931	77%	328	45%
	2021	927,688	775,663	84%	308	46%
	2022 2023	857,314 783,109	781,076 789,247	91% 101%	289 272	46% 47%
	2023	678,956	798,497	118%	255	47%
	2025	568,694	809,963	142%	239	48%
	2026	522,590	838,574	160%	224	48%
Projected	2027	476,533	869,774	183%	210	49%
Future	2028	435,125	900,532	207%	197	50%
Experience	2029	398,776	932,806	234%	184	50%
(60 Years)	2030	364,677	959,831	263%	172	51%
	2031	332,637	981,879	295%	160	51%
	2032	302,406	1,007,049	333%	149	52%
	2033	273,820	1,033,142	377% 425%	139 128	53% 53%
	2034 2035	246,845 221,477	1,050,230 1,065,621	481%	119	54%
	2036	197,701	1,069,300	541%	109	55%
	2037	175,478	1,064,680	607%	101	55%
	2038	154,793	1,047,628	677%	92	56%
,	2039	135,669	1,026,941	757%	84	56%
,	2040	118,129	1,000,389	847%	77	57%
,	2041	102,179	963,833	943%	69	57%
,	2042	87,791	922,794	1,051%	63	58%
,	2043	74,899	879,251	1,174%	57	58%
	2044	63,458	843,263	1,329%	51	58%
	2045	53,379	802,005	1,502%	45 150	59%
	2046-2050 2051-2055	157,120 53,980	3,308,978 2,035,401	2,106% 3,771%	159 77	60% 61%
	2051-2055	15,049	933,557	6,203%	31	61%
	2061-2065	3,178	302,393	9,516%	10	61%
	2066-2070	429	62,755	14,645%	2	61%
l l			02,,00	1 1,0 10 /0	_	3170

[1] With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.

### Attachment 4-a

### **MedAmerica and BCNEPA**

Written Premium and Paid Claim Experience and Projections by Calendar year Pennsylvania-Specific Experience Before Requested Rate Increase Series 11 and Prior Policy Forms

		Actual or Pr	ojected Experienc	e using Current A	
			Without Interest		Cumulative
	Calendar	Written	Paid	Loss	Loss Ratio
	Year	Premium	Claims	Ratio	w/ Interest <sup>[1]</sup>
	1992	127,778	0	0%	0%
	1993	771,602	435	0%	0%
	1994	1,647,609	45,498	3%	2%
	1995	1,721,848	63,694	4%	3%
	1996	1,554,555	57,268	4%	3%
	1997	1,395,031	34,233	2%	3%
	1998	1,334,225	1,801	0%	2%
	1999	1,284,381	169,733	13%	4%
	2000	1,267,453	413,900	33%	6%
	2001	1,241,128	488,498	39%	9%
	2002	1,491,230	609,346	41%	12%
Historical	2003	1,584,510	748,375	47%	15%
Experience	2004	1,622,474	647,095	40%	17%
Lxperience	2004	· · ·	-	42%	18%
		1,563,379	660,435		
	2006	1,461,251	842,743	58%	20%
	2007	1,384,005	909,721	66%	22%
	2008	1,305,641	953,070	73%	24%
	2009	1,225,623	769,442	63%	26%
	2010	1,088,659	781,353	72%	27%
	2011	1,044,006	922,011	88%	28%
	2012	1,065,668	1,110,217	104%	30%
	2013	1,051,905	1,452,492	138%	33%
	2014	970,770	1,354,569	140%	35%
	2015	884,570	1,342,599	152%	36%
	2016	823,673	953,861	116%	38%
	2017	769,615	897,485	117%	39%
	2018	718,093	958,472	133%	40%
	2019	669,243	899,585	134%	41%
	2020	623,220	930,825	149%	41%
	2021	576,596	950,145	165%	42%
	2022	526,381	961,898	183%	43%
	2023	484,398	972,646	201%	44%
	2024	413,849	984,943	238%	45%
	2025	352,191	999,547	284%	46%
	2026	323,193	1,017,856	315%	47%
Projected	2027	292,762	1,041,224	356%	48%
Future	2028	266,991	1,068,974	400%	49%
Experience	2029	243,557	1,100,597	452%	49%
(60 Years)	2030	221,674	1,134,530	512%	50%
(=======	2031	201,166	1,169,002	581%	51%
	2032	181,888	1,204,108	662%	52%
	2033	163,785	1,240,034	757%	53%
	2034	146,810	1,274,484	868%	54%
	2035	130,980	1,306,592	998%	55%
	2036	116,260	1,333,988	1,147%	55%
	2037	102,606	1,354,874	1,320%	56%
	2037	90,025	1,366,798	1,518%	57%
				1,744%	
	2039	78,501	1,369,351	*	58%
	2040	68,032	1,362,562	2,003%	58%
	2041	58,609	1,345,800	2,296%	59%
	2042	50,170	1,319,150	2,629%	60%
	2043	42,682	1,283,625	3,007%	60%
	2044	36,083	1,242,698	3,444%	61%
	2045	30,305	1,196,986	3,950%	61%
	2046-2050	89,211	5,159,449	5,783%	63%
	0054 0055		3,573,337	11,540%	65%
	2051-2055	30,964			
	2056-2060	8,806	2,027,424	23,024%	65%
	2056-2060 2061-2065	8,806 1,887	2,027,424 896,357	23,024% 47,489%	65% 65%
	2056-2060	8,806	2,027,424	23,024%	65%

<sup>[1]</sup> With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.

### Attachment 4-b

### **MedAmerica and BCNEPA**

Written Premium and Paid Claim Experience and Projections by Calendar year Pennsylvania-Specific Experience After Requested Rate Increase Series 11 and Prior Policy Forms

		Actual or Pr	ojected Experienc	e using Current A	
			Without Interest		Cumulative
	Calendar	Written	Paid	Loss	Loss Ratio
	Year	Premium	Claims	Ratio	w/ Interest <sup>[1]</sup>
	1992	127,778	0	0%	0%
	1993	771,602	435	0%	0%
	1994	1,647,609	45,498	3%	2%
	1995	1,721,848	63,694	4%	3%
	1996	1,554,555	57,268	4%	3%
	1997	1,395,031	34,233	2%	3%
	1998	1,334,225	1,801	0%	2%
	1999	1,284,381	169,733	13%	4%
	2000 2001	1,267,453	413,900	33% 39%	6% 9%
		1,241,128	488,498	41%	9% 12%
Historical	2002 2003	1,491,230	609,346	41% 47%	15%
	2003	1,584,510	748,375	47% 40%	17%
Experience		1,622,474	647,095		
	2005	1,563,379	660,435	42%	18%
	2006 2007	1,461,251	842,743	58% 66%	20% 22%
	2007	1,384,005	909,721 953,070	73%	24%
	2009	1,305,641	-	63%	24 % 26%
	2009	1,225,623 1,088,659	769,442	72%	20% 27%
	2010	1,044,006	781,353 922,011	88%	21 % 28%
	2011	· · ·	1,110,217	104%	30%
	2012	1,065,668 1,051,905	1,452,492	138%	33%
	2013	970,770	1,354,569	140%	35% 35%
	2014	884,570	1,342,599	152%	36% 36%
	2016	823,791	953,861	116%	38%
	2017	958,775	893,767	93%	38%
	2018	1,108,669	932,027	84%	39%
	2019	1,043,105	851,499	82%	40%
	2020	974,900	862,004	88%	40%
	2021	903,335	864,314	96%	41%
	2022	826,010	862,095	104%	42%
	2023	762,416	861,126	113%	42%
	2024	649,864	863,432	133%	43%
	2025	551,731	869,311	158%	44%
	2026	508,243	879,225	173%	44%
Projected	2027	461,803	894,006	194%	45%
Future	2028	422,758	912,812	216%	46%
Experience	2029	387,221	935,055	241%	46%
(60 Years)	2030	353,881	959,334	271%	47%
(00 100.0)	2031	322,477	984,244	305%	47%
	2032	292,785	1,009,836	345%	48%
	2033	264,747	1,036,080	391%	49%
	2034	238,278	1,061,242	445%	49%
	2035	213,439	1,084,739	508%	50%
	2036	190,174	1,104,810	581%	51%
	2037	168,435	1,120,172	665%	51%
	2038	148,262	1,128,934	761%	52%
	2039	129,648	1,130,686	872%	52%
	2040	112,620	1,125,469	999%	53%
	2041	97,193	1,112,737	1,145%	54%
	2042	83,295	1,092,583	1,312%	54%
	2043	70,895	1,065,806	1,503%	54%
	2044	59,914	1,035,156	1,728%	55%
	2045	50,267	1,000,936	1,991%	55%
	2046-2050	146,908	4,373,833	2,977%	57%
	2051-2055	49,779	3,094,328	6,216%	58%
1				40.0000/	E00/
	2056-2060	13,733	1,780,149	12,963%	58%
	2056-2060 2061-2065	13,733 2,869	795,450	12,963% 27,726%	58%
				· ·	

<sup>[1]</sup> With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.

# Attachment 5 MedAmerica and Affinity Partners Breakdown of Historical Incurred Claims and Reserve Balances at December 31, 2015 Series 11 and Prior Policy Forms

**Nationwide Experience** 

		Discounted to the Year of Incurral						
Incurred	Incurred	Paid	Disabled	IBNR	Total Claim	Active Life		
Year	Claims <sup>[1]</sup>	Claims	Life Reserve	Reserve	Reserve <sup>[2]</sup>	Reserve <sup>[3]</sup>		
1992	0	0	0		0			
1993	112,935	112,935	0		0			
1994	28,746	28,746	0		0			
1995	109,652	109,652	0		0			
1996	134,262	134,262	0		0			
1997	264,541	264,541	0		0			
1998	631,867	631,867	0		0			
1999	1,469,714	1,469,714	0		0			
2000	1,172,992	1,172,992	0		0			
2001	2,210,887	2,210,887	0		0			
2002	4,131,980	3,969,608	162,373		162,373			
2003	3,506,680	3,410,832	95,848		95,848			
2004	6,602,535	6,338,845	263,690		263,690			
2005	6,824,784	6,608,736	216,048		216,048			
2006	7,359,318	7,123,498	235,820		235,820			
2007	10,552,392	10,302,510	249,882		249,882			
2008	8,394,073	7,853,745	540,328		540,328			
2009	11,313,758	10,270,931	1,042,827		1,042,827			
2010	15,723,015	13,340,663	2,382,352		2,382,352			
2011	13,541,344	11,693,315			1,848,029			
2012	17,141,023	11,983,432	5,157,592		5,157,592			
2013	14,626,127	9,305,173	5,320,953		5,320,953			
2014	22,967,435	8,862,880	14,104,555		14,104,555			
2015	20,806,755	2,005,949	14,959,761	3,841,045	18,800,806	329,207,078		

Pennsylvania-Specific Experience

		Year-End				
Incurred	Incurred	Paid	Disabled	IBNR	Total Claim	Active Life
Year	Claims <sup>[1]</sup>	Claims	Life Reserve	Reserve	Reserve <sup>[2]</sup>	Reserve <sup>[3]</sup>
1992	0	0	0		0	
1993	112,935	112,935	0		0	
1994	28,746	28,746	0		0	
1995	55,039	55,039	0		0	
1996	5,871	5,871	0		0	
1997	114,890	114,890	0		0	
1998	235,553	235,553	0		0	
1999	377,829	377,829	0		0	
2000	481,212	481,212	0		0	
2001	713,556	713,556	0		0	
2002	745,816	745,816	0		0	
2003	464,534	464,534	0		0	
2004	958,964	958,964	0		0	
2005	656,165	656,165	0		0	
2006	747,377	747,377	0		0	
2007	934,486	934,486	0		0	
2008	889,567	784,542	105,025		105,025	
2009	771,521	771,521	0		0	
2010	811,757	811,757	0		0	
2011	1,402,724	1,331,010	71,715		71,715	
2012	1,323,126	1,261,051	62,075		62,075	
2013	996,135	936,730	59,406		59,406	
2014	1,300,809	655,297	645,511		645,511	
2015	1,856,480	240,980	1,445,243	170,257	1,615,500	7,525,018

<sup>[1]</sup> Incurred claims are the sum of paid claims, disabled life reserve, and incurred but not reported (IBNR) reserve.

<sup>[2]</sup> Claim reserve is the sum of disabled life reserve and IBNR reserve.

<sup>[3]</sup> Active life reserve is defined as interpolated terminal reserves plus unearned premium reserves.

# Attachment 6-a MedAmerica and Affinity Partners Nationwide Experience and Projections by Policy Year - Before Requested Rate Increase Series 11 and Prior Policy Forms

	Actu	ıal and Projected	Experience using	Current Assumpti	
					Cumulative
Policy	Earned	Incurred	Incurred	End of Year	Loss Ratio
Year	Premium	Claims	Loss Ratio	Lives	w/ Interest <sup>[1]</sup>
1	39,714,300	1,873,040	5%	26,100	5%
2	36,465,689	1,674,359	5%	24,605	5%
3	34,723,527	3,372,217	10%	23,556	6%
4	33,359,938	7,843,770	24%	22,604	10%
5	32,386,798	6,097,120	19%	21,977	11%
6	31,503,775	9,122,213	29%	21,378	14%
7	30,769,063	9,449,497	31%	20,774	16%
8	30,167,988	14,389,062	48%	20,095	19%
9	29,723,101	15,220,149	51%	19,437	21%
10	29,979,620	14,218,055	47%	18,866	23%
11	23,047,474	15,433,463	67%	18,273	26%
12	22,606,311	17,595,144	78%	17,732	28%
13	22,107,261	19,781,631	89%	17,179	31%
14	21,584,367	20,138,316	93%	16,583	33%
15	20,912,331	21,475,369	103%	16,023	35%
16	20,130,535	22,729,779	113%	15,445	38%
17	19,220,178	25,824,388	134%	14,882	40%
18	18,306,177	28,794,038	157%	14,317	43%
19	17,363,971	29,700,038	171%	13,741	46%
20	16,431,983	31,878,537	194%	13,208	49%
21	14,682,745	33,511,685	228%	12,649	51%
22	13,724,956	35,061,524	255%	12,049	54%
23	12,794,911	37,049,001	290%	11,534	57%
24	11,888,585	39,248,931	330%	10,979	60%
25	11,007,873	41,514,685	377%	10,426	63%
26	10,155,885	43,723,582	431%	9,876	66%
27	9,335,676	45,923,757	492%	9,333	69%
28			492% 562%		
29	8,549,020 7,797,993	48,038,657 49,925,122	640%	8,796 8,268	73% 76%
			728%		
30 31	7,084,480	51,545,113		7,751	79%
	6,409,719	52,962,096	826%	7,246	82%
32	5,773,638	54,136,549	938%	6,754	85%
33	5,175,768	55,024,261	1,063%	6,275	88%
34	4,617,361	55,661,679	1,205%	5,812	91%
35	4,099,209	55,854,923	1,363%	5,367	94%
36	3,621,082	55,603,493	1,536%	4,939	97%
37	3,182,209	54,956,704	1,727%	4,531	99%
38	2,781,809	53,960,002	1,940%	4,144	102%
39	2,419,447	52,654,011	2,176%	3,778	104%
40	2,093,945	51,047,843	2,438%	3,435	106%
41	1,803,259	49,107,016	2,723%	3,114	108%
42	1,545,289	46,935,557	3,037%	2,815	110%
43	1,317,766	44,606,890	3,385%	2,538	112%
44	1,118,575	42,086,232	3,762%	2,283	113%
45	945,434	39,427,780	4,170%	2,050	114%
46	795,765	36,668,409	4,608%	1,836	116%
47	667,097	33,902,782	5,082%	1,642	117%
48	557,217	31,206,626	5,600%	1,465	118%
49	463,914	28,601,955	6,165%	1,305	119%
50	385,063	26,096,744	6,777%	1,161	119%
51-55	1,120,518	95,817,456	8,551%	4,102	122%
56-60	406,922	51,617,565	12,685%	2,162	123%
61-65	135,121	24,302,728	17,986%	1,034	123%
66-70	39,677	9,625,261	24,259%	409	123%
00 70					

<sup>[1]</sup> With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.

268%

558,674

1,844,016,804

689,002,314

Total

123%

# Attachment 6-b MedAmerica and Affinity Partners Nationwide Experience and Projections by Policy Year - After Requested Rate Increase Series 11 and Prior Policy Forms

	Actua	and Projected E	xperience using (	Jurrent Assumptio	
Dallan	Famad	la access d	In account of	F = 1 = ( ) / = = =	Cumulative
Policy	Earned	Incurred	Incurred	End of Year	Loss Ratio
Year	Premium	Claims	Loss Ratio	Lives	w/ Interest <sup>[1]</sup>
1	39,714,300	1,873,040	5%	26,100	5
2	36,470,673	1,674,279	5%	24,603	5
3	34,757,162	3,371,725	10%	23,550	6
4	33,465,352	7,842,011	23%	22,589	10
5	32,597,337	6,093,094	19%	21,950	11
6	31,878,403	9,114,060	29%	21,337	14
7	31,331,755	9,435,122	30%	20,716	16
8	30,847,431	14,368,421	47%	20,033	19
9	30,529,442	15,191,748	50%	19,370	21
10	30,976,543	14,177,633	46%	18,790	23
11	24,289,123	15,373,636	63%	18,183	25
12	24,190,936	17,501,980	72%	17,606	28
13	24,359,889	19,618,550	81%	16,994	30
14	25,092,036	19,794,062	79%	16,212	32
15	26,868,023	20,694,703	77%	15,468	34
16	28,040,458	21,429,413	76%	14,777	36
17	28,567,289	23,880,379	84%	14,124	37
18	28,414,382	26,181,891	92%	13,528	39
19	27,645,661	26,519,377	96%	12,949	41
20	26,619,543	28,171,144	106%	12,424	43
21	23,992,098	29,265,056	122%	11,880	45
22	22,640,893	30,375,671	134%	11,352	47
23	21,207,093	31,994,453	151%	10,828	49
24	19,817,038	33,793,660	171%	10,305	51
25	18,425,618	35,678,374	194%	9,788	53
26	17,034,109	37,554,281	220%	9,278	55
27	15,669,320	39,451,165	252%	8,774	57
28	14,356,637	41,285,229	288%	8,277	59
29	13,101,970	42,932,829	328%	7,787	61
30	11,908,669	44,366,953	373%	7,306	64
31	10,778,907	45,639,678	423%	6,837	66
32	9,712,892	46,714,483	481%	6,379	68
33	8,710,117	47,548,592	546%	5,932	70
34	7,772,923	48,170,839	620%	5,501	72
35	6,902,722	48,408,027	701%	5,084	74
36	· · ·	48,268,157	791%	4,684	76
37	6,099,279	47,785,313		· ·	
	5,361,365	, ,	891%	4,302	78
38	4,687,672	47,002,885	1,003%	3,938	80
39	4,077,571	45,949,670	1,127%	3,595	82
40	3,529,190	44,633,478	1,265%	3,272	83
41	3,039,088	43,019,463	1,416%	2,969	85
42	2,603,882	41,194,485	1,582%	2,688	86
43	2,219,792	39,223,043	1,767%	2,426	87
44	1,883,295	37,074,523	1,969%	2,185	88
45	1,590,661	34,789,740	2,187%	1,964	89
46	1,337,586	32,408,692	2,423%	1,761	90
47	1,119,989	30,008,983	2,679%	1,576	91
48	934,205	27,657,474	2,961%	1,408	92
49	776,527	25,373,562	3,268%	1,256	93
50	643,343	23,169,907	3,601%	1,118	93
51-55	1,860,872	85,178,753	4,577%	3,963	95
56-60	667,032	45,867,231	6,876%	2,100	96
61-65	218,766	21,599,460	9,873%	1,009	96
66-70	63,635	8,548,660	13,434%	400	96

<sup>[1]</sup> With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.

# Attachment 7-a MedAmerica and BCNEPA Pennsylvania-Specific Experience and Projections by Policy Year - Before Requested Rate Increase Series 11 and Prior Policy Forms

	Actua	I and Projected I	Experience using	Current Assumpt		
					Cumulative	
Policy	Earned	Incurred	Incurred	End of Year	Loss Ratio	
Year	Premium	Claims	Loss Ratio	Lives	w/ Interest <sup>[1]</sup>	
1	3,432,705	141,681	4%	1,862	4%	
2	2,690,018	35,491	1%	1,638	3%	
3	2,388,162	71,375	3%	1,512	3%	
4	2,220,471	148,292	7%	1,423	4%	
5	2,098,827	295,852	14%	1,347	5%	
6	2,002,461	849,104	42%	1,293	10%	
7	1,895,506	1,003,609	53%	1,228	14%	
8	1,785,397	1,024,653	57%	1,159	17%	
9	1,694,438	814,667	48%	1,084	19%	
10	1,602,874	895,913	56%	1,015	22%	
11	1,491,744	778,479	52%	947	23%	
12	1,406,779	1,700,582	121%	878	27%	
13	1,315,969	1,142,603	87%	832	29%	
14	1,249,918	991,183	79%	782	31%	
15	1,179,099	1,540,711	131%	734	34%	
16	1,092,508	1,202,064	110%	672	36%	
17	1,003,139	1,016,090	101%	604	37%	
18	926,994	1,894,934	204%	539	40%	
19	871,598	1,507,254	173%	498	42%	
20	820,540	1,557,366	190%	461	44%	
21	667,908	1,419,467	213%	420	46%	
22	595,462	1,111,861	187%	385	47%	
23	535,737	1,178,621	220%	355	49%	
24	482,464	1,206,347	250%	328	50%	
25	434,046	1,235,527	285%	303	51%	
26	389,171	1,260,609	324%	278	53%	
27	347,932	1,284,785	369%	256	54%	
28	310,249	1,299,604	419%	234	55%	
29	275,993	1,317,005	477%	214	57%	
30	244,963	1,332,990	544%	196	58%	
31	216,869	1,340,935	618%	178	59%	
32	191,454	1,345,868	703%	162	60%	
33	168,520	1,364,575	810%	147	62%	
34	147,874	1,374,668	930%	133	63%	
35	129,334	1,369,786	1,059%	121	64%	
36	112,694	1,359,853	1,207%	109	65%	
37	97,767	1,342,547	1,373%	98	66%	
38	84,401	1,308,465	1,550%	88	67%	
39	72,484	1,273,639	1,757%	78	67%	
40	61,900	1,227,113	1,982%	70	68%	
41	52,552	1,181,189	2,248%	62	69%	
42	44,325	1,125,080	2,538%	55	70%	
43	37,121	1,057,611	2,849%	48	70%	
44	30,850	983,537	3,188%	42	70%	
45	25,447	916,493	3,602%	36	71%	
46	20,823	834,348	4,007%	31	71%	
47	16,893	756,303	4,007 % 4,477%	27	72% 72%	
48	13,584	678,587	4,477%	23	72% 72%	
49	10,826		·	23 19	72%	
50		599,523 527,344	5,538% 6,169%			
	8,548 20,995	527,344		16 48	73% 73%	
51-55		1,673,969	7,973%	48		
56-60	4,690	591,077	12,604%	16	74%	
61-65	702	140,460	19,997%	4	74%	
66-70	52	19,774	37,876%	1	74%	
Total 39,023,776 55,651,461 143% 25,086 74%						
			imum valuation intere	•		

<sup>[1]</sup> With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.

# Attachment 7-b MedAmerica and BCNEPA Pennsylvania-Specific Experience and Projections by Policy Year - After Requested Rate Increase Series 11 and Prior Policy Forms

	Actu	al and Projected I	Experience using	Current Assumpt	
		_		•	Cumulative
Policy	Earned	Incurred	Incurred	End of Year	Loss Ratio
Year	Premium	Claims	Loss Ratio	Lives	w/ Interest <sup>[1]</sup>
1	3,432,705	141,681	4%	1,862	4%
2	2,690,018	35,491	1%	1,638	3%
3	2,388,162	71,375	3%	1,512	3%
4	2,220,471	148,292	7%	1,423	4%
5	2,098,827	295,852	14%	1,347	5%
6	2,002,461	849,104	42%	1,293	10%
7	1,895,506	1,003,609	53%	1,228	14%
8	1,785,397	1,024,653	57%	1,159	17%
9	1,694,438	814,667	48%	1,084	19%
10	1,603,000	895,913	56%	1,015	22%
11	1,492,715	778,481	52%	947	23%
12	1,410,128	1,700,553	121%	878	27%
13					29%
14	1,333,985	1,142,503	86% 76%	831 779	
	1,305,424	989,491			31%
15	1,299,004	1,530,122	118%	726	34%
16	1,275,793	1,176,975	92%	658	35%
17	1,272,141	965,814	76%	585	36%
18	1,215,509	1,830,064	151%	521	39%
19	1,164,146	1,427,498	123%	480	41%
20	1,108,822	1,464,814	132%	443	42%
21	882,985	1,316,675	149%	403	44%
22	801,363	1,000,139	125%	368	45%
23	738,360	1,053,590	143%	337	46%
24	693,385	1,059,758	153%	309	47%
25	652,211	1,065,159	163%	282	48%
26	602,335	1,072,074	178%	259	49%
27	543,231	1,086,815	200%	238	50%
28	487,007	1,095,534	225%	218	51%
29	435,646	1,105,821	254%	200	52%
30	388,866	1,115,067	287%	183	53%
31	346,253	1,118,433	323%	167	53%
32	307,441	1,119,628	364%	152	54%
33	272,161	1,131,925	416%	138	55%
34	240,147	1,138,189	474%	125	56%
35	211,158	1,133,535	537%	113	57%
36	184,921	1,125,395	609%	102	58%
37	161,186	1,111,526	690%	92	58%
38	139,751	1,084,718	776%	83	59%
39	120,482	1,058,148	878%	74	60%
40	103,230	1,022,291	990%	66	60%
41	87,887	987,741	1,124%	59 53	61% 61%
42	74,292	945,108	1,272%	52	61%
43	62,319	893,114	1,433%	46	62%
44	51,848	834,226	1,609%	40	62%
45	42,786	780,437	1,824%	35	63%
46	35,002	713,822	2,039%	30	63%
47	28,369	650,089	2,292%	26	63%
48	22,778	585,750	2,572%	22	63%
49	18,116	519,257	2,866%	19	64%
50	14,268	457,968	3,210%	16	64%
51-55	34,731	1,466,184	4,222%	46	64%
56-60	7,577	526,748	6,952%	16	64%
61-65	1,103	128,120	11,612%	4	64%
66-70	78	18,773	24,108%	1	64%
		, 0	,	• 1	2.70
Total	43,481,925	49,808,708	115%	24,726	64%
			imum valuation intere	•	

<sup>[1]</sup> With interest values are accumulated or discounted at the maximum valuation interest rate for contract reserves applicable for the year of issue.



Independent Licensee of the Blue Cross and Blue Shield Association

Registered Mark of the Blue Cross and Blue Shield Association

19 North Main Street, Wilkes-Barre, Pennsylvania 18711-0302

#### Letter of Authorization

To: Department of Insurance

MedAmerica Insurance Company ("MedAmerica") has entered into a service agreement with Milliman, Inc. ("Milliman") effective January 2, 2003, that includes long-term care rate filing services on our behalf. The agreement provides, in part, that Milliman is responsible for preparing and filing for approval with state insurance departments MedAmerica's long-term care rate increase filings and filings made by MedAmerica on behalf of insurers which are reinsured by MedAmerica. Milliman is also authorized to receive, on MedAmerica's behalf, written and oral communication from each state department of insurance for the purpose of completing the rate increase filing process.

Please accept this letter of authorization for the purpose stated above. Should you have any questions regarding the above, please forward your comments to:

MedAmerica Insurance Company 165 Court Street Rochester, NY 14647

John & Moon - Director, Financial Services 1/11/10

Date





